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Abstract
Thymidine phosphorylase (TP) cleaves thymidine, giving 2-deoxy-D-ribose-1a- 
phosphate and hence the angiogenic mediator 2-deoxy-D-ribose. Poly(ADP-ribose) 
polymerase-1 (PARP-1) is responsible for controlling cellular DNA repair and inhibitors 
have potential as chemosensitisers and radiosens'itisers in cancer therapy, lnosine-5’- 
monophosphate dehydrogenase (IMPDH) is a key enzyme in the de novo biosynthesis 
of guanine nucleotides and inhibitors, such as tiazofurin, are cytotoxic. The substrates 
for all three enzymes are ribosides or 2-deoxyribosides. In this thesis, mimics of the 
substrates are designed with the tetrahedral sulfoximine group replacing the anomeric 
carbon.
Synthetic approaches to 1 R,3R,4R-1 -aryl-4-hydroxy-3-hydroxymethyl-1 ?i4-isothiazole-
1-oxides were studied. Several routes were investigated to produce sulfoximines; the 
most effective was rhodium-catalysed oxidative imination of sulfoxides with trifluoro- 
acetamide and iodosobenzene diacetate. However, reaction of anions derived from S- 
methylsulfoximines to aldehydes gave only low yields of the required secondary 
alcohols. Alternatively, diastereomeric 4S,5R-4-(benzyloxymethyl)-2,2-dimethyl-5-(3- 
arylsulfonimidoylmethyl)-1,3-dioxolanes were synthesised by thio-Mitsunobu coupling 
of thiophenols with 4S,5S-4-(benzyloxymethyl)-2,2-dimethyl-5-hydroxymethyl-1,3- 
dioxolane, followed by sulfoxidation and imination. The separated diastereoisomers 
were identified by X-ray crystallography. Deprotection gave the vicinal diol, which was 
subjected to cyclisation studies.
The second series of targets, 1 S.3R.4R-1 -arylimino-3-hydroxy-4-hydroxymethyltetra- 
hydro-1A,6-thiophene-1-oxides, were approached initially through 1,3-dipolar cyclo- 
additions of chiral (£)-3-benzyloxypropenoates with the H2C=S+-C H 2‘ but technical 
difficulties frustrated this route. Following an alternative strategy, a Dieckmann 
cyclisation furnished racemic 3-oxotetrahydrothiophene-4-carbonitrile. Reduction of the 
ketone and hydration of the nitrile gave trans 3-hydroxytetrahydrothiophene-4- 
carboxamide, as shown by NMR and X-ray crystallography. The secondary alcohol 
was protected and the sulfur was oxidised to the sulfoxide. In this sequence, it only 
remains to develop methods for imination at the sulfoxide and conversion of the 
carboxamide to a CH2OH group.
Thus the major hurdles in the synthetic routes to both types of sulfoximine-based 
riboside mimics have been overcome, providing late intermediates with appropriate 
configurations for future elaboration to the targets.
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1.1 Anti-cancer drug discovery -  the call for target-driven strategy
Despite continuous research effort and breakthrough, cancer maintains its position as 
one of the biggest causes of death in the world. There is a great need for better 
treatment options to decrease mortality rates and increase the quality of life for cancer 
patients. Traditional medical intervention centres on chemotherapy, radiotherapy and 
surgery. However, most available techniques lack selectivity and result in undesirable 
adverse effects and treatment failure. Current research aims to identify and investigate 
tumour-specific enzymes and markers as potential drug targets, with the recent 
discovery of agents such as Gleevec® and Herceptin® providing examples of this 
approach in the treatment of chronic myelogenous leukaemia and metastatic breast 
cancer, respectively.1,2 The positive outcomes of these agents further reinforce the 
necessity of understanding tumour biology and the importance of targetted agents in 
anti-cancer drug discovery.
Cancer cells possess elaborate systems that enable them to grow and spread rapidly, 
with a protective mechanism against conventional cancer treatment. For the purpose of 
this thesis, the following tumour cellular processes as potential drug targets will be 
discussed:
• Tumour angiogenesis (Section 1.2)
• Mis-regulated cell proliferation and differentiation (Section 1.3)
• DNA repair and resistance to anti-cancer therapy (Section 1.4)
1.2 Tumour angiogenesis
1.2.1 Introduction
Angiogenesis, the formation of new blood vessels from existing vasculature, occurs in 
a number of physiological processes, such as wound healing, regrowth of the uterine 
lining after menstruation, pregnancy and foetal development.3 It is a complex, multi- 
step process that begins with the activation of endothelial cells (ECs) by an angiogenic 
stimulus (vide infra, Figure 1). Injured or diseased tissues synthesise and release 
angiogenic factors which bind to the EC receptors. The activated ECs release 
proteases to break down the basement membrane surrounding the vessels; matrix 
metalloproteases (MMPs) are also released to break down extracellular matrix and 
allow for invasion, migration and proliferation through the disrupted basement 
membrane, creating a capillary sprout. Adhesion molecules (integrins avp3 and (Xvp5)
1
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are employed to pull the sprouting vessel forward, forming a blood vessel tubule. 
Finally, new basement membrane and muscle layer are created to form a new capillary 
network4
3. Proteases break 4 ECs mjgrate and
down basement proliferate to form a
membrane capillary sprout 6. After further reconstruction of the 
vessel, pericytes are 
incorporated to 
provide structural 






1. Injured tissues produce 
and release angiogenic 
factors
2. Binding of 
angiogenic factors 
on the receptors 
activate endothelial
Figure 1. The angiogenic process, highlighting the steps involved in developing a new capillary network.4
Tumour
7. Angiogenic “switch’ 
promotes further 
sprouting of the blood 
vessel
Host vasculature
8. Blood vessel grows 
toward and infiltrates 
tumour mass; tumour 
cells travel along the 
neovessels to distant 
organs
9. Tumour metastasis
Figure 2. Tumour angiogenesis and subsequent metastasis via the newly developed neovascular 
network.4
Tumour cells acquire oxygen and nutrients for their growth and metastasis from nearby 
host neovasculature by simple passive diffusion. However, once tumours grow up to 
the size of 1-3 mm3, this blood supply is no longer sufficient for further growth and the 
angiogenic “switch” is turned on to accommodate the increasingly high metabolic 
demand.5 This may be a result of genetic changes, hypoxia or oxidative stress. The 
“on-switch” triggers the recruitment of host vasculature to encourage further sprouting
2
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of blood vessels, which subsequently grow toward and infiltrate the tumour mass, 
providing the required circulation of oxygen and nutrients (vide supra, Figure 2).
In metastasis, the tumour cells are able to travel to distant organs through this newly 
developed capillary network and form secondary tumours. Furthermore, a disrupted 
vessel remodelling mechanism is known to be responsible for the twisted chaotic 
tumour neovasculature, which ultimately leads to hypoxia, and the tumour 
angiogenesis process is repeated.6
1.2.2 Regulation of angiogenesis
In normal conditions, angiogenesis is tightly controlled by a balanced activity of 
angiogenic stimulators and inhibitors (Table 1 and Table 2)7 In cancer, increased 
levels of angiogenic factors, along with reduced levels of angiogenic inhibitors, disturb 
the balance and lead to excessive angiogenesis. Triggered by the tumour angiogenic 
switch, activating factors are released by tumour cells, by the surrounding tissue or by 










Table 1. Angiogenesis stimulators.3,7 (Abbreviations: VEGF -  vascular endothelial growth factor; IL -  
interleukin; FGF -  fibroblast growth factor; TGF -  transforming growth factor, TP -  thymidine 
phosphorylase; PD-ECGF -  platelet-derived endothelial cell growth factor; MCP -  macrophage 
chemoattractant protein; MMP -  matrix metalloprotease; NOS -  nitric oxide synthase; TNF -  tumour 
necrosis factor.)
The most active angiogenic factors belong to the VEGF family (VEGF-A, -B, -C, -D and 
-E).8 They regulate vascular permeability, ECs proliferation and apoptosis in many 
tumour types. VEGF-A, particularly, is highly expressed in many tumours, including 
those in the lung, brain and gastrointestinal tract.
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Among the numerous naturally occurring angiogenesis inhibitors, angiostatin is the 
most well known. It is a product of proteolysis of plasminogen and it inhibits ECs 
proliferation.9
The mechanisms of initiating the angiogenic switch are complex and only partly known. 
The angiogenic stimulators and inhibitors play different roles under different 
circumstances. Certain oncogenes and tumour-suppressor genes also regulate 
angiogenesis. Ras, myc, raf, HER-2/neu, src and c-Jun upregulate VEGF or down- 
regulate thrombospondin-1 (TSP-1) ;7,10 mutant p53 upregulates VEGF, whereas 
wild-type p53 upregulates TSP-1 and downregulates VEGF.11 The angiogenic pathway 
is linked to apoptosis, with certain naturally occurring angiogenic inhibitors (angiostatin, 
endostatin, IL and TSP-1) inducing apoptosis in both EC and tumour cells.8
Naturally occurring angiogenic inhibitors
Angiostatin Endostatin (collagen XIII fragment)
Antithrombin-lll fragment TSP-1
IF-a,p IL-4, 12, 18
Plasminogen activator inhibitor Canstatin
Fibronectin fragment Heparinases
Prolactin Retinoids
Table 2. Angiogenesis inhibitors.3,7,8 (Abbreviations: TSP -  thrombospondin; IL -  interleukin; IF -  
interferon)
1.2.3 Thymidine phosphorylase (TP) in angiogenesis
1.2.3.1 Background
Thymidine phosphorylase (TP, EC 2.4.2.4) catalyses the phosphorolysis of thymidine 
1, with inorganic phosphate to give thymine 2 and 2-deoxy-D-ribose-1a-phosphate 3. 
Dephosphorylation of the latter generates 2 -deoxy-D-ribose 4 {vide infra, Scheme 1). 
The enzyme also catalyses 2-deoxyribosyl transfer from one deoxynucleoside to 
another nucleobase.12 TP forms part of the catabolic / salvage pathway of pyrimidine 
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Scheme 1. TP-catalysed phosphorolysis of thymidine 1.12
1.2.3.2 Structure of TP
TP was first described in 1954 by Friedkin and Roberts as a nucleoside metabolism 
enzyme.13 Purification of the enzyme from both Escherichia coli and Salmonella 
typhimurium in the mid-1970s provided the first glimpse at the structure of TP.14 E. coli 
TP is a homodimer of 45 KDa subunits, whilst human TP is a homodimer of 55 KDa 
subunits.15 The expressed E. coli protein contains 441 amino acids and shows 34% 
homology to human TP. In the 1980s, an angiogenic protein extracted from human 
platelet lysate was named platelet-derived endothelial cell growth factor (PD-ECGF) 
and was later found to be identical to TP.16
A crystal structure of thymine 2 bound to E. coli TP reveals the structure of the active 
site (vide infra, Figure 3). Thymine interacts with a cavity at the top of the active-srte 
cleft via hydrogen bonds to the heterocyclic ring (Arg 202, Tyr 199, Ser 217) and 
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Figure 3. Interactions of thymine 2 within the active site of TP .17,18 (Hydrophobic interactions -  red; 
hydrogen bonds -  blue)
1.2.3.3 Functions of TP
Upregulation of TP is stimulated by hypoxia, hypoglycaemia and cytokines (TNF-a, 
IL-1, IF-y) within the tumour microenvironment. Radiotherapy and chemotherapeutic 
agents such as taxanes and cyclophosphamide are also known inducers of TP.12
TP has been implicated in tumour growth and metastasis and high levels of the 
enzyme have been found in many solid tumours, including those of colon, stomach, 
lung, bladder, pancreas, cervix, uterus, ovary, kidney, thyroid, oesophagus and 
breast.16 An increase in TP expression as high as 260-fold was found in invasive 
bladder tumours compared to the level in normal tissue.19 A separate investigation 
found that human KB epidermoid carcinoma cells transfected with TP had a higher 
angiogenic activity and apoptotic index than non-transfected cells20 Additionally, the 
growth rate of KB/TP cells was significantly higher than that of normal cells under 
hypoxic conditions.21
TP stimulates chemotaxis of endothelial cells in vitro and angiogenic activity in vivo.22 
The exact mechanism is unclear but it was hypothesised that the angiogenic activity 
involves either the reduction of extracellular thymidine levels, which is inhibitory to 
angiogenesis, or the activity of 2-deoxy-D-ribose as an angiogenic mediator.16 The 
latter also displays chemotactic properties in vitro and angiogenic activity in vivo, it 
stimulates cell migration in the endothelium via its concentration gradient. A hypothesis 
supporting this activity is that 2-deoxy-D-ribose could be intracellularly phosphorylated 
to 2-deoxy-D-ribose-5-phosphate, which is then cleaved to acetaldehyde and 
glyceraldehyde 3-phosphate. These molecules can enter the glycolytic pathway and 
generate ATP, therefore serving as an cellular energy source.22 2-Deoxy-D-ribose has 
also been shown as an anti-apoptotic factor in hypoxia 23 Studies suggested that this is
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achieved by the ability of 2-deoxy-D-ribose to suppress the effects of several apoptotic 
factors such as caspase 3 and HIF-1a (hypoxia-inducible factor), although more 
experimental data are required for a better understanding.24,25
Brown et al. described the role of 2-deoxy-D-ribose-1a-phosphate in TP-induced 
oxidative stress and subsequent secretion of angiogenic factors.26 The group revealed 
that 2-deoxy-D-ribose-1a-phosphate is a strong reducing sugar that is capable of 
generating oxygen radicals during protein glycation. The putative mechanism involves 
transition metal-catalysed auto-oxidation of 2-deoxy-D-ribose-1a-phosphate. The latter 
is converted to 2-deoxy-D-ribose-5a-phosphate by phosphopentomutase; the 
open-chain ribosyl group of the product is coupled to an amino residue of an intra­
cellular protein and this condensation product (Schiff base) rearranges to give an 
a-hydroxyketone which reacts with oxygen and, in the presence of oxidised 
redox-active transition metal ions (Cu2+, Fe3*), give a superoxide anion that is further 
converted to hydrogen peroxide and hydroxyl radicals 25,25
It is interesting to note that, while 2-deoxy-D-ribose is a recognised angiogenic 
mediator, 2-deoxy-L-ribose, the enantiomer, has been found to have activity opposite 
to those of both TP and 2-deoxy-D-ribose. 2-Deoxy-L-ribose was shown to inhibit EC 
migration and endothelial tube formation; it suppressed TP-induced angiogenesis, 
tumour growth and metastasis, and increased the proportion of apoptotic cells by 
suppressing TP-stimulated production of angiogenic factors (VEGF and IL-8 ).27,28 
Further study is required to explore the potential of 2-deoxy-L-ribose as a useful 
therapeutic agent in angiogenesis.
1.2.3.4 Therapeutic potentials of TP inhibition
Scheme 2 (vide infra) summarises the diverse activities of TP in tumour development. 
Targetting this enzyme is of great pharmacological interest because inhibition of TP 
could promote apoptosis and suppress tumour angiogenesis and metastasis.
Whilst TP inhibition is of great value, few TP inhibitors are currently known. Most are 
mono-cyclic derivatives of uracil, with TPI (5-chloro-6-[1-(2-iminopyrrolidinylmethyl)]- 
uracil hydrochloride, 5), with a reported IC50 of 35 nM (vide infra, Figure 4), being the 
most potent inhibitor.29 An increase in both the rate of growth of the KB cells and the 
density of blood vessels in the tumours were observed when the cells were subjected 
to high TP concentrations. In addition, the proportion of apoptotic cells was also raised,
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supporting the role of TP in apoptosis and angiogenesis. TPI caused a substantial 
reduction in tumour growth of human KB epidermoid carcinoma cells with high TP 
activity. Prior to the discovery of TPI, the strongest inhibitor was 6-amino-5-bromouracil 
6 (vide infra, Figure 4) with an ICsoOf 30 jiM.30
TNF-a, IL-1, IF-y 
Hypoxia — ► TP
Scheme 2. Schematic overview of the roles of TP and the clinical application of TP inhibitors.
The 2-iminopyrrolidine cation in TPI 5 was designed to mimick the intermediate 
oxonium in TP-catalysed phosphorolysis of thymidine 1 (vide supra, Scheme 1). 
Recently, the structure-activity relationship (SAR) of TPI was established with a crystal 
structure of human TP in complex with the inhibitor, thereby giving information on the 
structure of human TP active site. It consists of two components, one interacting with 
the uracil ring and the other with the 2-iminopyrrolidinyl moiety, with a network of water 
molecules occupying the phosphate-binding site. A number of hydrogen bonds to the 
uracil ring and the 2-iminopyrrolidinyl moiety are present within the active site (vide 
infra, Figure 4); the chlorine atom is responsible for several hydrophobic interactions. 
The SAR and improved inhibitory profile of TPI provides opportunities for future in silico 
screening and drug design.31
1.2.3.5 TP: The two-face Janus
Interestingly, the early focus on TP in anti-cancer drug discovery was associated with 
the relationship between the enzyme activity and sensitivity to chemotherapy. Besides 
all the roles discussed above, TP also catalyses the conversion of the antimetabolite 
5-fluorouracil (5-FU) to 5-fluoro-2’-deoxyuridine, the first step in its metabolism to the 
anti-cancer compound, 5-fluoro-2’-deoxyuridine triphosphate, a thymidine synthetase 
inhibitor. Doxifluridine (5’-deoxy-5-fluorouridine), cepecitabine (N-4-pentyloxy- 
carbonyl-5’-deoxy-5-fluorocytidine) and tegafur [1-(tetrahydro-2-furanyl)-5-fluorouracil] 
are prodrugs of 5-FU that are established anti-cancer agents. Furthermore, as 
discussed before, certain chemotherapeutic agents (taxanes, cyclophosphamide)
Other stimuli
TP inhibitors





increase TP levels and co-administration with prodrugs of 5-FU would provide a 
synergistic effect. For these TP-target agents, high enzyme levels in tumours are 
required for their activities thus deeming TP inhibition in combination with 5-FU or its 
prodrugs inappropriate.32
To circumvent this problem, a potential solution is to inhibit specifically the downstream 
mediators of the TP catalysis pathway rather than to inhibit TP activity directly.
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Figure 4. TP inhibitors. Recent crystallography of TPI 5 with human TP provides valuable information on 
the structure of active site and aids future drug screening. TPI was found to possess a 1000-fold higher 
inhibitory activity than 6-amino-5-bromouracil 6, one of the most potent TP inhibitors previously 
synthesised.2M1 (W -w a te r  molecule; hydrogen bonds -  blue; hydrophobic interactions -  red)
1.3 Mis-regulated cell proliferation and differentiation in cancer
1.3.1 Tumour cell proliferation -  an imbalanced biosynthesis of nucleotides
The relationship between malignancy and cell differentiation has long been a target for 
anti-cancer drug design. An increase in the rate of cell proliferation and growth is 
essential for rapidly dividing cells and an accumulation of mutations of oncogenes and 
tumour suppressor genes allows tumour cells to escape the normally controlled nature 
of the cell cycle.
In normal cells, enzymes in the anabolic (synthetic) pathways and the catabolic 
(degradation) pathways act as the rate-limiting factors in DNA and RNA biosynthesis
9
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and their activities are balanced. Tumour cells have a reprogrammed metabolic and 
enzymatic imbalance, resulting in an elevation of the activity of anabolic enzymes with 
decreased activity of opposing enzymes. This altered nucleotide metabolism 
contributes to rapid tumour growth and the identification of the enzyme targets offers 
opportunities fortargetted drug therapy.33
1.3.1.1 Purine nucleotide metabolism
Nucleotides are synthesised from simple building blocks in a step-wise manner (de 
novo pathway, vide infra, Scheme 3) or by the recycling of preformed bases (salvage 
pathway). The former starts with the synthesis of purine ring from amino acids 
(aspartate, glycine, glutamine), tetrahydrofolate derivatives and C02. The sugar 
phosphate moiety comes from 5-phosphoribosyM-pyrophosphate (PRPP), a product of 
ribose-5-phosphate and ATP. This is the central precursor of purine nucleotide 
metabolism and a series of reactions gives rise to the branch-point purine nucleotide, 
inosine 5-monophosphate (IMP, 7, vide infra, Scheme 3). Adenine 5-monophosphate 
(AMP, 8 , vide infra, Scheme 3) is synthesised from IMP by substitution of an amino 
group for the carbonyl oxygen atom at C-6 , with aspartate and GTP contributing for the 
amino group and phosphate group, respectively. Oxidation of IMP gives xanthosine
5-monophosphate (XMP, 9, vide infra, Scheme 3) with nicotinamide adenine 
dinucleotide (NAD4) as the hydrogen acceptor; subsequent conversion of XMP 
produces guanine 5-monophosphate (GMP, 10, vide infra, Scheme 3) by the insertion 
of an amino group at C-2 with glutamine as the amine donor and ATP as the 
phosphate donor.34
Free purine bases formed by the hydrolytic degradations of nucleic acids and 
nucleotides can be recycled by the salvage pathway via the utilisation of PRPP. The 
ribose phosphate moiety of PRPP is transferred to a free purine ring, forming the 
corresponding ribonucleotide. Two salvage enzymes operate to recover purine bases; 
adenine phosphoribosyl transferase catalyses the formation of AMP and hypoxanthine- 





















6 1 2 












( I XV  N NH-
Ribosei
P
AMP, 8 IMP, 7 XMP, 9 GMP, 10
Scheme 3. Schematic representation of the de novo biosynthesis of purine ribo- and 2 ’-deoxy- 
ribonucleotides; IMPDH catalyses the key step in the biosynthesis of guanine nucleotides, coverting IMP 7 
to XMP S 34 [Enzymes: 1 = inosine 5’-monophosphate dehydrogenase (IMPDH); 2 -  GMP synthase; 3 -  
GMP kinase; 4 -  ribonucleotide reductase; 5 -  nucleoside diphosphate kinase; 6 (i) adenylsuccinate 
synthetase; (ii) AMP lyase; 7 -  AMP kinase]
1.3.1.2  Control of purine biosynthesis
A feedback mechanism and other regulatory mechanisms operate in the regulation of 
purine synthesis. The reactions leading from IMP, the branch point in synthesis, are 
main sites of feedback inhibition. AMP inhibits the conversion of IMP to adenylo­
succinate, its immediate precursor; GMP inhibits the oxidation of IMP to XMP in a 
similar fashion. These two feedback inhibitors also act at the site of PRPP conversion 
to IMP.
1.3.2 lnosine-5’-monophosphase dehydrogenase (IMPDH) in guanine 
nucleotide biosynthesis
1.3.2.1 Background
As shown above, IMPDH (EC 1.1.1.205) is the key enzyme involved in the de novo 
biosynthesis of guanine nucleotides. It catalyses the irreversible oxidative conversion of
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IMP 7 to XMP 9 using NAD+ as a reagent (Scheme 3 and Scheme 4). The reaction 
involves a nucleophilic addition of a cysteine residue to C-2 of the purine ring, followed 
by hydride transfer to NAD+. Upon the release of the reduced NAD+, NADH, the C-S  
covalent bond of E~XMP 13 is hydrolysed to release XMP from E«XMP 14 (Scheme
4) .35 It is noteworthy that this reaction follows an ordered Bi-Bi sequence, where IMP 
binds to the active site before NAD+, and NADH is released prior to XMP.36 This 
mechanism is different from most NAD+-dependent dehydrogenases, in which there is 
either a random order of binding or they require NAD+ binding before the substrates.
o o  o o
A  m NADI-U A  N
) x X y
E .IM P 11 E -IM P 12 E -X M P 13 E*XMP 14
Scheme 4. Proposed mechanism of IMPDH reaction. After IMP binding to the enzyme active site (E«) and 
subsequent binding of NAD*, a covalent bond (~) is formed between C-2 and a cysteine residue. Hydride 
transfer at this E -IM P  intermediate 12 releases NADH, giving the thioimidate intermediate E-XM P 13. This 
is hydrolysed to E«XMP 14 and XMP is released from the active site, completing the enzymatic reaction.35
Given the central position of IMPDH in guanine nucleotide biosynthesis, targetting this 
enzyme is of great pharmacological interest. The enzyme is upregulated in rapidly 
proliferating tumour cells and investigations have demonstrated that lymphocytes, in 
particular, are dependent on the de novo pathway of nucleotide biosynthesis, thus 
making IMPDH a potential immunosuppressive target.36
1.3.2.2 Structure of IMPDH
The active enzyme has a molecular weight of 56-58 KDa per subunit and is a tetramer 
comprised of identical subunits. Two isoforms of the enzyme are known to exist: type I 
and type II. In human IMPDH, each of the two genes encodes a protein of 514 amino 
acids with high levels of sequence homology between the two isoforms (84% amino 
acid identity) .37 Type I isoform is constitutively expressed in normal cells, while type II is 
predominantly upregulated in neoplastic and rapidly proliferating cells,38 including 
human leukaemic cell lines39 human ovarian tumours and leukaemic cells from 
patients with chronic myeloid leukaemia.39,40
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Each IMPDH monomer consists of two domains. The 394-residue catalytic domain, 
with attached N- and C-terminals, contains the active site. Catalysis occurs through 
binding at two sites -  a substrate-binding region (IMP) and a co-factor-binding region 
(NAD+). The smaller domain (residues 110-244) lies adjacent to the catalytic domain. 
The function of this domain is unknown; it is not required for activity but may act as a 
regulatory region.41
The structure of IMPDH in complex with an XMP reaction intermediate provides 
information on the active site (Figure 5). This reaction intermediate (E-XMP, 13, vide 
supra, Scheme 4) is generated after both the hydride transfer and NADH release but 
before the production of XMP.36 A covalent bond between C-2 of XMP and the sulfur 
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Figure 5. XMP reaction intermediate (E~XMP, 13) in complex with IMPDH.36 (W  -  water molecule; 
hydrogen bonds -  blue)
1.3.2.3 Therapeutic potentials of IMPDH inhibition
Depletion of the pool of guanine nucleotides and consequent reduction in tumour DNA 
and RNA biosynthesis are the primary effects of IMPDH inhibition. Together with the 
marked increase of enzyme activity in tumour cells as a drug target, several IMPDH 
inhibitors have been widely described in the literature.
Tiazofurin (TF, 15, vide infra, Figure 6 ), 2-(p-D-ribofuranosyl)thiazole-4-carboxamide, is 
a C-nucleoside NAD+ analogue that has been used to investigate effects of IMPDH 
inhibition42 It requires metabolic activation: TF penetrates cell membranes and is 
phosphorylated by adenosine kinase to tiazofurin 5’-monophosphate (TFMP), which is 
coupled with AMP by NAD+-pyrophosphorylase to give thiazole-4-carboxamide adenine
13
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dinucleotide (TAD). The latter is an NAD+ analogue where the nicotinamide ring is 
replaced by thiazole-4-carboxamide and is more potent than TFMP or TF itself, with a 
K,of» 0.2 pM against IMPDH Type II. Kinetic studies suggest that TAD inhibits IMPDH 
by binding at the NAD+ site.41 TF showed significant anti-tumour activity in phase II 
trials for patients with end-stage acute non-lymphocytic leukaemia or myeloblastic 
crisis of chronic myeloid leukaemia.41 However, the adverse effect profile (severe 
neuro- and cardiovascular toxicities) is a limiting factor for treatment with TF. 
Analogues of TF have since been synthesised with modification of the ribose moiety or 
the thiazole ring with the aim of providing better pharmacological profiles.43 In fact, an 
analogue containing selenium instead of sulfur was synthesised and its corresponding 
dinucleotide was found to be more potent (by 5- to 10-fold) than TF.44 Selenazofurin 
(16, vide infra, Figure 6 ) is converted to selenazole-4-carboxamide adenine 
dinucleotide (SAD, 17, vide infra, Figure 6 ) in the same fashion as TAD and the crystal 
structures of both dinucleotides in complex with IMPDH provided SAR-related 
information.
In the crystal structure of SAD bound to human type II IMPDH, an interaction is 
observed between the carboxamide group and Asn 303 (vide infra, Figure 6 ). The 
selenazole ring binds in an antf-conformation with the selenium atom adjacent to the 
furanose oxygen, suggesting an intramolecular Se-O interaction. In addition, the 
electrophilic Se atom makes contact with Gin 334. The adenosine ring is stacked 
between four residues (Phe 282, His 253, Thr 45 and Thr 252) together with hydrogen 
bonds from the amino group and N-3. Additional interactions with the adenine ribose 
and the two phosphates are also observed.41 The crystal structure of TAD bound to 
horse liver alcohol dehydrogenase revealed that, in addition to the intramolecular 
interaction between the sulfur atom and the furanose oxygen similar to that seen with 
selenium in SAD, the thiazole-4-carboxamide group fitted in the NAD+-nicotinamide 
pocket via three hydrogen bonds from the amide and the carboxamide NH2 group is cis 
to the thiazole ring nitrogen.45
To conclude, interactions are observed from the carboxamide group and this is 
consistent with the requirement of a 4-carboxamide in the thiazole or selenazole ring 
for activity. The thiazole or selenazole ring binds in an anft-conformation with the 
positively charged sulfur or selenium atom adjacent to the furanose oxygen. This 
intramolecular electrostatic interaction limits rotation around the glycosidic bond which 
fixes the conformation.46-48 The antf-conformation is in accord with NMR studies 
suggesting that this conformation is adopted by NADH bound to IMPDH. In the case of
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TAD, the cis conformation of the thiazole-4-carboxamide is also consistent with the 
NMR data.49
Another synthetic nucleoside designed as an NAD+ analogue in IMPDH inhibition is 
3-p-D-ribofuranosylbenzamide (benzamide riboside, 18, Figure 6), where the 
nicotinamide group is replaced by a benzamide.50 In addition to promising toxicity 
against IMPDH (K, = 0.118 jiM), benzamide riboside was found to be more potent 
(3-fold, IC50 = 2.5 fxM) than TF (IC50 = 7.5 jxM) against human myelogenous leukaemia 
K562 cells in culture.50,51 Furthermore, a study using K562 cells incubated with isotope- 
labelled adenosine and benzamide riboside or TF revealed that the corresponding 
active metabolite of benzamide riboside, benzamide adenine dinucleotide (BAD), was 
produced in 2-3 fold higher quantities than TAD.50,51 Similar to TF and selenazofurin, 
benzamide riboside requires anabolism to BAD.50,51
Despite their promising inhibitory profiles, these adenine dinucleotides are not ideal 
IMPDH inhibitors because of their metabolic instability. They are quickly degraded by 
cellular phosphodiesterases to the corresponding nucleosides and resistance to TF is 
associated with both the decreased anabolic activity of NAD+-pyrophosphorylase (the 
converting enzyme) with increased degradation of TAD by phosphodiesterase.52
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Figure 6. IMPDH inhibitors tiazofurin (TF, 15), selenazofurin 16 and benzamide riboside 18, with 
interactions of SAD 17 to the active site of IMPDH.41,42,44,50,51 (Electrostatic interactions -  purple; hydrogen 






Mycophenolate mofetil (MMF, CellCept®, 19, Figure 7), an ester prodrug of the natural 
product mycophenolic acid (MPA, 20, Figure 7), is an uncompetitive IMPDH inhibitor 
and was approved for the prevention of acute kidney and heart transplantation rejection 
in combination with steroids and cyclosporin A.53 MPA was preferred to TF because the 
latter must be activated by phosphorylation. The efficacy of cell phosphorylation varies 
in different ceil types. In addition, the toxicity profile of TF prompted a new candidate 
with reduced side effects and enhanced anti-tumour activity. MPA (K, = 11 nM) displays 
a 5-fold preference towards type II IMPDH than type I.54 In additional to the role in 
depleting guanine nucleotides pool, it induces apoptosis of activated T-lymphocytes, 
thereby eliminates cells responding to antigenic stimulation and suppresses the 
recruitment of lymphocytes into sites of graft injection and inflammation.37
Interactions between MPA and IMPDH reveal that one face of the bicyclic ring system 
is stacked on the XMP hypoxanthine ring, while the other makes contact with the active 
site (Figure 7) .55 Van der Waals interactions are seen from the hexenoic acid chain, 
methyl and methoxy substituents of the benzofuranone core with Asp 274, Arg 322, 
Asn 303, Gly 415 and Met 414, together with several hydrogen bonds.
The gastrointestinal toxicity associated with CellCept® highlights the importance in 
selectively inhibiting type II over type I IMPDH. Further research in developing 
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Figure 7. IMPDH inhibitor MMF 19, a prodrug of the natural product MPA 20; MPA interactions with the 
active site reveal numerous hydrophobic contacts.5* -55 (Hydrophobic interactions -  red; hydrogen bonds -  
blue)
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1.4 Tumour DNA repair and resistance to chemotherapy and radiotherapy
1.4.1 DNA repair
The survival and integrity of a cell relies fundamentally on genome stability. DNA is 
frequently damaged by many agents such as oxygen radicals, UV light, ionising 
radiation, and DNA-damaging chemotherapy, and it is estimated that the average rate 
of damage is about 104 events per cell per day.56 Highly conserved DNA damage 
sensor mechanisms are employed to respond to potential cytotoxic effects. There are 
four complex systems:57
1. DNA repair
2. Cell cycle checkpoint control
3. Apoptosis
4. Damage tolerance
DNA repair is the most effective defence system by directly removing the lesions from 
DNA and comprises five mechanisms:
1. Base excision repair (BER)
2. Nucleotide excision repair (NER)
3. Mismatch repair (MMR)
4. Recombinational repair
5. Direct reversal of damage
Endogenous DNA damage (base damage and single strand breaks) is mainly repaired 
by BER, whereas NER is an important mechanism for removing a variety of damages, 
especially lesions of bulky DNA adducts. MMR corrects mismatched bases 
(insertion/deletion). Recombinational repair is required for double strand breaks and is 
important for damages induced by radiation. Direct reversal of damage is highly 
specialised; 0 6-methylguanine-DNA methyltransferase (MGMT) is responsible for the 
irreversible and stoichiometric transfer of a methyl group directly from 0 6-methyl- 
guanine from within the DNA.
Cell cycle checkpoint control involves prolongation of the G1 and G2  phases of the cell 
cycle to permit more effective DNA repair and avoids DNA synthesis in the presence of 
excessive DNA damage. Induction of apoptosis eliminates heavily damaged ceils, thus 
protecting the genomic stability and integrity.
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Some DNA lesions with high levels of damage or poorly repaired lesions often escape 
the above systems and persist through replication of DNA, in which case cells adapt 
the damage tolerance system to allow replication in the presence of DNA damage by 
lesion bypass and template switching. Lesion bypass directly utilises the damaged 
template by a) incorporating nucleotide opposite the lesion, followed by b) extension of 
DNA synthesis. Template switching involves synthesis of DNA on the undamaged 
template only.
Most anti-tumour agents and radiotherapy target cancer cells by damaging cellular 
DNA; alkylating agents directly damage DNA, whereas topoisomerase inhibitors inhibit 
DNA strand repair. Radiotherapy employs ionising radiation (X-ray, y-ray) that induces 
damage either by attacking the DNA sugar backbone or producing free radicals. In the 
less aggressive tumour tissues, sufficient damage can be sustained to achieve 
cytotoxicity and treatment success. However, the increasing problem of drug resistance 
and remission indicates that tumour cells employ a highly efficient surveillance system 
that senses and repairs such damages; another common disadvantage of the 
conventional treatment is dose-related toxicity to the surrounding healthy tissues. 
Therefore, it is clear that inhibiting the specific DNA repair proteins are beneficial for 
tumour selectivity and increased treatment response.
1.4.2 Poly(ADP-ribose) polymerase-1 (PARP-1): the “guardian angel” of the 
genome
1.4.2.1 Background
BER is involved in the repair of single-strand breaks, leading to the resistance of 
ionising radiation and alkylating chemotherapeutic agents. This pathway is divided into 
short-patch and long-patch repair. Short-patch repair (major pathway) removes one 
base only, whereas long-patch repair can remove 2-15 nucleotides. Short-patch BER 
removes the incorrect or damaged base by a DNA glycosylase; this generates an 
apurinic/apyrimidinic site which is cleaved by an AP endonuclease/3’-phosphodi- 
esterase, leaving a single-strand break.58 Replacement of the damaged base and 
religation of the DNA involves the binding of poly(ADP-ribose) polymerase-1 (PARP-1) 
and/or PARP-2, members of the PARP superfamily, then recruitment of a repair 
complex including DNA polymerase (3, DNA ligase I or III and XRCC I (X-ray 
cross-complementing) .56,59 Long-patch repair is thought to contribute to the repair of 
oxidised or reduced apurinic/apyrimidinic sites as a minor sub-pathway.
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PARP-1  (EC 2.4.2.30) is the founding member of the PARP enzyme family. It is a 
abundant nuclear protein (about 10s molecules / cell) .60 The number of PARP-family 
members has recently been increased to 17 and the main members are categorised 
into the following groups:61
• DNA-damage-dependent PARPs (PARP-1 and PARP-2)
• Tankyrases (tankyrase-1 and tankyrase-2)
• Other PARPs (PARP-3, PARP-4/vPARP, PARP-6 , PARP-8 , PARP-10 and 
PARP-11)
In addition to PARP-1, five members of the PARP superfamily are well characterised:62 
PARP-2 is most similar to PARP-1; it is a 64.8-KDa DNA-binding protein with a similar 
activity to PARP-1 and includes a nuclear localisation signal (NLS) and a severely 
modified DNA-binding domain (vide infra, Figure 9). PARP-3 is a 60-KDa protein that is 
thought to interfere with the progression of cell cycle through G1-S phase. Both PARP- 
2 and PARP-3 lack an automodification domain. PARP-4/vPARP is the largest PARP 
member (193 KDa) and is the catalytic domain of vault particles, which are 
barrel-shaped ribonucleoprotein complexes that are involved in multidrug resistance of 
human tumours. Tankyrase-1 (PARP-5a) is a 142-KDa protein and a positive regulator 
of telomere length. Telomeres are proteins situated at the end of eukaryotic 
chromosomes and are essential for chromosomal stability. Tankyrase-2 (PARP-5b) 
shows 85% amino-acid homology to tankyrase-1 but its role has not been determined.
1.4.2.3 Mechanism of action of PARP-1: poly(ADP-ribosyl)ation
Poly(ADP-ribosyl)ation occurs in almost all nucleated cells of mammals, plants and 
lower eukaryotes but is absent from yeast.63 It consists of the synthesis of ADP-ribose 
polymer on target proteins and both PARP-1 activation and poly(ADP-ribosyl)ation 
represent an immediate cellular response to DNA damage.64
PARP-1 functions as a DNA-nick sensor; it binds to and is activated by DNA strand 
breaks and concomitantly cleaves NAD+ 21 into nicotinamide 23 (vide infra, Scheme
S) .65 Cleavage of the nicotinamide-ribose bond proceeds via a transition state 22 and 
the pyridinium-N-glycosidic bond breaking gives rise to the intermediate oxocarbenium 
ion (24, vide infra, Scheme S) .66 This is followed by the transfer of the resulting 
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Scheme 5. The proposed mechanism of NAD+ cleavage of PARP-1.66
Subsequent polymerisation of ADP-ribose units occurs on the 2’-hydroxyl group of the 
adenine ribose (chain elongation), with an a(1” -> 2’) glycosidic bond linking the C-1 of 
the nicotinamide ribose; polymerisation also occurs on the 2”-OH of the nicotinamide 
ribose, with a (1”’ -> 2”) glycosidic bond linking the C-1 of the nicotinamide ribose 
(branching). The size of the branched polymer can be up to 200 ADP-ribose units 
(Figure 8).67 Mostly, the target acceptor protein of poly(ADP-ribosyl)ation is PARP-1 
itself (automodification), but many other proteins have been described including p53, 
NF-kB (nuclear factor-KB), histones, DNA ligases, DNA polymerases, topoisomerases I 
and II and DNA-dependent protein kinase.68 The net effect of linking a long, negatively 
charged polymer to a protein is altered protein activity.69 As discussed above, most 
substrates of PARP-1 are proteins involved in DNA replication, transcription and repair. 










Figure 8. Poly(ADP-ribosyl)ation: initiation, elongation and branching.67
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Poly(ADP-ribosyl)ation is a dynamic process with a short (< 1 min) half-life of the 
polymer in vivo67 Upon automodification of PARP-1 on the DNA lesion site, the 
enzyme departs under the effects of electrostatic repulsion between the negatively 
charged ADP-ribose chains and the negatively charged DNA. Local relaxation of the 
chromatin allows access of DNA-repair enzymes and poly(ADP-ribose) glycohydrolase 
(PARG, EC 3.2.1.143) is recruited to hydrolyse ADP-ribose polymers rapidly (Scheme
6).70,71 ADP-ribosyl protein lyase is another enzyme responsible for PARP-1 
catabolism. While PARG cleaves ribose-ribose bonds of both linear and branched 
poly(ADP-ribose) polymers, ADP-ribosyl protein lyase removes the protein-proximal 
ADP-ribosyl group from the acceptor protein (vide supra, Figure 8).71
PARP-1 detects and binds to DNA 
and breaks
2. Poly(ADP-ribsoyl)ation 
using NAD* as a substrate; 
polymers can be added onto 
PARP-1 itself or onto acceptor 
proteins
3. Upon polymerisation of 
ADP-ribose units, PARP is 
released from the DNA and 
the polymers are degraded 
by PARG
4. Recruitment of DNA 
repair machinery to the 
lesion site
Scheme 6. Mechanism of action of PARP-1.70,71
1.4.2.4 Structure of PARP-1
The human PARP-1 is a 113-KDa protein composed of 1014 amino acid residues72 
The gene coding for this protein is at the q41 -  q42 position of the chromosome72 
Under normal conditions, inactive PARP-1 resides in the nucleoplasm and in the 
mitochondria.73 There are three functional domains (vide infra, Figure 9):73
• The N-terminal DNA-binding domain with a molecular weight of 46 KDa. It 














protein-protein interactions. The first zinc finger is essential for PARP-1 
activation upon DNA damage, whereas the second is essential for recognition 
of DNA single-strand breaks but not double-strand breaks. A DNA nick sensor, 
nuclear localisation signal (NLS) is also present within a caspase-cleavage site 
(DEVD).
• The 22-KDa central automodification domain is rich in glutamic acid residues, 
which is consistent with the fact that poly(ADP-ribosyl)ation occurs on such 
residues. It contains a BRCT motif (breast cancer susceptibility protein, 
BRCA1, C-terminus), which is common in many DNA repair and cell cycle 
checkpoint proteins. Through BRCT, PARP-1 participates in protein-protein 
interactions.
• The C-terminal catalytic domain (54 KDa); it is highly conserved in 
eukaryocytes. The active site consists of a 50-amino acid sequence known as 
the “PARP-1 signature” that shows 100% homology among vertebrates. It is 
essential for NAD+ binding, ADP-ribosyl transfer, elongation and branching 
reactions.
DNA-binding domain Automodification domain Catalytic domain 
[7T| E l  NLS BRCT  Active site______
n IH H H H  H IH  c
1 202 231 385 463 662 859 908 1014v I
DEVD
Figure 9. Schematic representation of the structure of hPARP-1, showing the three functional domains.73
1.4.2.5 Therapeutic potentials of inhibition of PARP-1
In addition to its role in DNA repair, PARP-1 activation also regulates both apoptosis 
and necrosis and the extent of DNA damage directly affects the mode of cell death.74 
Moderate DNA damage induces apoptosis, and caspases recognise the DEVD motif in 
the NLS and cleave PARP-1 into two fragments: p89 and p24. The enzyme cleavage 
separates the DNA-binding domain from the catalytic domain and inactivates the 
enzyme. The fragments further suppress the activity of PARP-1 by inhibiting 
dimerisation and further binding of intact PARP-1 to DNA.75,76
In cases of severe DNA damage, PARP-1 is overactivated and excessive utilisation of 
the intracellular storage of NAD+ depletes ATP. This prevents cells from initiating
22
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apoptosis because many stages in the apoptotic pathway rely on ATP and cells are 
subjected to necrosis.77 It is confirmed that necrosis is a more severe mode of cell 
death compared to apoptosis. Necrosis is associated with the disintegration of plasma 
membrane; leakage of cellular contents from necrotic cells into the surrounding tissue 
may contribute to organ injury and inflammation. In comparison, apoptotic cells remain 
intact and are rapidly cleared from the tissues by macrophages. Therefore, PARP-1 
serves as a determinant in the survival of cells and can shift the mode from necrosis to 
apoptosis (Scheme 7).78
DNA damage
PARP inhibitors PARP inhibitors
LimitedMild Excessive
NECROSIS
Depletion of ATPDNA repair
SURVIVAL APOPTOSIS
PARP-1 activationPARP-1 activation PARP-1 overactivation
DNA repair 
(insufficient)
Cancer treatment Inflammation and organ




Scheme 7. PARP-1 inhibition in cell survival and death. Degree of DNA damage determines the outcome 
of cell survival and death. In the case of mild DNA damage, PARP-1 inhibitors suppress repair mechanism, 
leading to cell apoptosis; if the damage is severe, PARP-1 inhibition protects energy pools thus shifting 
necrosis to apoptosis.78
The design of PARP-1 inhibitors is based on the interaction of NAD+ with the enzyme 
active site. The carboxamide group on the nicotinamide ring, adenine ribose phosphate 
and the adenine ring all form hydrogen bonds with the DNA-binding domain. In 
addition, there are tc-tc interactions between the nicotinamide ring and the active site 
(vide infra, Figure 10). Early structure-based drug design used nicotinamide as a NAD+ 
mimic. However, nicotinamide was found to be a poor candidate for PARP-1 inhibition 
due to weak inhibitory activity and lack of specificity. It is a target for 




Benzamide, a close analogue of nicotinamide, was shown to be an effective inhibitor 
because it lacks a ring nitrogen and therefore cannot be metabolised by NAD+- 
metabolising enzymes. Unfortunately, the poor solubility of this hydrophobic compound 
prompted search for related compounds with better solubility.66
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Figure 10. Interactions of NAD* 21 with PARP-1 active site.68 (Hydrogen bonds -  blue; tc- tc interactions -  
red brackets)
A systemic investigation of benzamide derivatives in the 1980’s revealed that 
substitution at the 3-position with polar groups improved solubility in water while 
retaining inhibitory activity (vide infra, Figure 11) .79 This position mimics the ring 
nitrogen of nicotinamide and these 3-substituted benzamides occupy the 
nicotinamide-binding site with the 3-substituent binding to the ribose nucleoside-binding 
domain. These compounds lack a cleavable C-N bond and are incapable of 
undergoing analogous C-N bond cleavage, thus serving as competitive inhibitors. The 
carbonyl oxygen interacts with the active site as an electron donor and the ability to 
form hydrogen bonds is further enhanced by conjugation to an electron-rich aromatic 
ring. In addition, there is also non-polar interaction between the aromatic ring and the 
active site. A free amido hydrogen is also necessary for hydrogen bond interaction with 
the active site. The preferred antf-conformation of the carboxamide group mimics the 
biologically active conformation adopted by enzyme-bound NAD+. 3-Aminobenzamide 
and 3-methoxybenzamide became the “benchmark” PARP-1 inhibitors with excellent 
water solubility and K, values of less than 2 pM.66 Thereafter, a large number of 
PARP-1 inhibitors have been synthesised with attention to increased potency and 
improved pharmacokinetics profile. Bi-, tri- and tetracyclic derivatives and the more 








At least one free NH group
Non-cleavage C-X bond
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Figure 11. SAR properties for benzamide inhibitors of PARP-1.66,79
1.4.2.6 PARP-1 inhibitors in cancer
Inhibition of PARP-1 has been extensively studied with the theory that by suppressing 
PARP-1 activity, cytotoxicity induced by chemotherapy or radiotherapy is enhanced by 
impairing the DNA repair system and promoting cell apoptosis in response to sustained 
damage. Furthermore, its role in cell necrosis may also assist in protection against 
chemotherapy-induced toxicity. Several lines of investigations have supported the 
significant clinical indications of PARP-1 inhibitors as chemosensitisers, radio- 
sensitisers and as protective agents in treatment-induced toxicities85,86
A number of studies have evaluated the potential role of PARP-1 inhibitors as 
chemosensitisers; co-administration of a PARP-1 inhibitor with cytotoxic drugs that 
cause single- and double-strand DNA breaks potentiates their effects and causes 
persistent DNA damage.
Temozolomide (TMZ) is a methylating agent for treatment of primary brain tumours and 
metastases, including malignant melanoma. However, frequent drug resistance 
presents a problem for its clinical response. One of the modified bases is
06-methylguanine (06-MeG) and resistance to TMZ is the result of efficient repair of 
methyl adducts from Oe-MeG by high levels of Oe-alkylguanine-DNA alkyltransferase 
(AGT) and tolerance to O6-MeG toxicity due to functional defects of the mismatch 
repair (MR) system. In AGT-proficient or MR-deficient tumour cells, inhibition of 
PARP-1 restored susceptibility to TMZ by disrupting the function of PARP-1 in the BER 
process. Treatment with PARP-1 inhibitors prior to exposure to TMZ results in 
increased DNA strand breaks, apoptosis and tumour growth inhibition.87-89
PARP-1 inhibitors have been shown to enhance the cytotoxicity of DNA topoisomerase 
I inhibitors camptothecin and irinotecan. Topoisomerase I cleaves a single strand of
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DNA and relaxes DNA supercoiling, favouring DNA replication and RNA transcription. 
Topoisomerase I inhibitors act by binding non-covalently to topoisomerase l-DNA thus 
stabilising the cleaved complex and preventing DNA re-ligation. PARP-1 interacts with 
and promotes the activity of topoisomerase I and poly(ADP-ribosyl)ated PARP-1 
facilitates resealing of strand breaks.87-90
Similar lines of research also identified potential chemopotentiating effects of PARP-1  
inhibitors in combination with a number of anti-cancer agents such as bleomycin, 
doxorubicin, cisplatin and the DNA minor-groove binder MeOS0 2(CH2)2-lexitropsin 
(Me-Lex) .87-89
Another potential application of PARP-1 inhibitors is radiopotentiation. Ionising 
radiation generates single- and double-strand breaks and induces apoptosis. While 
single-strand breaks are repaired by BER and activated PARP-1, double-strand breaks 
are mostly repaired by the recombinational pathway that recruits DNA-dependent 
protein kinase (DNA-PK). PARP-1 inhibitors have been shown to increase single- and 
double-strand breaks and potentiate cytotoxicity of y-radiation. Although PARP-1 is 
mainly associated with single-strand breaks, evidence suggests that it also stimulates 
DNA-PK activity, thus facilitating repair of double-strand breaks.87-89
The use of PARP-1 inhibitors as adjuvant therapies to counteract toxicity induced by 
anti-cancer drugs has also been considered. As shown before, PARP-1 is actively 
involved in the regulation of cell necrosis and inhibition of the enzyme protects normal 
tissues from oxidative stress generated by chemotherapy that can cause serious side 
effects. Clinical uses of doxorubicin and cisplatin are limited by their serious, often 
irreversible, dose-dependent cardiotoxicity (cardiac myopathy and heart failure) and 
nephrotoxicity (kidney damage), respectively. Both agents cause oxidative stress by 
the production of reactive oxygen species, which leads to single-strand breaks and 
PARP-1 activation. Studies have shown that co-administration of PARP-1 inhibitors 
with doxorubicin or cisplatin significantly reduced the level of drug-induced toxicities.89
1.4.2.7 PARP-1 inhibitors in other clinical indications
The cellular protective effect of PARP-1, due to its role as a determinant in cell death 
mode, makes the enzyme inhibitors useful agents in the treatment of a range of 
pathophysiological diseases including stroke,91 myocardial infarction,92 diabetes,93 
shock,94 glaucoma,85 neurodenegerative diseases and several other inflammatory
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diseases.85,87,94-96 PARP-1 inhibition prevents the decrease in intracellular NAD+ and 
ATP levels, thereby shifting the necrotic cell death to apoptosis and preventing cell 
dysfunction and organ injury.
1.5 Use of sulfoximines in drug design
1.5.1 Discovery of sulfoximines
Between the years 1946 and 1950, several publications described a toxic agent in 
processed flour.97 Flour made from freshly milled wheat is unsuitable for baking and it 
requires aging with treatment agents, including nitrogen trichloride, “agene". However, 
agenised flour, used traditionally as part of a diet for dogs, gave rise to epileptic 
seizures and death. In 1949, a highly active crystalline material was isolated from 
agenised gluten and zein as a sulfur-containing compound with a formula of 
C5H12N20 3 S.97 It was concluded that “a molecule C5H12N20 3S can be regarded formally 
as being derived from methionine sulfoxide by the addition of =NH, or from methionine 
sulfone by the replacement of O by =NH. In such a molecule there is clearly the 
possibility that the sulfur atom is asymmetric”. This new class of compounds was called 







98Figure 12. Structure of methionine sulfoximine (MSO, 25), the first sulfoximine discovered.
1.5.2 Structure and properties of sulfoximines
Sulfoximines are chemically and configurationally stable compounds. They possess 
extremely versatile chemistry and are tetrahedral in shape (vide infra, Figure 13). The 
sulfur atom carries both a nitrogen and oxygen function, with the nitrogen being weakly 
basic. If the two carbon substituents are different, the sulfur atom is chiral. The whole 
unit is electron-withdrawing. The sulfoximine group also contains acidic hydrogens on 
the a-carbon and the nitrogen.98
27
Chapter 1 1ntroduction
weakly basic acidic H
stereogenic if R1 *  ChkR'
acidic (adjustable by R3) 
(pKa = 32 if R3 = Me) 
(p/Ca = 23 if R3 = Ts)
Figure 13. The versatile sulfoximine group, with a stereogenic sulfur atom, basic nitrogen and acidic 
a-hydrogens.98
The IR spectra of sulfoximines exhibit absorption bands for 0=S=N (v 1100-1200 cm'1) 
and for the NH stretch (free sulfoximines) at 3100-3400 cm"1.98 The chemical shifts of 
the a-methylene protons in the NMR spectra are similar to those for the corresponding 
sutfone, with a small downfield shift because sulfoximines are more acidic. The whole 
unit is slightly more electron-withdrawing than the sulfone (if R3 is electron-withdrawing) 
and more so than the sulfoxide. The chemical shift of the a-protons resonates in the 
range of 8  3.0-3.5 depending on the nature of the N-substituents.98
Due to the chirality at both the sulfur atom and carbon atom, MSO has four isomers. 
The absolute configuration of the biologically active isomer was found to be S.S (Figure
1.5.3 Biological activities of sulfoximines
1.5.3.1 Methionine sulfoximine (MSO)
MSO was identified as a convulsant and an irreversible inhibitor of glutamine 
synthetase (GS, EC 6.3.1.2)." Glutamine (Gin) is a major nitrogen source in 
amino-acid biosynthesis and GS catalyses the formation of Gin from glutamate and 










Figure 14. The biologically active MSO has the absolute configuration of S,S.97
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Glutamate + NH4+ Glutamine + H+
ATP ADP + Pi
Scheme 8. Glutamine synthetase-catalysed conversion of glutamate to glutamine.34
Ronzio and Meister first investigated the mechanism of inhibition of GS by MSO in 
1968 and revealed that the irreversible inhibition of GS by MSO is associated with its 
phosphorylation by ATP at the sulfoximine nitrogen and the tight binding of this 
phosphorylated derivative." They confirmed that MSO adopts a conformation similar to 
that proposed for L-glutamate and thus can bind to both the glutamate- and 
ammonia-binding sites as a bifunctional reagent. Subsequent data by Ronzio and 
Meister identified the following properties of MSO:100-103
i. Only one of the four isomers, (S,S)-MSO, is phosphorylated by GS and 
produces irreversible inhibition. Furthermore, the tetrahedral nature of 
(S,S)-MSO is closely related to the tetrahedral intermediate formed in 
GS-catalysed Gin synthesis;
ii. The same isomer that inhibits GS is also responsible for the convulsant 
effect; administered MSO was found to cause swelling of nerve endings and 
loss of synaptic vesicles especially of the noncholinergic types.
Following on this body of evidence, Richman et al. documented another activity of 
MSO.104 A different enzyme is also involved in the utilisation of glutamate: y-glutamyl- 
cysteine synthetase (y-GCS, EC 6.3.2.2), which catalyses the first step in the synthesis 
of glutathione (y-GluCysGly, GSH), a highly important tripeptide (vide infra, Section 
1.5.4.2). An amide linkage is formed between 4he y-carboxyl group of glutamate and 
the amino group of cysteine in the presence of ATP. Subsequent condensation with 
glycine, catalysed by the enzyme glutathione synthetase, gives rise to glutathione 
(Scheme 9) .34
glutamate y-GluCys ^ 2 2 * -  y-GluCysGly (GSH)
ATP ADP + Pi ATP ADP + Pi
Scheme 9. y-Glutamylcysteine synthetase (y-GCS) catalyses the first step of the synthesis of 
glutathione.34
Both of these reactions involve a y-glutamyl intermediate 26 (vide infra, Figure 15) and 
it was this consideration that led Richman et al. to examine the effect of MSO on
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y-GCS.104 They found that MSO inhibits y-GCS in a similar fashion, i.e. it involves the 
formation of a phosphorylated derivative (ATP) at the sulfoximine nitrogen (29, Figure 
15). However, MSO phosphate 29 binds more tightly to the active site of GS than 
y-GCS, and the same isomer, i.e. (S,S)-MSO that inhibits GS, also inhibits y-GCS. It is 
interesting to note that MSO-induced convulsions were shown to associate with 
inhibition of GS, not of y-GCS.
Subsequent structural studies by Griffith and Meister revealed that, by replacing the 
methyl group of MSO with other alkyl groups (ethyl or propyl), the inhibition of GS 
decreases but not that of y-GCS.105 Computer mapping of the active site of GS 
indicated that the methyl group of MSO binds to the ammonia-binding site 28 in the 
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Methionine sulfoximine phosphate 29
Figure 15. Diagrammatic representation of substrate- and inhibitor-bound active sites of y-GCS and GS. 
S-methyl of MSO occupies the ammoium ion site 28.106 Therefore, substituting the methyl group with 
bulkier alkyls diminishes the affinity for GS (smaller binding site) but not for y-GCS (large binding site for 
cysteine 27).
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1.5.3.2 Buthionine sulfoximine (BSO)
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A series of MSO analogues were studied for their inhibitory activity of y-GCS based on 
the structural information above.107 The most potent is the butyl derivative, buthionine 
sulfoximine (BSO, 30, vide infra, Figure 16). The active isomer, (S,S)-BSO, inhibited 
y-GCS 2 0  times more effectively than the propyl derivative, prothionine sulfoximine, 
and at least 1 0 0  times more effectively than MSO. Hence, it was confirmed that bulky 
substituents at the sulfoximine sulfur affect the selectivity and affinity for GS and
Figure 16. 2S,5S-Buthionine sulfoximine (BSO, 30), the most potent inhibitor of y-GCS.107,108
More recent evidence suggested that both MSO and BSO inhibit y-GCS by serving as a 
tetrahedral intermediate or transition-state analogue formed in the reaction of 
enzyme-bound y-glutamyl phosphate with cysteine (Scheme 1 0 ).109
Scheme 10. Proposed mechanisms of the y-GCS-catalysed reaction, with the initial formation of 
y-glutamylphosphate 26, followed by nucleophilic attack of cysteine via a tetrahedral intermediate 31.109
1.5.4 Pharmaceutical applications of sulfoximines
1.5.4.1 Glutamine (Gin)
Gin is the most abundant amino acid in the body, with its primary source in the skeletal 
muscle, from where it is released into the bloodstream and transported to various 
target organs and cells such as kidney, intestine, liver, heart, neurons, lymphocytes, 
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large variety of cellular reactions and it is an important fuel in cell functions. A high rate 
of glutamine uptake is characteristic of rapidly dividing cells and in the absence of Gin, 
tissues cells cannot grow.111 Many studies have been performed to study the various 
functions of Gin and the main features are summarised in Table 3 .110-111
Activity Mechanism of action
Cell metabolism and 
proliferation
Cellular fuel: precursor of glucose; nitrogen source for urea synthesis; 
carbon source for lipid synthesis 
Induces cell swelling in hepatocytes
Precursor of amino acids, peptides, proteins, purines and pyrimidines, 
and thus of nucleic acids and nucleotides -  regulates DNA and protein 
synthesis
Cell defence and repair
Immune function
Enhancer of heat shock proteins (HSP), which are important in cellular 
survival and endurance of physiological stresses.
Inhibits nitric oxide synthesis in vivo in rats; protects cells from stress 
response and prevents organ injury
Glutamate source for glutathione (GSH) synthesis via the y-glutamyl 
cycle (vide infra, Scheme 11) -  GSH is a major determinant in redox 
status and a key cellular antioxidant (vide infra, Section 1.5.4.2). 
Protects leukocytes against apoptosis by upregulating Bcl-2 
(anti-apoptotic) and downregulating Bax and Bcl-X* (pro-apoptotic) 
expression; prevents activation of caspases-3 and -8  in enterocytes
Source for cytokine production (e.g. TNF-a, IL-1p and IL-6 )
Oxidative response -  increases production of superoxide anion (O2") 
by NADPH oxidase in neutrophils
Table 3. Main functions of the multifaceted amino-acid, glutamine (Gin) .110111
GS catalyses the ATP-dependent synthesis of Gin from glutamate and ammonia. It is 
found in all organisms and contributes to ammonia detoxification and, in neural tissues, 
the recycling of the neurotransmitter glutamate via localisation of the enzyme to the 
cytoplasm of glial cells. There are three types of GS: GS-I is found mostly in 
prokaryotes, GS-II is located mostly in eukaryotes and GS-III, also found in 
prokaryotes.112 GS-I is the most characterised and the structure is determined to be a 
dodecamer, with each monomer containing ~470 residues. There are two domains 
within a monomer, the smaller N-terminal domain and the larger C-terminal domain, 
with the latter holding most of the active site residues. Two metal ions (Mg2+ or Mn2+) 
present in each active site are crucial to the enzymatic activity.112 The structure of the
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smaller eukaryotic GS-II (~370 residues) has just been studied from the plant 
Phaseolus vulgaris and found to be an octamer with four active sites. It binds to eight 
ATP molecules but only four molecules of MSO.112
1.5.4.2 Glutathione (GSH)
GSH is present in most mammalian and many prokaryotic cells and is the most 
abundant intracellular thiol (0.1-10 mM).113 It can be present as a reduced form (GSH) 
and an oxidised form, glutathione disulfide (GSSG). GSH is kept in its reduced form by 
the NADPH-dependent GSSG reductase intracellularly, and, under physiological 
conditions, the concentration of the reduced form is 10-100 fold higher than the 
oxidised form.114 When cells are subjected to oxidative stress, the ratio of GSH/GSSG 
is decreased with a raised concentration of GSSG or depleted GSH levels and this 
ratio is important in relation to cell death.111
The first step in the synthesis of GSH is catalysed by y-GCS in the y-glutamyl cycle 
(Scheme 11).113 The E. coli y-GCS has been cloned and sequenced and found to be a 
single polypeptide chain; the rat kidney enzyme was the first mammalian form to be 
purified and investigated and was found to be highly homologous to the human 
enzyme.113 It is a heterodimer with two subunits. The heavy 73-KDa subunit is 
catalytically active and contains the site of GSH feedback inhibition. The lighter 31-KDa 
subunit has no catalytic activity but exhibits a regulatory effect on the heavier subunit
when they are co-expressed. 115


















5-oxoproline —  5-oxoprolinase — ► glutamate
Scheme 11. Glutathione (GSH) synthesis -  the y-glutamyl cycle.113
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Besides its role as a redox buffer, GSH is involved in the metabolism and maintenance 
of the thiol moieties of proteins and low molecular weight compounds such as cysteine. 
GSH is a cellular antioxidant, and detoxification is achieved by reacting with toxic 
exogenous or endogenous compounds and forming GSH conjugates.114
1.5.4.3 Clinical aspects in cancer
It is clear that both Gin and GSH play important roles in cell proliferation, function and 
death. Gin mainly contributes to tumour growth and cell proliferation, being a precursor 
in nucleotide and nucleic acid synthesis and a fuel source for cells, along with its role in 
apoptosis. However, the most striking feature among the many functions of Gin is its 
relation to GSH biosynthesis, the latter being a valuable redox factor in oxidative stress 
and tumour growth. GSH is essential in protecting cells from oxidative damage and the 
detoxifying activity has been implicated in resistance of tumours against effects of 
chemotherapeutic agents that act by producing oxygen radicals and/or by causing 
oxidative stress and eventual apoptosis. The role of GSH has been studied extensively, 
and many data demonstrate that it is a good target for cancer and that inhibition by 
BSO may be beneficial (vide infra, Scheme 1 2 ).
Levels of GSH were found to increase in many drug-resistant tumours and tumour cell 
lines.116 Intracellular inactivation of cisplatin has been proposed as a mechanism of 
cisplatin resistance. Rudin et al. investigated this hypothesis in MCF-7 breast cancer 
cell lines transfected with the apoptotic inhibitor Bcl-2.117 Overexpression of Bcl-2 has 
been shown to increase cisplatin resistance by antagonising the apoptotioinduced 
production of reactive oxygen species (ROS). The investigators found that the 
Bcl-2/MCF-7 cells had a nearly 3-fold increase in cellular GSH levels and an increased 
cisplatin resistance. Treatment with BSO reduced glutathione levels and prevented 
Bd-2-mediated cisplatin resistance without affecting Bcl-2 expression. Therefore, 
inhibition of glutathione in Bd-2-positive tumours that may prove to be a potential anti- 
cancer target.
Calvert et al. reported that L1210 murine leukaemia cells with melphalan resistance 
had higher GSH levels than normal cells and that drug sensitivity was restored 
completely by decreasing GSH concentrations.116 Anderson and Reynolds observed a 
similar synergistic cytotoxicity of BSO and melphalan in neuroblastoma cell lines.116 
Phase I dinical trials at a later stage by Bailey documented an increase in myeio- 
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Scheme 12. Roles of MSO and BSO in Gin and GSH synthesis and metabolism. (PAG -  phosphate- 
activated glutaminase)
Subsequent investigations of the effect of GSH with other chemotherapeutic agents, 
such as the bioreductive agent tirapazamine, mitomycin C and doxorubicin all 
demonstrated the relation of drug resistance and treatment failure to GSH levels, 
reinforcing the role of BSO and other glutathione inhibitors in anti-cancer therapy.120'122 
A recent publication by Chew et al. highlighted the role of GSH in modulating apoptosis 
induced by a novel series of heteroaromatic-substituted hydroxycyclohexadienones 
(quinols) synthesised in their laboratory.123 These compounds exhibited in vitro 
anti-tumour activity by apoptosis against a variety of cancer cell lines and in vivo 
anti-tumour activity in different tumour xenografts. Increased GSH levels were 
observed upon treatment with the anti-tumour quinols, indicating the recruitment of 
GSH in response to protect cells from oxidative damage caused by the quinols. 
Furthermore, the cells were found to be 6-10 times more sensitive to the compounds 
when GSH levels were depleted by administration of BSO.
Recent studies also pointed to the inhibition of GS being clinically relevant in the 
treatment of Mycobacterium tuberculosis infections.124 GS released by mycobacteria is 
involved in the formation of the pathogen’s cell wall and GS inhibitors may be useful 
antibacterials.
Interestingly, the sulfoximine moiety has itself been applied in the design of 
transition-state analogue inhibitors of E. coli y-GCS. The compound synthesised by 
Hiratake et al. (32, vide infra, Figure 17) has a carboxyl function at the p-carbon to the
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tetrahedral central heteroatom mimicking the carboxyl group of cysteine in the 
transition state (31, Figure 17).125
The sulfoximine analogue 32 (Figure 17) was found to be a potent ATP-dependent 
inactivator of y-GCS with an overall affinity (K, = 99 nM) of a thousand times greater 
than that of BSO (K, = 49 pM). The E. coli enzyme was inactivated only by the 
(R)-sulfoximine, not (S)-sulfoximine. The latter demonstrated a reversible inhibitory 
effect with a K, of 12 pM. It was concluded that the two diastereoisomers may be 
interesting species-selective drug targets based on the geometry of individual enzyme 
active sites and the required stereochemistry.125
1.5.4.4 Sulfoximine pseudopeptides
The use of peptides in pharmaceutical applications can be affected by their poor 
bioavailability and rapid degradation by peptidases. In recent years, pseudopeptides 
have been extensively studied in order to overcome these problems. However, it is 
important to bear in mind that these modified peptides must possess the same specific 
activity of the original peptides. Several publications by Bolm et al. reported the 
synthesis of a variety of pseudopeptides bearing a sulfoximine group as chiral 
backbone-modifying element; the stability of these peptidomimetics towards proteinase 
K was investigated and they displayed enhanced bond stability (bond A) and reduced 
reactivity (bond B) towards enzymatic hydrolysis (Figure IS ) .126-128
t
SH
Transition state, 31 32
Figure 17. Sulfoximine transition-state analogue of y-GCS, 32.125
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Figure 18. Comparison of sulfoximine pseudopeptides 33 and a p-amino acid 34 .126'128
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1.5.4.5 Miscellaneous applications
Apart from the targets discussed above, the chemically stable sulfoximines have been 
candidates for the design of transition state or intermediate analogues. Back in the 
1990’s Mock et al. had designed sulfoximine transition-state-analogue inhibitors for 
carboxypeptidase A.129,130 The sulfoximine nitrogen atom coordinates strongly with a 
Zn2+ ion, mimicking the transition-state carbonyl oxygen atom. The stable tetrahedral 
configuration correlates to the preferred geometry of active site binding and it replaces 
the enzymatically-unstable amide linkage. The same structural features also prompted 
Levenson and Meyer to design transition-state analogues as potential dihydroorotase 
inhibitors, with the sulfoximine group mimicking the presumed tetrahedral transition 
state in the enzymatic reaction.131
1.5.5 Drug molecules containing chiral sulfur atoms
Drug enantiomers often have different physiological actions and pharmaceutical 
properties. A good example of pharmaceutical agents containing chiral sulfur atoms is 
the successful sulfoxide drug, omeprazole (Losec®, 35, Figure 19), a proton-pump 
inhibitor used for the treatment of gastrointestinal diseases such as peptic ulcers and 
gastro-oesophageal reflux disease.132 It is formulated as a racemate and both isomers 
undergo biotransformation to the active metabolite.132 However, omeprazole has 
variable pharmacokinetics and patients with a cytochrome P450 deficiency require 
higher doses.132 A drug with improved bioavailability was sought and the S-enantiomer 
of omeprazole was synthesised, with enhanced bioavailability and potency. 
Esomeprazole (Nexium® 36, Figure 19) has replaced omeprazole as the “golden” drug 
for gastro-oesophageal reflux disease.
Me OMe Me OMe
Omeprazole, 35 Esomeprazole, 36
Figure 19. The best-selling sulfoxide drug, omeprazole 35, and its chiral successor esomeprazole 36.132
Despite the versatile chemistry and the many successful sulfoxide and sulfonamide 
drugs, relatively little information is available on the use of sulfoximines in medicinal
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applications, with BSO being the only candidate in clinical trials. Therefore, the 
utilisation of sulfoximines in drug design is innovative.
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2.1 Aim
Chapter 2 Aims and Objectives
The principal aim of this project is to develop a new approach to inhibition of enzymes, 
which use ribonucleosides and 2 -deoxyribosides as substrates and which are important 
in cancer.
2.2 Research proposal
The specific objectives are:
1. To identify innovative analogues of 2-deoxyribonucleosides and 2-deoxyribose 
in the design and development of novel enzyme inhibitors and anti-angiogenic 
agents.
2. To synthesise mimics of nucleosides and 2-deoxynucleosides in which the 
anomeric carbon has been replaced by the tetrahedral sulfoximine.
3. To synthesise mimics of 2 -deoxyribose containing sulfoximines in this position 
as anti-angiogenic agents.
There is a relatively small amount of research on the application of sulfoximines in drug 
design and their application in the design of ribose mimics has not been previously 
reported. Most published inhibitors of TP, PARP-1 and IMPDH have a pharmacophore 
based on the relevant bases of nucleosides and 2-deoxynucleosides. For example, 
uracil analogues have been studied for their inhibitory activity to TP; tiazofurin and 
selenazofurin are good IMPDH inhibitors where the nicotinamide of NAD* is replaced 
by thiazole-4-carboxamide and selenazole-4-carboxamide, respectively; a great deal of 
attention has been focussed on the benzamide analogues as PARP-1 inhibitors. There 
is very little known, to date, on the direct modification of the substrate ribosyl moiety for 
these enzyme targets.
Structures of the proposed target compounds are shown in Figure 2 0  (vide infra). 
Compounds 37 and 38 are designed as inhibitors of TP. Target 37 is a
2-deoxy-D-ribose-1a-phosphate analogue with a carboxylate anion located in the 
phosphate site. The anomeric carbon is replaced by the sulfoximine sulfor atom and 
with the basic nitrogen mimicking the ribosyl oxygen. In 38, the anomeric carbon is also 
replaced by the tetrahedral sulfoximine group; since it is not known which of the 
interconverting anomers of 2 -deoxyribose binds to its receptor, both diastereoisomers 
38a and 38b would be synthesised.
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Compounds 39 and 40 are mimics of nicotinamide riboside. As the parent compound, 
these are designed as PARP-1 inhibitors and, after conversion to the corresponding 
dinucleotide with adenosine, are expected to also be IMPDH inhibitors. This conversion 
may be metabolic in a similar fashion as seen with tiazofurin and selenazofurin, or, for 
the purpose of biological evaluation for enzyme inhibition, synthetic. Target 39 is a 
strict analogue of benzamide 2 -deoxyriboside with the sulfoximine replacing the 
anomeric carbon. Target 40 is designed as a transition-state nucleoside mimic for 
PARP-1 inhibition. The first step in the mechanism of PARP-1 is stretching of the C-N  
bond between the anomeric carbon of the ribose and the nicotinamide. This stretched 





38a: R1 -  NH, R2 » O 
38b: R1 = O, R2 = NH
2-Deoxy-D-ribose
conh 2 c o n h 2
OH OH
39 Benzamide 2-deoxyriboside
c o n h 2
ADPO.CONH2
40 PARP-1 transition state
Figure 20. Structures of target molecules.
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Synthesis of a benzamide 2-deoxyriboside
analogue
Chapter 3 Results and Discussion I
3.1 Route I: addition of a three-carbon unit to a one-carbon unit
3.1.1 Retrosynthesis
The first target compound investigated was the benzamide 2-deoxyriboside analogue 
39, designed as a potential PARP-1 inhibitor and, after conversion to the corresponding 
dinucleotide with adenosine, as an IMPDH inhibitor. The tetrahedral sulfoximine group 
replaces the anomeric carbon, with the nitrogen mimicking ribosyl oxygen. The 
configuration of the sulfur atom would be established independently to the other two 
chiral centres of the five-membered ring. In the design of synthetic routes, efficiency 
and utilisation of reliable reaction types that will allow good stereocontrol are key 
issues.
The retrosynthetic analysis for target 39 is illustrated in Scheme 13 (vide infra). 
Disconnection at the C-N bond of the ribose ring, i.e. the ring-opening, focuses on the 
formation of an intramolecular cyciisation between the amine and the secondary 
alcohol. The convergent Mitsunobu reaction is reasonable, as it is a well-documented 
procedure; the conditions are mild and the ring-closure will proceed with inversion of 
configuration at the electrophilic centre. Synthesis of 39 from parent compound 41 
requires removal of the hydroxy protecting groups and a functional group 
interconversion (FGI). A nitrile group is a potential starting functional group for an 
amide since nitriles are relatively stable and can be hydrated to amides.
Some fine adjustment of protecting groups of both nitrogen and oxygen centres led to 
the intermediate 43. Disconnection at the C-C bond of this aldol-like product led to two 
starting materials: a mefa-substituted aromatic sulfoximine bearing a nitrogen 
protecting group and chirality at the sulfur atom 45 (one-carbon unit) and 
S-2,2-dimethyl-1,3-dioxolane-4-carboxaldehyde 44 (three-carbon unit). The synthesis 
of 44 is well-reported, highly efficient and reliable (vide infra, Scheme 26). Strong base 
(e.g. butyl lithium) will form a nucleophilic S-methyl anion of 45 and addition to the 
aldehyde 44 should proceed with diastereoselectivity, since stereocontrol is governed 
by the chirality of 44. Therefore, the four-carbon addition product 43 would have all 
three chiral centres with the required configuration. The N-protecting group may play a 
role in diastereoselectivity, thus two protecting groups (Boc, SiMe3) will be investigated 
to test the hypothesis.
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Therefore, this synthetic sequence is convergent: two of the chiral centres are provided 
by separate compounds (chiral sulfoximine and chiral aldehyde), while the third is 
generated in a diastereoselective addition to a chiral aldehyde (C-C bond formation).
.CON He
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Scheme 13. Retrosynthesis of target compound 39, an analogue of benzamide 2-deoxyriboside. (PG = 
protecting group)
It was decided that a model reaction with racemic S-methyl-S-phenylsulfoximine would 
first be explored to clarify any synthetic difficulties. An aromatic aldehyde would be
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used to probe the stereocontrol of different N-protecting groups in the critical C-C  
bond-forming step. Ultimately, enantioselective synthesis of the required configuration 
at the sulfur of a 3-substituted S-methyl-S-phenylsulfoximine would be pursued either 
via a chiral sulfoxidation or resolution of a racemate using (+)-1 0 -camphorsulfonic acid 
(CSA) . 133,134
3.1.2 Synthesis of S-methyl-S-phenylsulfoximine
In general, sulfoximines can be prepared by three strategies: nucleophilic substitution 
of sulfonimidoyl halides, oxidation of sulfilimines and imination of sulfoxides (Scheme 
14). The latter is the most widely reported and utilised method.135
o
0 oxidation [I imination 9




X = Cl, Br
Scheme 14. Routes of synthesis of sulfoximines.
Armed with this knowledge, the first step of the model reaction would be to synthesise 
(±)-S-methyl-S-phenylsulfoxide 47 (vide infra, Scheme 15). This is followed by 
imination to give the corresponding sulfoximine (50, vide infra, Scheme 15). Although 
both compounds, including the individual enantiomers, are commercially available, it 
was decided that the literature methods on their syntheses would be studied in order to 
determine the most efficient synthetic route. The acidic NH proton of 50 can then be 
easily deprotonated and a suitable protecting group will be introduced to form the 
model sulfoximine.
3.1.2.1 Sulfoxidation
The most common reagents for the oxidation of sulfides to sulfoxides are mefa-chloro- 
peroxybenzoic acid (mCPBA) ,136 sodium periodate and hydrogen peroxide.137,138 
However, their use is often complicated with over-oxidation of sulfoxides to sulfones. 
Despite careful monitoring of reaction time, temperature and amount of oxidants, it
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remains a common problem in almost all oxidation conditions and column 
chromatography is often required for separating sulfoxides from the corresponding 
sulfones.
The first step of the model reaction involved an investigation into the efficiency and 
reliability of the above three oxidants for comparative purposes. Thioanisole (46, vide 
infra, Scheme 15), which is commercially available and cheap, was treated with 
mCPBA in dichloromethane (DCM), sodium periodate in MeOH/water, and the 
recently-reported system using 35% aq. hydrogen peroxide and phenol.138 The use of 
phenol as a solvent with hydrogen peroxide is particularly interesting because the 
system is thought to minimise the formation of sulfones from sulfoxides. Xu et al. 
proposed that an interaction between phenol and H20 2 increases the electrophilicity of 
peroxy oxygen atom and assists the leaving group (H20) in departing.138 Moreover, the 
strong hydrogen bond formed between the OH of phenol and H20 2 decreases the 





















Scheme 15. Synthesis of the model racemic N-protected S-methyl-S-phenylsulfoximine. Both the N-Boc 
and N-SiMe3 compounds would be investigated in the subsequent aldehyde addition reaction. Reagents 
and conditions: (i) NalO4, MeOH, H2O; (ii) MSH 49, DCM; (iii) Et2NSiMe3, MeCN, 65 °C; (iv) BocN3 53, 
FeCI2, DCM, 0°C; (v) TFA, DCM, 0°C; (vi) Na2C 0 3, MeOH.
This comparative study found that Nal04 is superior to mCPBA and H20 2 in oxidising 
46 to the corresponding sulfoxide (±)-47 in terms of yield, lack of over-oxidation and 
ease of handling (vide infra, Table 4). The use of the H^^phenol system is limited to
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small-scale reactions, due to the relatively large amount of phenol required and its 
subsequent neutralisation using NaOH. Hence Nal04 was the preferred reagent.
Oxidant Reaction conditions Work-up Over-oxidation Yield
(%)
mCPBA136 1 mol equiv., DCM, 0°C Wash with N aH C 03 Yes 92
N a l04137 1 mol equiv., MeOH, RT Filtration No 93
h 2o 2138 2 mol equiv., 12 mol Excess H20 2 quenched with No 92
equiv. phenol, RT Na2S0 3 i phenol neutralised
with NaOH.
Table 4. Oxidative conditions applied for the conversation of thioanisole 46 to racemic S-methyl-S-phenyl- 
sulfoxide (±)-47.
3.1.2.2 Non-catalytic imination
With racemic S-methyl-S-phenylsulfoxide [(±)-47, vide infra, Scheme 15] in hand, 
attention was turned to explore the various imination strategies available. A large pool 
of data on the imination of sulfoxides has been reported, the oldest method being the 
hydrazoic acid (HN3) route.139 Sulfoxides are treated with NaN3 and concentrated 
H2S04, then basified to give the free N-H sulfoximine. However, concerns over the 
toxic and explosive nature of HN3 has diminished its utilisation since being discovered 
in the 1950’s. Besides the hazardous properties of HN3, another disadvantage is that, 
under such acidic conditions, racemisation may occur at the sulfur centre of chiral 
sulfoxides and thus it is not applicable in synthesising enantiomerically pure 
sulfoximines.
The explosive O-mesitylenesulfonylhydroxylamine (MSH, 49, vide infra, Scheme 16) 
was discovered to be a useful electrophilic sulfoxide-iminating agent by Tamura etal. in 
1972.140 Johnson et al. subsequently reported the synthesis of chiral sulfoximines from 
chiral sulfoxides using MSH and retention of configuration at the sulfur atom was 
observed.141 MSH 49 is normally prepared by acid-hydrolysis of ethyl 0-(mesitylene- 
sulfonyl)acetohydroxamate 48 with 70% aq. perchloric acid in dioxane at 0°C (vide 
infra, Scheme 16).142 A more recent example used 50% aq. H2S04 in Et20  and tri- 
fluoroacetic acid has also been used.143 However, in the present work, hydrolysis of 48 
could not be achieved in numerous attempts using different acids at various 
temperatures. The reason for encountering such difficulty in synthesising this 
widely-reported compound remains unknown.
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Conditions
Scheme 16. Attempted synthesis of MSH 49. Reagents and conditions: (i) HCIO4, 1,4-dioxane, 0°C; (ii) 
HCIO4, THF, 0°C; OH) TFA, THF, O'C; (iv) TFA, THF, 45°C; (v) 50% aq. H2SO4, Et20.
To avoid the use of toxic and potentially explosive traditional imination agents such as 
HN3 and MSH, efforts have been concentrated on the search for alternative methods. 
An interesting electrochemical imination was recently developed by Siu et al. using 
N-aminophthalimide as a nitrene source.144 The reaction proceeds with retention of 
configuration and no racemisation occurred during the nitrene transfer. Furthermore, 
the group solved the “chemically impossible” removal of the N-phthalimido group by an 
electrochemical reductive N-N bond cleavage.
Krasnova et al. also studied the use of N-aminophthalimide in imination of sulfoxides.145 
lodosobenzene diacetate [Phl(OAc)2] was found to promote nitrene formation by 
forming a reactive iminoiodane (vide infra, Figure 21) and a number of sulfoxides were 
converted to the corresponding sulfoximines in good yields.
3.1.2.3 Metal-catalysed imination
Recent interest focuses on metal-catalysed nitrene-transfer reactions to sulfoxides and 
these are summarised in Table 5 (vide infra). They often proceed under relatively mild 
conditions with retention of configuration at sulfur.
Muller et al. first reported the use of the iminoiodane [N-0>-toluenesulfonyl)imino]- 
phenyliodinane (Phl=NTs) as a reagent for imination of racemic and chiral sulfoxides in 
1998 (vide infra, entry 1, Table 5) . 146 Copper(l) triflate was used as a catalyst and a 
range of N-tosylsulfoximines were afforded in high yield, with retention of configuration 
at the sulfur atom.
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metal-catalysed ®
-------------------------------------------- S
imination Rr ||v R2
NR3
Entry Metal catalyst Nitrene source R1 R2 R3 Yield (%)
1 CuOTf 
(5 mol % )148
Phl=NTs Ph Me Ts 84
2 CuPFe 
(5 mol % )147
Phl=N-X  
X = Ts, Ns, Ses
Ph Me Ts, Ns, Ses 59-69
3 Cu(OTf)2 
(10  mol % )148
PhNNTs Et p-tolyl Ts 96
4 AgNOs 
(8  mol % )149
X-NH2, Phl(OAc)2 
X = Ns, Ts, Ses
Ph Me Ns, Ts, Ses 79-83
5 Fe(acac)3 
(5 mol % )150
X-NH2, P hl=0  
X = Ns, Ts, Ses
Ph Me Ns, Ts, Ses 66-96
6 Rh2(OAc)4 Phl=NNs Ph Me Ns 93
(2.5 mol % )151 X-NH2lPhl(OAc)2 
X = COCFa, Ns, 
Ms
Ph Me COCF3, Ns, Ms 79-86
7 FeCI2 
(50 mol % )152-153
BocNs Ph Me Boc 74
Table 5. Metal-catalysed imination methods of sulfoxides (Abbreviations: Tf = trifluoromethanesulfonyl; Ts 
= p-toluenesulfonyl; Ns = p-nitrophenylsulfonyl; Ses = trimethylsilylethylsulfonyl; p-tolyl = p-methylphenyl; 
Ms = methanesulfonyl; acac = acetylacetonate).
Other copper catalysts such as CuPF6 and Cu(OTf)2were investigated (Table 5, entries 
2 and 3 ) .147’148 Furthermore, since most N-Ts sulfoximines are difficult to convert to the 
free amines, iminoiodanes with other protecting groups such as nosyl- (Ns, p-nitro- 
phenylsulfonyl) and Ses- (trimethylsilylethylsulfonyl) protected sulfoximines were 
studied. Cren et al. found that MSH-resistant sulfoxide substrates could be successfully 
iminated to the corresponding N-protected sulfoximines in good yield and the group 
reported, for the first time, the efficient deprotection of N-Ns and N-Ses sulfoximines.147 
The Ns group could be removed using thiophenol and Cs2C03 in acetonitrile in 59% 
yield; removal of the Ses group proceeded smoothly with TBAF in THF at 50°C in 8 6 % 
yield.
Iminoiodanes are hypervalent iodine (III) reagents first described about thirty years ago 
and have since been recognised as useful nitrene precursors (vide infra, Figure 21 ) .154
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However, their preparations are often tedious and irreproducible (usually synthesised 
from the corresponding amide and iodosobenzene diacetate with potassium hydroxide 
in methanol). Recent advances in the preparation in situ allow more convenient one-pot 
procedures {vide infra, Scheme 24).
R = Ts, Ns, Ses
0  R 
Iminoiodanes
Figure 21. Types of N-substituted iminoiodanes.
Several independent reports by the Bolm Group described the use of silver (AgN03) , 149 
iron [Fe(acac)3] and rhodium [Rh2(OAc)4] salts with /n-s/fu-formed iminoiodanes [X-NH2> 
Phl(OAc)2/Phl=0] in nitrene transfer reactions and this provides additional information 
on the type of metal catalysts compatible with the system {vide supra, entries 4-6, 
Table 5) .150,151 The group synthesised a range of sulfoximines bearing new protecting 
groups such as N-mesyl and N-trifluoroacetyl groups. It is noteworthy that the same 
group also described, in a subsequent publication, a metal-free imination method 
during investigation of silver catalysts.155 They found that imination also proceeds 
without AgN03 and that the nitrogen-transfer agent is formed in situ from NsNH2 and 
Phl(OAc)2. However, the high temperature (reflux in acetonitrile over a period of 16 h) 
required for this metal-free imination contributes to partial racemisation of 
enantiomerically pure (S)-S-methyl-S-phenylsutfoxide, making this method unsuitable 
for asymmetric synthesis.
However, despite the positive results described above, the use of Ns or Ses in 
sulfoximination is not without limitations. A simpler process involving a nitrene source 
that is easy to synthesise, with the introduction of a versatile N-protecting group, is 
essential to reduce the number of synthetic steps.
Bach et al. investigated the role of ferf-butoxycarbonyl azide (BocN3, 53) as a 
nitrene-transfer reagent with the aid of FeCI2 as a catalyst {vide supra, entry 7, Table 
152,153 gQC group jS a universally known protecting group and the deprotection 
procedure is well documented.152,153 N-Boo-protected sulfoxides were synthesised; 
enantiomerically pure (R)-(+)-S-methyl-S-phenylsulfoxide was converted to 
(/?)-(-)-S-methyl-S-phenylsulfoximine with good stereoselectivity (85% ee).
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With this procedure in mind, BocN3 53 was synthesised by diazotisation of ferf-butyl 
carbazate 52 with sodium nitrite in acetic acid and water (vide infra, Scheme 17).156 
Since BocN3 is explosive, it was treated immediately, as a concentrated solution in 
DCM, with sulfoxide 47. N-Boc sulfoximine [(±)-54, vide supra, Scheme 15] was 
synthesised in moderate yield (53%).
Scheme 17. Synthesis of B0CN3 53. Reagents and conditions: (i) N aN 02, H2O, AcOH, DCM, 0°C.
It was postulated that an intermediate Fe(IV)-nitrene complex (Scheme 18), formed 
once FeCI2 reacts with BocN3 53, acts as the nitrene-transfer reagent. Upon 
nucleophilic attack by a sulfoxide, the corresponding N-Boc sulfoximine is formed.157
Scheme 18. Proposed mechanism of BocNs/FeCh nitrene transfer reaction by Bach et a/.157
3.1.3 Addition of model methylthio carbanions to aldehydes
Having obtained the N-Boc sulfoximine (±)-54, attention was turned to study the 
influence of N-protecting groups on the diastereoselective addition of sulfoximine 
carbanions to achiral aldehydes. N-protecting groups are required to prevent anion 
formation at the nitrogen instead of the S-methyl carbon atom. Hwang et al. reported 
that,158 with the trimethylsilyl (TMSi) group, this type of sulfoximine anion adds to 
aldehydes with some diastereoselectivity, which was thought to be caused by the size 
of the N-protecting group, with the use of larger N-silyl groups enhancing 
diastereoselectivity. Therefore, this diastereoselectivity is driven by the configuration at 
the sulfur of the sulfoximines. Hwang et al. reasoned that TMSi groups are sterically 
bulky and lack metal-coordinating properties.158 However, the electron-withdrawing Boc 
group stabilises the carbanion formed with possible metal-coordinating activities.
52 53
R1 T  R2 
NBoc
BocN3 Fe(IV)-nitrene complex N-Boc sulfoximine
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The use of a Boc group was initially explored by treating (±)-54 with benzaldehyde and 
n-BuLi. However, after a series of attempts the reaction failed to proceed, leading only 
to the discovery of starting materials. Therefore, the more potent tert-BuU was used 
instead and the reaction gave a mixture of three products (Scheme 19). The least poiar 
product was separated chromatographically and was characterised as the alkene 
(±)-56. This condensation product was confirmed as the E isomer by the 1H NMR 
spectrum which showed a coupling constant J = 15.3 Hz between the alkene protons. 
The other two products (formed in 62% total yield) were inseparable. 1H NMR showed 
that these were the diastereomeric alcohols (±)-57a/b, formed in the ratio 7:1. Since 
they were afforded as a colourless oil, X-ray analysis was not possible. Therefore, a 
tentative assignment of the relative configuration was made on the basis of a NOESY 
spectrum of the mixture in CDCI3. The conformation of both diastereoisomers appears 
to contain an intramolecular hydrogen bond from the OH, giving six-membered rings in 
approximate chair conformations (vide infra, Figure 22a/b). In both (±)-57a/b, the C-Ph 
group is equatorial, as shown by the 3J = 9.9 Hz coupling between Hx and H*. The 
Heq-Hx coupling is as expected for the major isomer (3J = 2.0 Hz) but is slightly smaller 
in the minor isomer (3J =1.2 Hz). Interestingly, the couplings between OH and Hx 
follow the same pattern, with 3J = 2.0 Hz for the major isomer and 3J = 1.2 Hz for the 
minor isomer. These data point to a full chair for the major isomer and a slightly 
flattened chair for the minor.
Ph Ph Ph OH
A0  || Me O ^ M ^ ^ P h  +
NBoc NBoc NBoc H
(±)-54 (±M £)-56 (±)-57a/b
3% 62%
Scheme 19. Diastereoselective addition of N-Boc S-methyl-S-phenylsulfoximine (±)-54 to benzaldehyde. 
Reagents and conditions: (i) t-BuU, PhCHO, THF, -7 8  °C.
Attention was then turned to study if the OH is hydrogen-bonded to the sulfoximine 
oxygen or to the sulfoximine nitrogen. Hwang et al. suggested that, in the 
corresponding molecule lacking the Boc group, the intramolecular hydrogen bonding 
occurs from OH to the basic nitrogen.158 Similarly, Hainz et al. showed hydrogen 
bonding from OH to sulfoximine nitrogen in a related structure in which the nitrogen 
earned a methyl group.159 In both cases, the basicity of the nitrogen is claimed to play a 
role. For the present diastereoisomers, it could be argued that the carbamate nitrogen 
is not basic and should not be capable of being a hydrogen-bond acceptor. Hence, two
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structures are possible for the major isomer, one with the nitrogen in-ring and one with 
the sulfoximine oxygen in-ring. The NOE connectivities from the S-Ph to Heq and Hx 
shown that the S-Ph must be axial in the major isomer; therefore the two possible 
structures 58a/b for this isomer are those shown in Figure 22b (vide infra). These 
structures are diastereomeric. There is a weak NOE between the 'Bu protons and H^; 
this is much more consistent with structure 58a with hydrogen bonding to the 
sulfoximine oxygen. These two arguments, the relative hydrogen-bond acceptor 
strengths and the NOE, point strongly to 58a being the structure of the major isomer, 
with relative configuration R,R. Thus the minor isomer 59a has relative configuration 
S,R, as borne out by NOE connectivities. This diastereoselectivity in the addition of the 
sulfoximine anion to the aldehyde is opposite to that seen by Hwang et al., who used 
TMSi protection at nitrogen, rather than Boc.158 The group reported that, with 
N-TMSi-S-methyl-S-phenylsulfoximine, the major diastereomeric alcohol has relative 
configuration S,R and the minor diastereoisomer having relative configuration S,S.
S-Ph 
ortho H
14 3 26 58 7
Figure 22a. 1H-1H NOESY spectrum of (±)-2-[N-(tert-butoxycarbonyl)-S-phenylsulfonimidoyl]-1-phenyl- 
ethanol 57a/b.
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58a (Hydrogen bonding to sulfoximine oxygen) 58b (Hydrogen bonding to sulfoximine nitrogen)
Figure 22b. 1H-1H NOESY spectrum assignment of 57a/b points strongly to the hydrogen-bonding 
conformations represented by structures 58a and 59a. Lack of NOEs between the ferf-butyl protons and 
Heq dismisses the presence of 58b. (Intramolecular hydrogen bonds -  blue; NOEs -  purple)
This piece of exciting data prompted further study of the comparative 
diastereoselectivity of different aromatic aldehydes with electron-withdrawing, 
electron-donating and heterocyclic properties. Four para-substituted aromatic 
aldehydes were chosen: 4-nitrobenzaldehyde, 4-methoxybenzaldehyde, 4-methyl- 
benzaldehyde and 5-nitro-thiophene-2-carbaldehyde and they were treated with the 
carbanion of the N-Boc sulfoximine (±)-54 under the same conditions as described with 
benzaldehyde (vide infra, Scheme 20). However, the expected addition reaction did not 
occur. Only the corresponding benzyl alcohols were recovered, complicated with a 
considerable loss of starting N-Boc sulfoximine. This suggests that the lithiation was 
not complete and that the residual base reduced the starting aldehydes. Reactions with 
4-nitrobenzaldehyde and 4-methoxybenzaldehyde proceeded in very low yield, making 
determination of diastereoselectivity impossible. Several attempts at extended lithiation 
times, use of sec-BuLi rather than fe/f-BuLi to avoid hydride donation and increased 
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Scheme 20. Attempted addition reactions of (±)-54 with para-substituted aromatic aldehydes. Reagents 
and conditions: (i) t-BuLi /  s-BuLi, aldehyde, THF, -78°C  to RT.
Attention was then turned to a comparative study on the N-SiMe3 group as described 
by Hwang et a/ .158,160 N-TMSi-S-methyl-S-phenylsulfoximine was prepared in two steps: 
removal of the Boc group of (±)-54 with trifluoroacetic acid (TFA) gave the trifluoro- 
acetate salt (±)-55, which was basified to give S-methyl-S-phenylsu!foximine (±)-50 
(vide supra, Scheme 15). Treatment with (trimethylsilyl)diethylamine furnished N-(tri- 
methylsilyl)-S-methyl-S-phenylsulfoximine (±)-51 in almost quantitative yield (vide 
supra, Scheme 15).160
Contrary to the results seen with the N-Boc compound (±)-54 and those reported by 
Hwang et al. ,158 addition of the corresponding anion of compound (±)-51 to 
benzaldehyde afforded only a complex mixture of unidentifiable products (Scheme 21).
Scheme 21. Attempted anion addition to benzaldehyde with the N-TMSi compound (±)-51 did not generate 
the desired products, the alkene (±)-60 and the diastereomeric alcohol (±)-61. Reagents and conditions: (i) 
t-BuU, PhCHO, THF, -78°C.
When the synthesis of (±)-54 was attempted on a larger scale, the target could only be 
obtained as an inseparable mixture (2:3) with BocNH2. As mentioned before, a key 
component in the iron-catalysed nitrene transfer by BocN3 is the reactive Fe(IV)-nitrene
Phi
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complex which is attacked by a sulfur nucleophile to form the corresponding 
sulfoximine. However, when it is attacked by Fe(ll), a p-imido Fe(lll) complex is formed; 
hydrolysis of the latter releases the amide BocNH2 (Scheme 22).157 Therefore, the 
presence of BocNH2 in the repeat synthesis of (±)-54 indicates two possibilities:
1. Inadequate amount of sulfoxide led to residual Fe(IV)-nitrene complex being 
hydrolysed.
2. Insolubility of FeCI2.
Scheme 22. BocNHb, a hydrolysed product of BocN3, is formed via the attack of the Fe(IV)-nitrene 
complex by Fe(ll).
Modifications of the synthetic method included increasing the sulfoxide concentration to 
five molar equivalents and by using pentane-2,4-dione to solubilise the Fe(ll) catalyst 
through complexation. Disappointingly, these changes only increased the ratio of 
product (±)-54 to BocNH2to 4:1. Different transition metal catalysts were also employed 
[CuCI, RuCI3, Rh2(OAc)4] but they did not improve the outcome.
Since BocNH2 was inseparable from (±)-54, it was decided that different protecting 
groups would be studied and, eventually, the N-Boc group would be introduced by a 
simple protection on a free NH sulfoximine.
(Fluoren-9-ylmethoxy)carbonyl azide (FmocN3, 63) is a known compound and readily 
available from the chloroformate 62 in one simple step (stirring with ice-cold NaN3 in 
acetone/water, vide infra, Scheme 23).161 Its application in a nitrene transfer to 
sulfoxides has not been reported previously. However, when sulfoxide (±)-47 was 
allowed to react with FmocN3, only FmocNH2 and starting sulfoxide were recovered 
(vide infra, Scheme 23).
Fe(IV)-nitrene complex p-imido Fe(lll) complex BocNH2
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Scheme 23. FmocN3 63 was synthesised from the chloroformate 62 in 83% yield; subsequent reaction 
with sulfoxide (±)-47 did not give the desired N-Fmoc sulfoximine (±)-64. Reagents and conditions: (i) 
NaN3, acetone, H20 , 0<C; (ii) 63, FeCh, DCM, 0°C.
The N-trifluoroacetyl (N-TFA) group was considered next as it is easily removed by 
nucleophiles (ammonia, sodium carbonate) to generate the free NH compounds. The 
rhodium-catalysed iminating method reported by Okamura et al. (vide supra, Table 5) 
is a simple one-pot system carried out under mild conditions.151 All the reagents are 
stable in air or moisture, thus requiring neither an inert atmosphere nor anhydrous 
solvents. The iminoiodane, N-(trifluoroacetyl)imino]phenyliodinane [(Phl=NCOCF3)], is 
formed in situ from trifluoroacetamide and iodosobenzene diacetate (Scheme 24). 
Acetic acid is generated as a by-product from iodosobenzene diacetate and it can 
reduce the catalytic activity of Rh2(OAc)4. The basic magnesium oxide serves as an 
acid scavenger and neutralises the reaction.162
Scheme 24. Mechanism of the formation in situ of Phl-NCOCF3 from trifluoroacetamide (CF3CONH2) and 
iodosobenzene diacetate [Phl(OAc)2].
The protocol was followed and N-trifluoroacetyl-S-methyl-S-phenylsulfoximine [(±)-65, 
vide infra, Scheme 25] was obtained in moderate yield. Removal of the N-TFA group 
proceeded smoothly with ammonia/MeOH, giving the free NH compound (±)-50. With 
this new easy access to S-methyl-S-phenylsulfoximine, the introduction of N-TMSi and 
N-Boc groups gave the corresponding N-substituted sulfoximines (±)-51 and (±)-54, 
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Scheme 25. Synthetic routes to S-methyl-S-phenylsulfoximine (±)-50, the N-TMSi (±)-51 and N-Boc (±)-54 
derivatives. Reagents and conditions: (i) CF3CONH2, MgO, Rh2(OAc)4, Phl(OAc)z DCM; (ii) NH3, MeOH; 
(iii) NaH, (Boc)20, THF, 0°C; (iv) Et2NSiMe3, MeCN, 65 °C.
Compounds (±)-51 and (±)-54 were lithiated as described before and addition of the 
anions to S-glyceraldehyde acetonide 44 was studied. The latter was synthesised from 
the commercially available 1,2:5,6-diisopropylidene-D-mannitol 66 via a oxidative 
cleavage by Nal04 and NaHC03 (vide infra, Scheme 26).163 TLC of the addition 
reaction with N-TMSi compound (±)-51 indicated that there were no starting materials 
remaining and showed numerous inseparable species. This finding discouraged further 
attempts with the N-TMSi derivative.
Many attempts were made to encourage the addition reaction with the N-Boc 
sulfoximine [(±)-54, Scheme 26] but to no avail. They are summarised in Table 6 (vide 
infra). Contrary to the results observed with the N-TMSi compound (±)-51, TLC of 
reactions (vide infra, entries 1-4, Table 6) showed that there was no new product 
formed with the starting sulfoximine compound remaining.
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Scheme 26. Synthesis of S-glyceraldehyde acetonide 44 and subsequent attempted addition reactions. 
Reagents and conditions: (i) NaHC 03, N a!04, H20, DCM; (ii) t-BuLi, 44, THF, -78°C; (iii) t-BuLi, 44, THF, 
various conditions (see Table 6).
Entry Lithiation duration Reaction temperature 
(min.) (°C)
1 10 -7 8




Table 6. Various reaction conditions attempted with the N-Boc sulfoximine (±)-54 and the 
S-glyceraldehyde acetonide 44. A 1H NMR study was performed under the conditions stated in entry 5.
These puzzling results prompted an isotopic labelling study (entry 5, Table 6) to 
determine the reasons of the failed attempts. A few drops of deuterium oxide (D20) 
were added to the reaction mixture (after lithiation and addition of the aldehyde) and 
the following outcomes and deductions were possible:
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1. If no lithiation occurred, signals of both starting materials should be observed in 
the 1H NMR spectrum.
2. If lithiation were successful and a carbanion were present but it failed to react 
with the aldehyde, a diminution in the integral for the S-methyl proton region (5 
3.21) would be observed (Route 1, Scheme 27).
3. If the carbanion were to react with the aldehyde as a base by removing the 
a-proton, the starting compound (±)-54 should be recovered (confirmed by the 
presence of all the S-methyl protons) with the 4-H signal of the aldehyde (6 
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Scheme 27. Mechanistic representation of the isotopic labelling study, determining the possible reaction 
outcomes.
Interestingly, none of the above outcomes and deductions was observed in the isotopic 
labelling study (vide supra, entry 5, Table 6). Instead, extending the lithiation time to 90 
mins and increasing the reaction temperature to room temperature gave a new product 
on TLC. 1H NMR revealed that the anticipated product had not been formed, but 
instead the product isolated was tentatively assigned to be compound 71 (vide infra, 
Scheme 28). The diagnostic peaks, which indicate strongly the formation of 71, are § 
1.49 (tert-butyl protons of a Boc group), S 6.81 (NH), with the absence of the S-methyl 
protons in the region of § 2-3.5. Another proposed product, oxirane acetonide 72 was 
not isolated.
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Scheme 28. Proposed mechanism of the synthesis of unexpected by-product 71.
3.1.4 Synthesis of 3-methyithiobenzonitrile
In parallel with the studies on the addition of the carbanion to the aldehydes, an 
investigation was carried out on establishing an efficient and reliable sulfoximination 
method on a 3-substituted aryl sulfoximine. Rhodium-catalysed imination has been 
shown previously to proceed in good yield and the resulting N-TFA derivative proved to 
be invaluable in the subsequent adjustment of protecting groups (vide supra, Scheme 
25). With this strategy in hand, efforts were turned to the synthesis of the required 
retrosynthetic component, 3-(S)-S-methylsulfonimidoyl benzonitrile 45 (vide supra, 
Scheme 13), with an appropriate protecting group at the nitrogen. The precursor to 45,
3-(methylthio)benzonitrile 78, is not commercially available and either the 3-cyano 
group or the methylthio group would have to be introduced to the molecule.
The synthesis of 78 commenced with the introduction of a methylthio group to 3-bromo- 
benzonitrile 73. Omstein et a/.164 described the use of dimethyl disulfide as a source of 
alkylthiolate ion on a 3-bromo phenyl derivative. The group performed a metal-halogen 
exchange using butyl lithium, followed by quench with dimethyl disulfide, and 
replacement of the 3-bromo group with a SMe group was achieved in good yield 
(82%).164 However, when 3-bromobenzonitrile 73 was subjected to the same 
conditions, the reaction only led to decomposition of the starting material (vide infra, 
Route A, Scheme 29).
The introduction of a nitrile group in the mete-position was next considered. 
Preparation of aromatic nitriles has been studied extensively. Nitrites are important 
functional groups with installation of functionalities such as aldehydes, amines, acids 
and acid derivatives being widely accessible.
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One of the most common methods of introducing a nitrile group is by a Sandmeyer 
reaction. Diazotisation of the corresponding amine gives a diazonium salt, which reacts 
with copper(l) cyanide via a radical mechanism (vide infra, Scheme 30). The diazonium 
ion is reductively cleaved by the cuprous ion, resulting in the formation of an aryl 
radical. Excess cyanide ions required can be provided by potassium cyanide. The aryl 
radical then reacts with a cyanide radical from the copper(ll) salt, reducing it to the 
original copper(l) cyanide.165












Scheme 29. Attempts to synthesise 3-(methylthio)benzonitrile 78. Reagents and conditions: (i) n-BuLi, 
MeSSMe, THF, -7 8 °C; 00 H a , N aN 02, CuCN, KCN, H20 , 0 -5 °C /H B F 4, N aN 02, CuCN, KCN, H20 , 0°C; 
(iii) n-BuU, DMF, THF, -78<C; (iv) NH2OHHa, NaOAc, EtOH, 45°C; (v) CuCN, DMF, 150°C.
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R—N =N  X R—N =N  CN - uC^- R* + Cu(CN)2 + N2
X = C I, BF4
R* + Cu(CN)2 --------► RCN + CuCN
Scheme 30. Sandmeyer reaction.
Attempts to synthesise the nitrile 78 from the standard diazonium chloride method 
using the Sandmeyer conditions did not proceed as anticipated (vide supra, Route B, 
Scheme 29).166 The diazonium tetrafluoroborate salt was chosen as the next candidate. 
It was reasoned that the Sandmeyer reaction might proceed better if the diazonium salt 
could be isolated and then allowed to react with cyanides. The diazonium tetra­
fluoroborate was isolated by filtration and subsequently treated with CuCN and KCN. 
However, TLC of the reaction mixture only revealed numerous highly coloured products 
and separation of these proved difficult.
An attempt to synthesise a nitrile group from an oxime was pursued. Lithium-bromine 
exchange with 3-bromothioanisole 75 and quench with dimethylformamide (DMF) gave
3-methylthiobenzaldehyde 76 in low yield (vide supra, Route C, Scheme 29). 
Condensation with hydroxylamine hydrochloride furnished the aldoxime 77. A 
subsequent dehydration should afford the nitrile 78. However, poor yields in this 
synthetic sequence called for an alternative route to be developed.
Another traditional method of generating an aromatic nitrile is the Rosemund-von 
Braun reaction, which involves a nucleophilic substitution of the corresponding aryl 
halide by copper(l) cyanide in DMF. A Cu(lll) complex is formed through oxidative 
addition of the aryl halide. Subsequent reductive elimination gives the aromatic nitrile 
and cuprous halide (Scheme 31 ).167
ArX + CuCN — ( ArCN) CuX -------- ► ArCN + CuX X = B r , l
DMF
Scheme 31. Rosemund-von Braun reaction.
Prochazka et al. successfully obtained 3-(methylthio)benzonitrile 78 from 3-bromo­
thioanisole 75 in excellent yield using the Rosemund-von Braun conditions.167 
Surprisingly, under the same reaction conditions, the method could not be repeated
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and only decomposition of starting material was observed (vide supra, Route D, 
Scheme 29).
A major drawback of the Rosemund-von Braun reaction is the harsh conditions (150°C 
for 5-50 h), which makes many sensitive functional groups incompatible with the 
system. Good progress has been made in the search of alternative procedures. Recent 
reports concentrate on metal-catalysed cyanation of aryl halides and reactions with 
palladium [Pd(OAc)2> Pd2(dba)3 (dba = dibenzylideneacetone), Pd(PPh3)4], zinc (ZnBr2) 
and copper [Cu(BF4)2*6H20] catalysts demonstrated higher reaction rates and aryl 
nitriles were afforded in excellent yields.168-170 Furthermore, new cyanide reagents have 
also been investigated, as the cyanide source plays an important part for the 
applicability of a cyanation reaction. Zinc(ll) cyanide fZn(CN);2] and potassium ferro- 
cyanide (K4[Fe(CN)6]) have attracted consideration praise for their role in maintaining 
cyanide concentration in the catalytic cycle in palladium-catalysed cyanations.170,171
Sundermeier et al. presented mechanistic studies on the catalytic system.166 Pd(0) is 
the active species of palladium catalysts and reaction of Pd(0) with aryl halides is the 
key step in the cycle (Scheme 32).169 High concentrations of cyanide ions were 
reported to affect the palladium catalytic cycle by reacting with Pd(ll) species, forming 
the inactive Pd(ll)-CN complexes, thereby reducing the pool of active Pd(0). Zn(CN)2 
and K4[Fe(CN)6] are both sparingly soluble in most solvent systems which prevents the 
problem of early exposure of Pd(0) to cyanide.
Zn(CN)2 nj2+/v-M a _ nj /■%»■
ZnX
A r—CN Aryl nitrile
L = ligand (e.g. phosphine)
Aryl halide Ar—X
Pd catalysts e.g. Pd(PPh3)4
Scheme 32. Proposed mechanism of palladium-catalysed cyanation by Sundermeier et al.
K4[Fe(CN)6] is a particularly interesting reagent because it is inexpensive, easily 
handled, commercially available on multi-gram scale and non-toxic. Based on the
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positive reviews, an attempt to synthesise compound 78 commenced with the literature 
method using K4[Fe(CN)6] and Pd(OAc)2 in dimethylacetamide (DMA).170 However, TLC 




Scheme 33. Synthesis of the important intermediate 78 by palladium-catalysed cyanation with Zn(CN)2. 
Reagents and conditions: (i) K 4Fe(CN )d Pd(OAc)z  DMA, 120°C; (ii) Zn(CN)2, Pd(PPh3)4, DMF, 150°C.
Zn(CN)2 was next considered as a possible cyanide source. A separate literature 
method presented by Tatsumi et al. was adopted (Scheme 33).171 The group converted 
a bromothiophenyl derivative to the corresponding cyano compound in poor yield using 
a combination of Zn(CN)2 and tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] in 
DMF. Amazingly, using the same reaction conditions, 3-bromothioanisole 75 was 
converted to the nitrile compound 78 in quantitative yield.
3.1.5 Chiral sulfoxidation
Having successfully obtained compound 78, the next step was to introduce chirality at 
the sulfur atom. Chiral sulfoxidation is one of the most important steps in the synthesis 
of the key intermediate 45; enantioselective oxidation of the sulfur would give the 
desired (S)-configuration of the sulfoxide and subsequent sulfoximine. 3-Bromo- 
thioanisole 78 was used in a model reaction.
Chiral sulfoxidation has been a subject of constant interest for many years and the 
most acceptable method is the catalytic enantioselective oxidation of prochiral sulfides. 
In particular, the use of metal catalysts with chiral iigands is a powerful method to 
generate chiral sulfoxides. Among the numerous reported catalysts such as titanium, 
iron, and vanadium, the most popular choices are the modified Sharpless reagents, 
Ti(0/Pr)4/(fl,R)-(+)-diethyl tartrate (DET) (1:4) and Ti(0/Pr)4/(R,R)-(+)-DET / H20  
(1:2:1), described by Modena et al. and Kagan et al., respectively.172'174 Both systems 
led to the asymmetric oxidation of sulfides using fe/f-butyl hydroperoxide (TBHP) as 
oxidant (vide infra, Table 7) in similar yields. However, Kagal et al. showed that
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addition of water to the system dramatically improved the enantioselectivity and the 
following points were concluded:172
1. Ti(0/Pr)4/ (R,R)-(+)-DET / H20  / TBHP (1:2:1:1.1) is the best system in terms of 
yield and enantioselectivity.
2. Water significantly increases enantiomer composition and yield is satisfactory.
3. Optimum reaction temperature is -20°C.
4. The water-modified Sharpless reagent is prepared in DCM at room 
temperature, with sequential addition of Ti(0/Pr)4) DET and water. TBHP is 
added last. This order is important to avoid precipitation of Ti02 by early 
addition of water.
Although this system was first described in 1984 and subsequent reports of use of 
newer metal catalysts (vanadium and iron) proved positive, the modified Sharpless 
oxidation still remains a frequent method in chiral sulfoxidation because all the 
reagents are commercially available, cheap and easy to handle.172'174 DET is by far the 
most accessible chiral ligand and both enantiomers are available in multi-gram scales.
chiral o
o oxidation ''
R1 R2    R’ - S ' t f




1 Ti(0/Pr)4172174 (R ,R)-(+y  DET TBHP PhCH2 Me 70 46
2 Ti(0 /Pr)4/H20 172'174 (R,R)-(+)- DET TBHP Ph Me 80 89
3 Ti(0/Pr)4172,174 R-(+)-BINOL TBHP Ph Me 86 63
4 VO(acac)2174 Schiff base 
(R)-a
H20 2 Ph Me 73 59




H2O2 Ph Me 66 61
Table 7. Metal-catalysed chiral sulfoxidation. Structures of some unusual chiral ligands are presented in 
Figure 23 (vide infra). (BINOL = binaphthol, acac = acetylacetonate)
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Schiff bases a: X > Buf, b: X = IK-<+)-BINOL
Figure 23. Structures of some new chiral ligands utilised in metal-catalysed conditions.
The exact structure of the water-modified Sharpless reagent is still unknown. 
Fernandez et al. proposed that the active species is a dimer complex with two titanium 
atoms connected via an q-oxo bridge and delivery of the reactive oxygen is determined 






Figure 24. Tentative structure of the catalytically-active Sharpless reagent in chiral sulfoxidation as 
described by Fernandez et a/.172
As shown in Scheme 34 (vide infra), 3-bromothioanisole 75 was subjected to the 
modified Sharpless sulfoxidation conditions using (S,S)-(-)-DET as the chiral ligand 
and the corresponding (S)-sulfoxide 79 was afforded in 49% yield. The enantiomeric 
excess (ee) was measured by polarimetry and the optical rotation [a]200 was found to 
be -39.6°. Capozzi et al. reported a high ee value (97%) for (R)-(+)-3-bromophenyl 
methyl sulfoxide, with an [a]25D of +116.3° using water-modified Sharpless reagents 
with cumene hydroperoxide.175 An ee of 33% was calculated for sulfoxide 79. Some of 
the enantiomeric purity was lost due to warming of the reaction mixture to ambient 
temperature when it was left stirring overnight. However, despite careful control of 
temperature at the subsequent attempt of Sharpless oxidation with target intermediate 
78, TLC of the reaction mixture revealed only the presence of the starting material (vide 
infra, Scheme 34). It was reasoned that the presence of an electron-withdrawing
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3-cyano group in 78 might have reduced the nucleophilicity of the sulfur, making the 
oxidation difficult, although the meta relationship of the groups may compromise this 
explanation.
Since 3-(methylthio)benzonitrile 78 is an essential starting compound in the ongoing 
synthetic route and chiral sulfoxidation may prove to be difficult in the presence of the 
nitrile group, it was decided that, like the non-substituted counterparts, enantiomers 
















Scheme 34. Sharpless oxidation converted 3-bromothioanisole 75 to the corresponding S-sulfoxide 79 
with modest enantiomeric excess (due to raised temperature). The same reaction conditions failed to 
oxidise target intermediate 78 to the chiral sulfoxide 80. Reagents and conditions: (i) Ti(OiPr)4, 
(S,S)-(-)-DET, HzO, TBHP, DCM, -20 °C to R T ; 00 Ti(OiPr)4, (S,S)-(-)-DET, H20, TBHP, DCM, -20°C.
3.1.6 Addition of carbanions to aldehydes
Bearing this in mind, the synthetic sequence used to synthesise racemic 
S-methyl-S-phenylsulfoximine (±)-50 were followed, and 3-(S-methylsulfonimidoyl)- 
benzonitrile (±)-83 was obtained in 30% overall yield (vide infra, Scheme 35). The 
lower yields in mCPBA-oxidation and rhodium-catalysed imination with the 3-cyano 
derivatives further support the hypothesis that the existence of a nitrile group reduced 



















Scheme 35. Synthesis of the free NH sulfoximine (±)-83 and subsequent attempts to protect the nitrogen. 
Reagents and conditions: (i) mCPBA, DCM, OlC; (ii) CF3CONH2, MgO, Rt)2(OAc)4, Phl(OAc)2, DCM; (iii) 
NH3, MeOH; (iv) NaH, (Boc)2Of THF, 0 °C; (v) Et2NSiMe3l MeCN, 651C.
The intermediate NH sulfoximine (±)-83 was protected at the nitrogen with a Boc group, 
giving (±)-84 in good yield. However, unlike with S-methyl-S-phenylsulfoximine (±)-50, 
a TMSi group could not be introduced at the nitrogen (Scheme 35).
Nevertheless, the carbanion generated at the SMe group of the N-Boc protected 
sulfoximine (±)-84 using the strong base, f-BuLi, was treated with benzaldehyde and 
S-glyceraldehyde acetonide 44 (vide infra, Scheme 36). However, TLC of the reaction 
mixtures revealed only the presence of starting materials.
As it was unclear whether the failure of this reaction was due to the failure to 
deprotonate the SMe group or if the anion formed did not react with the electrophilic 
aldehydes, the reactions were repeated allowing 2 h of lithiation (at -78°C to RT) 
before the addition of aldehydes. Again, no products were obtained.
The inability to reproduce synthetic steps meant that the route outlined in Scheme 13 
(vide supra) was no longer viable.
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Scheme 36. Attempted anion addition to aldehydes with N-Boc sulfoximine (±)-84. Reagents and 
conditions: (i) t-BuLi, PhCHO, THF, -78°C; (ii) t-BuLi, 44, THF, -78°C.
3.2 Route II: introduction of a whole four-carbon unit
3.2.1 Retrosynthesis
Introduction of the ribose mimic 39 as a four-carbon unit as illustrated in Scheme 13 
{vide supra) relies on the addition of a carbanion of a SMe group (one-carbon unit) to 
the chiral glyceraldehyde acetonide 44 (three-carbon unit), resulting in a four-carbon 
unit necessary to form the required stereocentres of the ribosyl moiety. Since this step 
has been proven to be irreproducible, a new route was devised to introduce all four 
carboatoms with all chirality already set up at the two carbon chiral centres of a 
homochiral dioxolane 86 {vide infra, Scheme 37). This four-carbon component would 
be coupled with a sulfur nucleophile 87. The sulfoximine would be constructed later in 
the synthesis, with the configuration at the sulfur centre introduced either by separation 
of diastereoisomers during sulfoximination, or if it is not possible, via resolution of 
racemic free NH sulfoximines using (+)-CSA.134
This synthetic sequence {vide infra, Scheme 37) avoids the lithiation step and 
subsequent addition to aldehydes, which proved to be troublesome. The starting 
dioxolane compound 86 is readily available by literature methods,176 and 3-bromo- 
thiophenol 87 is commercially available. Since sulfoximination procedures have now 
been fully established in the previous retrosynthetic scheme, sulfide 88 will be 
subjected to the same conditions to afford the corresponding sulfoximine 91. Acetal 
hydrolysis gives the diol 92, which upon an intramolecular Mitsunobu dehydration 
should generate two ring-closure products: a four-membered ring and a five-membered 
ring compounds. As five-membered rings are favourable thermodynamically, the 
resulting product should be the precursor of target compound 39.
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Scheme 37. New synthetic approaches to target compound 39.
69
3.2.2 Formation of the C-S bond
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Accordingly, dioxolane 86 was set as the first target molecule in this new sequence and 
its synthesis is outlined in Scheme 38. R,R-(+)-DET 93 was converted through ketal 
exchange with 2,2-dimethoxypropane (DMP, 94) into the ^symmetric ester 95 and 
reduction with lithium aluminium hydride (LAH) gave the corresponding diol 96.176,177 
The symmetry of diol 96 was disrupted by monobenzylation using an equivalent 
amount of benzyl bromide to give compound 98; after investigation of several reaction 
conditions, it was concluded that freshly-pentane-washed sodium hydride gave the 
best result in terms of yield (71%) and ratio of mono- and dibenzylation (12:1), the latter 
being much superior to the statistical mixture.176,178
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Scheme 38. Attempted synthesis of model dioxolane sulfide 101. Reagents and conditions: (i) p-TsOH, 
DCM, reflux; (ii) UAIH4, THF, reflux; (iii) NaH, BnBr, DMF, 0°C; (iv) Pt)JP, CBr*, THF, 0°C; (v) LHMDS, 
100, THF, -78°C.
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Having obtained the monobenzylated dioxolane 98, the next step would be to replace 
the free hydroxy group with a reactive leaving group. Treatment with triphenyl- 
phosphine (TPP) and carbon tetrabromide afforded the bromomethyl dioxolane 99.179 A 
model reaction was devised to explore subsequent synthetic steps, in which 
thiophenolate 100 was used as a sulfur nucleophile. Surprisingly, generation of the 
thiophenolate anion, an exceptionally good nucleophile, with lithium hexamethyl- 
disilazide (LHMDS), and treatment with 99 did not give the desired condensation 
product 101. TLC of the reaction mixture indicated that a large amount of thiophenol 
100 was still present but the dioxolane compound 99 had been consumed along with 
generation of a new product spot, which disappeared upon aqueous work-up. This 
puzzling result may be tentatively explained by a base-catalysed elimination and the 
enol ether formed may have decomposed in aqueous media (Scheme 39).
Scheme 39. Postulated mechanism of a side reaction in the coupling of bromomethyl dioxolane 99 and 
thiophenol 100.
3.2.2.1 Mitsunobu reaction
Consequently, a different approach was sought involving a thio-Mitsunobu reaction 
between the hydroxymethyl dioxolane derivative 98 and thiophenol 100. Direct coupling 
of the two starting compounds using Mitsunobu reagents should afford the desired 
sulfide 101 under neutral conditions (vide infra. Scheme 40).
The Mitsunobu reaction has gained widespread interests in many fields of organic 
synthesis due to its reliability and applicability. The reaction is very simple with mild 
conditions and high yields. It was discovered by O. Mitsunobu in 1967 as a dehydration 
reaction between an alcohol and a carboxylic acid in the presence of diethyl azo- 
dicarboxylate (DEAD) and triphenylphosphine (TPP), generating the corresponding 
C -0  ester bond.180 With secondary alcohols, the largest use of the reaction is inversion 
of configuration at the alcohol centre and this application was mentioned in Scheme 13 
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carboxylic acid have emerged including phenols, thiols/thiophenols and amines for new 
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Scheme 40. Mechanism of the thio-Mitsunobu reaction with dioxolane compound 98.
The mechanism for secondary alcohol substitution and subsequent inversion of 
configuration is presented in Scheme 41 (vide infra).182 Addition of TPP to DEAD (step
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1) gives a zwitterionic quaternary phosphonium adduct, which is protonated by the 
nucleophilic component (2). Attack by the alcohol (3) forms a highly reactive alkoxy- 
phosphonium intermediate (4). SN2 displacement of the phosphonium results in the 
formation of a new C -0  bond with inversion of configuration (5).
Mitsunobu Reaction














Reaction product: new 





+ 0 = P P h 3
By-product 2: 
triphenylphospine oxide
Scheme 41. Mechanism of the Mitsunobu reaction, with inversion of configuration of secondary alcohols.
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A major disadvantage of the Mitsunobu reaction lies in the difficulty in the removal of 
excess reagents and their by-products, diethoxycarbonylhydrazine and triphenyl- 
phosphine oxide, formed by hydration of DEAD and oxidation of TPP, respectively. If 
the reaction can be performed in diethyl ether, both by-products can be precipitated 
and removed by filtration. However, since most Mitsunobu reactions are carried out in 
THF, careful column chromatography is often required to isolate the coupled product, 
which is time-consuming and may lead to deterioration of yield. A number of modified 
Mitsunobu agents (phosphines and azo compounds) have been recognised to 
circumvent this problem.
TPP still remains as a traditional reagent and is frequently used, despite the difficult 
separation of the excess starting material and the oxidised product. Alkylphosphanes 
such as tributylphosphine (TBP) and trimethylphosphine are popular alternative 
reagents since their oxidised products can be removed easily by aqueous work-up.183 
Recently, O'Neil et al. have demonstrated the utility of 1,2-bis(diphenylphosphino)- 
ethane (DPPE, Figure 25) as a phosphine reagent in the Mitsunobu reaction due to the 
greater polarity of the resulting bis(phosphine oxide).184 This by-product can be easily 
removed by a simple filtration of the reaction mixture prior to work-up and purification. 
The group used DPPE in combination with DEAD/DIAD and good yields (59-98% with 
DEAD, 57% with DIAD) were reported.
Diisopropyl azodicarboxylate (DIAD) has replaced DEAD as the more popular choice 
as a Mitsunobu reagent because it is less toxic, cheaper and easy to handle. Studies 
have shown that nucleophiles with a pKa higher than 11 are likely to contribute to lower 
reaction yields.185 A tentative explanation is that with the unavailability of an acidic 
nucleophile, the alcohol protonates the zwitterionic intermediate, leading to the 
undesired azodicarboxylate derivative (vide infra, Scheme 42). Another drawback of 
the Mitsunobu reaction is the limitation of compatible nucleophiles. The pKa of the 
conjugate adds of the nucleophiles must be lower than that of the zwitterionic 
intermediate (pKa ~ 13); therefore, only relatively acidic nucleophiles are compatible
Figure 25. Structure of DPPE.
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with the traditional Mitsunobu reagents. However, a new alternative has found a place 
in extending the utility of suitable nucleophiles.
Reports of the use of 1 ,1 ’-(azodicarbonyl)dipiperidine (ADDP) by Dembinski et al. 
provided a more versatile Mitsunobu reagent with higher basicity which works well with 
a broader range of nucleophiles such as carbon nucleophiles and amides, thus 
providing new C-C and C-N bond-forming strategies using a Mitsunobu reaction.185
For the synthesis of target intermediate 101 with the hydroxymethyl dioxolane 98 and 
thiophenol 100, a variety of Mitsunobu conditions were pursued to investigate reaction 
efficiency. Additionally, a Mitsunobu-like reaction was attempted using TBP, DIAD and 
diphenyl disulfide (PhSSPh) as the sulfur source, where the latter is reduced to the 
thiophenolate anion (PhS') under the reaction conditions. This procedure was originally 
reported by Knutsen et al. for the synthesis of adenosine analogues using DEAD as the 
azodicarboxylate reagent, and the C-S bond formation proceeded in moderate yield 
(57%).186 The results of attempted Mitsunobu reactions are summarised in Table 8 and 
the following conclusions were drawn:
1. The order of addition of the reagents does not seem to alter reaction outcome.
2. Reaction with DPPE, a promising new Mitsunobu phosphane, only led to 
recovery of starting materials.
3. Reaction using diphenyl disulfide (PhSSPh) as an alternative source for aryl- 
thiolate anion did not proceed as expected.
H
Undesired product
Scheme 42. Possible side-reaction with less acidic nucleophiles (pKa >11).
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4. Combination of TBP and ADDP gave the best yield; to achieve efficient stirring, 
the highly viscous reaction mixture was sonicated.
Entry Conditions (stated in the order of addition in reaction mixture) Yield (%)
1 TPP (2 equiv.), DIAD (2 equiv.), thiophenol 100 (1 equiv.), dioxolane 98 (1 
equiv.), THF (10 mL)
22
2 TPP (2 equiv.), thiophenol 100 (1 equiv.), DIAD (2 equiv.), dioxolane 98 (1 
equiv.), THF (10 mL)
18
3 TBP (1.5 equiv.), ADDP (1.5 equiv.), thiophenol 100 (1.5 equiv.), dioxolane 98 
(1 equiv.), THF (10 mL), sonication
44
4 DPPE (0.75 equiv.), DIAD (1.5 equiv.), thiophenol 100 (1.3 equiv.), dioxolane 
98 (1 equiv.), THF (10 mL), sonication
*
5 TBP (2 equiv.), DIAD (1.5 equiv.), diphenyl disulfide (1.5 equiv.), dioxolane 98 
(1 equiv.), THF (10 mL)
"
Table 8. Various Mitsunobu conditions attempted for the synthesis of sulfide 101. (TPP = triphenyl- 
phosphine, DIAD = diisopropyl azodicarboxylate, TBP = tributylphosphine, ADDP = 1,1’-(azodicarbonyl)- 
dipiperidine, DPPE = 1,2-bis(diphenylphosphino)ethane)
3.2.2.2 Synthetic approaches to the model phenyl sulfoximine intermediate
Having established the optimum Mitsunobu conditions and obtained the sulfide 101, it 
was treated with mCPBA at -78°C to give the sulfoxides 102a/b in excellent yield as a 
1:1 mixture of diastereoisomers (vide infra, Scheme 43).187
The 1H NMR spectrum of 102a/b showed two sets of signals, indicating the existence 
of two diastereomeric sulfoxides. The key region lies in the range of 5 2.8 to 8 4.6. In 
order to improve spectroscopic resolution and separation of signals, 1H NMR analysis 
was conducted with a 600 MHz spectrometer. With the support of the 1H-1H COSY 
spectrum, the assignment of the two sets of diastereomeric protons was possible. 
These spectroscopic data, along with the TLC results (two visible spots in identical 
sizes), point to a 1:1 diastereomeric ratio (vide infra, Figure 26).
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Scheme 43. Synthetic approaches to the model target 106. Reagents and conditions: (i) conditions (Table 
8); (ii) mCPBA, DCM, -78°C; (iii) CF3CONH2, MgO, Rh2(OAc)4, Phl(OAc)z  DCM; (iv) NH3, MeOH; (v) HC!, 
MeOH; (vi) TBP; ADDP, THF, sonication, R T to 45*0.
The two sets of CMe2 protons resonated as four singlets at § 1.37, 51.45, 5 1.46 and 
§1.47, each for one and a half protons. In the 1H spectrum of the starting sulfide 101, 
the signals of the CMe2 protons were shown as two singlets at § 1.40 and § 1.44. 
Therefore, the signals were shifted neither upfield nor downfield in the presence of the 
remote electronegative sulfoxide oxygen.
The anticipated effect on the SCH2 protons of the sulfoxide oxygen was relatively small. 
In the 1H NMR spectrum of starting sulfide 101, the SCH2 protons gave a double 
doublet signal more upfield (§ 3.19) than the signals for the BnOCH2 protons (§ 3.63). 
This effect was also observed with sulfoxides 102a/b. Signals for the SCH2 protons of 
both isomers of 102 resonated in the region of 5 2.83 to § 3.18.
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Figure 26. 1H NMR spectra of diastereomeric 102a/b. (A) is the 1-D 1H NMR spectrum of the key region 6 
2.8 to 5 4.6; (B) is the 1H-1H COSY spectrum, showing the cross-peak connections in each 
diastereoisomer.
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From the 1H-1H COSY spectrum (vide supra, Figure 26), it was clear that the SCH2 
protons of isomer A appeared as a pair of double doublets at 5 2.84 and § 3.06, each 
for half a proton, whereas the two double doublet signals for the SCH2 protons of 
isomer B, each for half a proton, were located at 5 3.04 and 6 3.22. With this 
information, assignment of 5-H for both isomers was also made possible by the 
cross-peak connections with 6 3.97 and 6 4.41, corresponding to the 5-H for isomer B 
and A, respectively.
The BnOCH2 proton signals of isomer A appeared as two double doublets integrating 
for a total of one proton at 6 3.55 and 6 3.68; a cross-peak connection with 4-H at 6 
3.91 was observed on the 1H-1H COSY spectrum. The pair of double doublet signals, 
each for half a proton, at 6 3.51 and 6 3.62 belonged to isomer B, with the signal of its
4-H located at 8 4.15.
The PhCH2 proton signals in the starting sulfide 101 were observed at 8 4.54 and 8 
4.57 as a pair of doublets. In the diastereomeric sulfoxides 102a/b, they appeared as a 
pair of doublets at 8 4.50 and 84.52 for one isomer for a total of one proton. 
Interestingly, the signal of the PhCH2 protons of the other isomer was a singlet for one 
proton at 8 4.55. Thus the PhCH2 protons are magnetically inequivalent in 101 and one 
of the isomer of 102 (as expected for diastereotropic protons) but are accidentally 
equivalent in the other isomeric 102.
In isomer A, the 4-H signal (8 3.91) is relatively upfield from that of 5-H (8 4.41), 
whereas in isomer B, the 4-H signal (8 4.15) is more downfield than that of 5-H (8 3.97). 
Therefore, 4-H is more upfield in isomer A than in isomer B, whereas 5-H is more 
downfield in isomer A than in isomer B. MM2 (Molecular Mechanics) energy-minimised 
calculations were carried out on the corresponding S-(R)- and S-(S)-sulfoxides in order 
to investigate these findings but no apparent reasons could be concluded to explain 
such effects (vide infra, Figure 27).
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S-(ft)-102 S-(S)-102
Figure 27. MM2-energy minimised models of S-(/?)-102 and S-(S)-102. The red colour refers to oxygen, 
the yellow refers to sulfur and the grey refers to the carbon atom.
Although the diastereoisomeric 102a/b could be easily seen by TLC (two spots) and 1H 
NMR, separation was not attempted as the Rf  values were very similar. Therefore, 
rather than separating them at this stage, a solution containing a mixture of the isomers 
in DCM was subjected to the Rh2(OAc)4-catalysed imination conditions and sulfoxides 
102a/b were converted to the N-TFA sulfoximines 103a/b in good yield (vide supra, 
Scheme 4 3 ).
The 1H NMR spectrum of 103a/b again showed two sets of signals, indicating the 
existence of two diastereomeric N-TFA sulfoximines (Figure 28). Due to an extensive 
overlap of signals in the spectrum, assignment of individual proton signals was 
extremely difficult. Moreover, the diastereomeric ratio of the N-TFA sulfoximines 
103a/b could not be determined by the integrals of the signals for the PhCH2 protons 
since only one singlet for two protons appeared in the spectrum. Therefore, a 19F NMR 
spectrum was used since 19F NMR chemical shifts are very sensitive to changes in 
environment; this is therefore a useful tool in measuring the diastereomeric ratio. The 
19F spectrum showed two singlet signals at 8 -76.0 and 5 -75.9 in a 3:2 ratio. This is 
inconsistent with the 1H NMR diastereomeric ratio of 1:1 observed in the starting 
sulfoxides 102a/b. This observation indicates that there was a small degree of 
diastereoselectivity in the imination step.
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Figure 28. 1H NMR spectrum (key region 6 3.0 to 5 4.6) of diastereomeric N-TFA sulfoximines 103a/b.
Careful interpretation of coupling constants in the 1H NMR spectrum of 103a/b allowed 
a tentative structural assignment of protons and unexpectedly, the signals for the SCH2 
protons appeared more downfield than the BnOCH2 protons. This proton assignment is 
contrary to that seen in the starting diastereomeric sulfoxides 102a/b. Further proton 
and carbon assignments were conducted by the different spectroscopic data from the 
13C NMR, 135-DEPT, 1H-13C COSY (HMQC) and long-range 1H-13C COSY (HMBC) 
spectra. From the HMBC spectrum, cross-peaks between the singlet signal for the 
PhCH2 protons at 5 4.49 and the signals for a quaternary carbon at 8 137.32/137.35, 
the ortho-carbon for the C-phenyl ring at 8 127.9 and a CH2 carbon at 8 69.6/69.7, 
indicating that the latter signal is due to the BnOCH2 carbon. Proton signals found to be 
attached to this carbon were the pair of double doublets at 8 3.42 and 8 3.43, and 
another pair of double doublets at 8 3.65 and 8 3.66. Therefore, it was assigned that 
these signals are due to the BnOCH2 protons. Consequently, cross-peaks between the 
double doublets at 8 3.79, 8 3.81, 8 3.99 and 8 4.03 and the CH2 carbons at 8 58.5 and 
8 59.3 showed that these signals are due to the diastereomeric pair of the SCH2 
groups.
A possible explanation for this downfield shift of the signals for the SCH2 protons 
relative to those for the BnOCH2 protons is that the addition of the TFA group caused a 
marked downfield effect in relation to the starting sulfoxides 102a/b in the region of the
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SCH2 protons, with the environment for the BnOCH2 protons being relatively unaffected 
and thus the relative locations of these two groups of protons were opposite to those 
observed in the starting materials 102a/b.
Interestingly, TLC of the diastereomeric mixture 103a/b showed only one visible spot. 
Therefore, due to identical Rf values, the two diastereoisomers could not be separated 
at this stage and a mixture containing both isomers was treated with ammonia to give 
the corresponding NH sulfoximines in a total yield of 64% (vide supra, Scheme 43). 
Separation of the two diastereoisomers was possible at this stage by careful 
chromatography and, contrary to the diastereomeric ratio determined from the N-TFA 
sulfoximines 104a/b, the diastereomeric NH sulfoximines S-(S)- and S-(R)-104 were 
obtained in a ratio of 1:1.1.
The 1H NMR spectra of both S-(R)- and S-(S)-104 revealed the following structural 
information:
1. The singlet signals of the CMe2 protons of S-(R)-104 were relatively downfield 
(8 1.33 and 5 1.37) compared to those of the S-(S)-isomer at 5 1.21 and 8 1.29. 
In both sets of signals, they were shifted relatively downfield in relation to the 
starting N-TFA sulfoximines 103a/b where the CMe2 protons resonated at 8 
1.16 to 8 1.26.
2. The signals of the SCH2 protons were affected the most by removal of the 
strongly electron-withdrawing TFA group. In the 1H NMR spectrum of the 
starting N-TFA compounds 103a/b, these protons resonated as two double 
doublets at 8 3.79 and 8 3.81 for one isomer, and at 8 3.99 and 8 4.01 for the 
other isomer, whereas in the 1H NMR spectrum of S-(R)-104, the two double 
doublet signals for the SCH2 protons were moved upfield to 8 3.30 and 8 3.45. 
For the S-(S)-isomer, one signal of the SCH2 protons appeared at 8 3.39 as a 
double doublet, and the other coincided with the chemical shift for the BnOCH2 
protons, forming a multiplet at 8 3.5 to 8 3.54.
Two-dimensional NMR analyses were performed on both isomers, with their COSY 
spectra showing the expected coupling relationships. In both isomers, cross-peaks 
connections of the BnOCH2 protons with the double triplet signals at 8 3.90 and 8 3.93 
showed that these signals were due to 4-H of S-(R)- and S-(S)-104, respectively. 
Similarly, cross-peaks connected the SCH2 to the double triplet signals at 8 4.45 and 
8 4.31 showed that these were due to 5-H of the (Ry and (S)-isomer, respectively.
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The 1H-1H NOESY spectrum of S-(S)-104 showed the expected connectivities between 
the PhCH2 protons and the BnOCH2 protons (vide infra, Figure 29). NOE connectivities 
were also observed between the two singlet signals for the CMe2 protons and the 
double triplets of 4-H and 5-H. A cross-peak connection between the singlet signal at 
51.21 and the double triplet of 4-H at 5 3.93 indicates that the former signal was due to 
the methyl group trans to BnOCH2 in the five-membered dioxolane ring. Similarly, a 
cross-peak between the singlet at 5 1.29 and the double triplet of 5-H at 5 4.31 
assigned the former signal to the methyl group cis to BnOCH2. NOE connectivities of 
different intensities were noted between 5-H and the BnOCH2 and SCH2 protons. A 
relatively weak cross-peak between 5-H to the double doublet signal for one of the 
SCH protons at 5 3.39 suggests that this SCH proton is far apart in space to 5-H i.e. 
they are trans to each other. This double doublet has coupling constants of J = 14.2,
8.2 Hz, where the former corresponds to the geminal coupling. A coupling constant of J 
= 8.2 Hz is within the range of an axial/axial coupling. A stronger cross-peak between 
5-H and the multiplet at 8 3.50 to 8 3.54 (one SCH proton and one BnOCH proton) 
indicates that this BnOCH proton and 5-H are close in space to each other.
Similarly, through-space correlations were seen between 4-H and the double doublet 
signal for one of the BnOCH2 protons and the multiplet at 8 3.50 to 8 3.54. The 
relatively weak NOE connectivity to the double doublet at 8 3.64 indicates that the 
BnOCH protons are on the opposite face of the dioxolane ring i.e. they are trans to 4-H. 
A stronger cross-peak seen between 4-H and the multiplet at 8 3.50 to 8 3.54 for two 
protons (a BnOCH proton and a SCH proton) again reveals that the SCH2 protons and
4-H are on the same face of the dioxolane ring i.e. they are cis to each other. Weak 
cross-peaks between 4-H and 5-H confirmed that the protons are on the opposite face 
of the five-membered dioxolane ring and are thus trans to each other. A vicinal 
coupling constant of 3J = ~ 8 Hz between 4-H and 5-H further supports this relative 
configuration.
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Figure 29. 1H-1H NOESY spectrum of 4S,5f?,S(S)-4-(benzyloxymethyl)-2,2-dimethyl-5-(phenyl-
sulfonimidoylmethyl)-1,3-dioxolane S-(S)-104.
The large number of artefacts and the relatively weak NOE connectivities in the 
NOESY spectrum of S-(fl)-104 made interpretation difficult. However, a number of 
observations could still be identified using coupling constants, since an improved 
separation of proton signals was seen with the 1H NMR spectrum of S-(R)-104. A 
coupling constant of 3J = 8.7 Hz was calculated for one of the SCH2 protons at 8 3.30 
which indicates an axial/axial relationship. A coupling constant of 3J = 2.9 Hz was 
calculated between the other SCH proton at 8 3.45 and 5-H, which is within the range
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of an axial/equatorial coupling. A vicinal coupling of 3J ~ 7.7 Hz between 4-H and 5-H 
supports the trans configuration of these protons with respect to the five-membered 
dioxolane ring.
In an attempt to study further the observed coupling constant values and NOE 
connectivities of both diastereoisomers of 104 in chloroform solution, an assumption 
was made to an intramolecular hydrogen-bonding interaction between the imino NH 
and the oxygen atom in the five-membered dioxolane ring in 104, resulting in a five- 
/six-membered fused-ring system (Figure 30).
BnOBnO S (R)
Figure 30. Postulated intramolecular hydrogen-bonding structures of 104 in chloroform. (Hydrogen bonds 
-  blue)
MM2 energy-minimised calculations were also carried out to study the probable 
structures of these intramolecular hydrogen-bonding systems (vide infra, Figure 31). 
For the (R)-isomer, severe ring strain was observed, with the twist-boat six-membered 
ring deforming the five-membered dioxolane ring; the resulting dihedral angle between
4-H and 5-H was calculated to be 93° (the corresponding dihedral angle in the 
non-hydrogen-bonded S-(fl)-104 = 168°). In the hydrogen-bonded S-(S)-104, the 
five-membered dioxolane ring adopted a half-chair conformation and the six-membered 
ring adopted a twist-boat conformation, with the dihedral angle between 4-H and 5-H = 
141° (the corresponding dihedral angle in the non-hydrogen-bonded S-(S)-104 = 169°). 
Three-bond couplings of 3J ~ 8 Hz and 3J ~ 7.7 Hz were calculated between 4-H and
5-H of S-(R)- and S-(S)-104, respectively. For the latter, the coupling constant value is 
consistent with the dihedral angle of 141°, whereas for the (R)-isomer, 3 J ~ 8 Hz is 
inconsistent with the dihedral angle of 93°. With this information and the severe ring 
strain observed by MM2 calculations, it was concluded that the intramolecular 
hydrogen-bonding interaction is more likely to exist in the chloroform solution state of
S-(S)-104 than that of the (R)-isomer.
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S-(/?)-104 S-(S)-104
H-bonded S-{R)-104 H-bonded S-(S)-104
Figure 31. MM2-energy minimised models of the sulfoximines S-(/?)-104 and S-(S)-104 with the 
corresponding intramolecular hydrogen-bonding structures. Dihedral angles (4-H)-(4-C)-(5-C)-(5-H) = 168° 
and 169° were calculated for S-</?)-104 and S-(S)-104, respectively. In the hydrogen-bonded system in the 
(R)-isomer, the corresponding dihedral angle was found to be 93°, whereas in the (S)-isomer, the 
corresponding dihedral angle was 141°. The red colour refers to oxygen, the yellow refers to sulfur, the 
blue refers to nitrogen and the grey refers to the carbon atom.
In addition, cyclohexane undergoes ring-flips to avoid 1,3-diaxial interactions and the 
preferred conformation of the bulky substituents is equatorial. Therefore, the 
six-membered ring in the five-/six-membered fused-ring system may also undergo 
ring-flip and two possible conformations are available for the intramolecular 
hydrogen-bonding system in 104 (vide infra, Scheme 44). Conformer B is the 
lower-energy conformation since the BnOCH2, methyl group and 5-H are all 
pseudo-equatorial, whereas in A, these substituents are axial.
Surprisingly, the coupling constant values and the NOE connectivities described above 
suggest that the conformation in both isomers in chloroform solution is likely to be A. 
Weak cross-peaks (i.e. far apart in space) associated with vicinal coupling constants of
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3J ~ 8-9 Hz, together with the stronger cross-peaks {i.e. close in space) associated with 
vicinal coupling constant of 3J of 3 Hz (the latter was only observed in S-(R)-104 due to 
signal overlap in the (S)-isomer), were noted between 5-H and the SCH2 protons in 
both the (S)- and (R)-isomers. In B, the conformations of the two substituents are 
axial/equatorial and equatorial/equatorial (see highlighted protons in Scheme 44). In 
the higher-energy and disfavoured conformation A, they are axial/equatorial and 
axial/axial. The coupling constant of 3J ~ 8-9 Hz is therefore too large to be an 
axial/equatoriai or equatorial/equatorial coupling, and the oniy possible conformer of 
this intramolecular hydrogen-bonding system is A.
Scheme 44. Conformational change in the fused-ring intramolecular hydrogen-bonding system of 104. 
(Hydrogen bonds -  blue; 5-H and SCH2 protons -  red)
Since the less polar S-(R)-104 was afforded as an oil, X-ray crystallography 
determination was not possible. However, the more polar S-(S)-104 was obtained as a 
solid. Recrystallisation (in EtOH/hexane) and subsequent X-ray analysis of the 
crystalline S-(S)-104 provided information on the solid-state conformation with probable 
intermolecular hydrogen-bonding interactions (vide infra, Figure 32). It is noteworthy 
that the comparison of dihedral angles with the corresponding coupling constants from 
the 1H NMR spectrum might not be consistent since coupling constants were derived 
from the proposed intramolecular hydrogen-bond conformation in solution in 
chloroform. Therefore, the conformations in the liquid and solid state might be different. 
Furthermore, only one set of coupling constants of both SCH2 and BnOCH2 could be 
calculated due to the overlapped signals of the protons (the multiplet at 6 3.50 to 5 
3.54). A vicinal coupling constant of 3J ~ 7.9 Hz between 4-H and 5-H corresponds with 
a dihedral angle (C8-H)-(C8-C)-(C9-C)-(C9-H) = 139°. A three-bond coupling constant 
of 3J = 5.3 Hz was calculated between 4-H and one of the BnOCH2 protons at 5 3.64, 




axial/equatorial 3J ~ 3-5 Hz 
axial/axial 3J  ~ 8-12 Hz
axial/equatorial 3J ~ 3-5 Hz 
equatorial/equatorial 3J  ~ 2-3 Hz
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167° or the dihedral angle (C9-H)-(C9-C)-(C10-C)-(C10-Hb) of 74°. A coupling constant 
of J = 8.2 Hz was calculated for the SCH proton at 6 3.39, which is consistent with the 
dihedral angle (C8-H)-(C8-C)-(C7-C)-(C7-Hb) of 179°. However, a coupling constant of 
3J = 3.4 Hz calculated between 5-H and one of the SCH protons at 5 3.50 to 8 3.54 is 
inconsistent to the dihedral angles (C8-H)-(C8-C)-(C7-C)-(C7-HA) of 65° or 















Figure 32. X-ray crystal structure of 4S,5R,S(S)-4-(benzyloxymethyl)-2,2-dimethyl-5-(phenylsulfonimidoyl- 
lmethyl)-1,3-dioxolane S-(S)-104, with crystallographic numbering.
Further examination of the dihedral angles was undertaken to explore the details of 
local conformations in the crystal and their values are summarised in Table 9.
Crystallographic numbering Dihedral angle (°)
C(14)-0(4)-C(10)-C(9) 173




S(1 )-C (7)-C(8)-0(2) 66
C(6)-C(1 )-S(1 )-0 (1 ) 14
C(6)-C( 1 )-S( 1 )-N( 1) 148
C(1 )-S(1 )-C(7)-C(8) 82
Table 9. Data for dihedral angles obtained from X-ray crystal structure of S-{S)-104.
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As expected, the bulky groups are anif-periplanar with respect to the O(4)-C(10) bond 
with (jitedisl angles C(14.)-Q(4)-C(1i))-Q(9) = 173° mad. C(1XDrQ(4>C(t4)haC15). = 164°. 
The BnO substituent is anti-periplanar with respect to the C(9)-C(8) bond, with dihedral 
angle O(4)-C(10)-C(9)-C(8) = 170°, but is gauche to 0(3) with dihedral angle 
O(4)-C(10)-C(9)-O(3) = 75°. The bulky sulfoximine-phenyl group is antf-periplanar with 
respect to the C(9)-C(8) bond with dihedral angle S(1)-C(7)-C(8)-C(9) = 177°, but is 
gauche to 0(2) with dihedral angle S(1)-C(7)-C(8)-0(2) = 66°. Interestingly, the 
sulfoximine oxygen atom is syn-periplanar to C(6) with dihedral angle 
C(6)-C(1)-S(1)-0(1) = 14°. The sulfoximine nitrogen atom is anticlinal to C(6) with 
dihedral angle C(6)-C(1)-S(1)-N(1) = 148°. The bulky sulfoximine-phenyl group and the 
dioxolane group are gauche with respect to the S(1)-C(7) bond with dihedral angle 
C(1 )-S(1 )-C(7)-C(8) = 82°.
The sulfoximine S=N bond length was found to be 1.517 A, with a S=0 bond length of 
1.459 A. Bond angle was also established and these values are presented in Figure 33 
(vide infra). They are consistent with those reported by Kumar et a/.,188 who studied a 
range of theoretical isomeric sulfoximines with a formula of H2S(=0)=NR, where R = H, 
Cl, F, Me. The group reported a calculated bond angle 0=S=N = 127.2°. In the 
sulfoximine of S-(S)-104, the bond angle 0=S=N was calculated to be 121.8°, which is 
consistent with the literature source.
Figure 33. Bond angles (°) and bond lengths (A) of a theoretical sulfoximine group studied by Kumar et aI. 
and the measured data of the sulfoximine-group in S-(S)~104.183
With the absolute configuration established, acid-hydrolysis of S-(R)-104 with HCI gave 
the corresponding diol S-(R)-105 in quantitative yield (vide supra, Scheme 43). 
Removal of the acetonide CMe2 group revealed the two hydroxy groups. The 
characterisation of S-(R)-105 was supported by the strong OH absorption (3305 cm-1) 
in the IR spectrum, in addition to the sulfoximine NH absorption observed previously. 
The 1H NMR spectrum showed the absence of the CMe2 acetonide protons together 
with signals for OH (a broad singlet at 5 2.68), SCH2 (two double doublets at 5 3.13 and
H Ph
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8 3.45), BnOCH2 (a multiplet at 8 3.59 to 8 3.63), 3-H (a multiplet at 8 3.69), PhCH2 and
4-H (an overlapped multiplet at 8 4*54 to 8 4.56) and ten aromatic protons. The 
multiplicity observed in the spectrum may be reasoned by possible intramolecular 
hydrogen bonding between the two hydroxy groups and the protons on the open chain.
3.2.3 Syntheticapproaches to the 3-bromophenyl sulfoximine intermediate
The proposed ring-closure strategy to synthesise the ribosyl moiety in target 39 using a 
Mitsunobu reaction was based on the knowledge of the reaction giving rise to inversion 
of configuration in secondary alcohols. However, to date, there are no literature 
methods describing a Mitsunobu condensation reaction between a sulfoximine NH and 
a secondary alcohol. A method described by Garofala et a/.,189 i.e. the use of TBP and 
ADDP in an interesting intramolecular Mitsunobu cyclisation of a disubstituted pyrrole, 
was followed but the reaction only led to recovery of the starting diol S-(fi)-105.
The group reasoned the use of a Mitsunobu condensation with the acidic pyrrole NH 
due to an electron-withdrawing aldehyde ortho-substituent and that the TBP/ADDP 
system is compatible even with weakly acidic protons (pKa ~ 13).190 Therefore, a 
speculative explanation for the failure of performing an intramolecular Mitsunobu 
cyclisation in S-(R)-105 is that the sulfoximine NH is not sufficiently acidic to be a good 
Mitsunobu reagent.
It was decided that the same synthetic sequences were to be applied on the target 
starting compound, 3-bromothiophenol 87, to give the corresponding meta-subsituted 
vicinal diol 92 (vide infra, Scheme 45). The presence of the bromine substituent might 
influence the acidity of the sulfoximine NH and subsequent Mitsunobu reaction 
outcome.
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Scheme 45. Synthetic approaches to intermediate 107. Reagents and conditions: (i) TBP, ADDP, 
3-bromothiophenol 87, THF, sonication; (ii) mCPBA, DCM, -7 8  °C; (iii) CF3CONH2, MgO, Rh2(OAc)4, 
Phl(OAc)2, DCM; (iv) NH3, MeOH; (v) HCI, MeOH; (vi) TBP, ADDP, THF, sonication, R T to  45°C.
Since the optimum Mitsunobu condensation reaction conditions have already been 
investigated with the model thiophenol 100, dioxolane compound 98 was treated with 
3-bromothiophenol 87 using the two most efficient systems: TPP/DIAD and TBP/ADDP 
in THF to give sulfide 88 in 49% and 69% yields, respectively. Subsequent mCPBA 
oxidation gave the corresponding diastereomeric sulfoxides 89a/b (Scheme 45).
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Apart from the apparent changes in the Br-Ph aromatic protons region, the 1H NMR 
and 1H-1H COSY spectra of 89a/b were similar to that of the non-substituted sulfoxides 
102a/b. Two separate sets of signals were observed in the 1H NMR spectrum, which 
pointed to the existence of two diastereomeric sulfoxides. Similar to the 1H NMR 
analysis of 102a/b, the key region of the spectrum of 89a/b lies in the range of 5 2.8 to 
8 4.6 and analysis was conducted in a 600 MHz spectrometer to improve resolution 
and separation of signals. Together with a 1H-1H COSY spectrum, the two sets of 
diastereomeric protons were assigned (vide infra, Figure 34). Furthermore, a 
diastereomeric ratio of 1:1 was calculated (together with the TLC results, showing two 
visible spots in identical sizes), indicating that the 3-bromo group did not influence 
diastereoselectivity.
The two sets of CMe2 protons gave two singlets each for one and a half protons at 
81.36 and 5 1.41, with another singlet signal for three protons at 8 1.45. In the 1H 
spectrum of the starting sulfide 88, the signals of the CMe2 protons were shown as two 
singlets at 8 1.39 and 81.43, each for one and a half protons. Therefore, there was no 
apparent upfield or downfield shift between the two diastereomeric sulfoxides 89a/b 
and between the starting material and the sulfoxide products. Expectedly, the presence 
of the 3-bromo group did not influence the chemical shifts of the CMe2 protons.
In the 1H NMR spectrum of starting sulfide 88, the multiplet signal of the SCH2 protons 
was more upfield (8 3.16 to 8 3.19) than the signals for the BnOCH2 protons (8 3.59 to 8 
3.66). This effect, which is similar to that of the non-substituted derivatives, was also 
observed with sulfoxides 89a/b. Signals for the SCH2 protons of both isomers of 89 
appeared in the region of 8 2.82 to 8 3.20, revealing that the anticipated downfield 
effect on the SCH2 protons of the electronegative sulfoxide oxygen was insignificant.
The 1H-1H COSY spectrum showed that the SCH2 protons of isomer A gave a pair of 
double doublets at 8 2.83 and 8 3.06, each for half a proton, whereas the two double 
doublet signals for the SCH2 protons of isomer B, each for half a proton, were located 
at 8 3.04 and 8 3.18. Subsequent assignment of 5-H for both isomers was possible by 
the cross-peak connections with 8 4.39 and 8 4.00, corresponding to the 5-H for isomer 
A and B, respectively.
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Figure 34. 1H NMR spectra of diastereomeric 89a/b. (A) is the 1-D 1H NMR spectrum of the key region 8 
2.8 to 5 4.6; (B) is the 1H-1H COSY spectrum, showing the cross-peak connections in each 
diastereoisomer.
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The BnOCH2 proton of isomer A gave a double doublet signal for half a proton at 5 
3.68, with the other half-proton signal coincided with that of the BnOCH2 half-proton 
signal of isomer B, resulting in a multiplet at 8 3.46 to 8 3.64. A cross-peak connection 
between the BnOCH2 protons and 4-H at 8 3.91 was also observed on the 1H-1H COSY 
spectrum. A double doublet signal for half a proton at 8 3.62 belonged to the BnOCH2 
proton of isomer B, with the signal of its 4-H located at 8 4.13.
The PhCH2 protons in the starting sulfide 88 gave a singlet at 8 4.57. In the 
diastereomeric sulfoxides 89a/b, these proton signals gave a singlet at 8 4.51 for one 
proton, and at 8 4.52 and 8 4.55 as two doublets each for half a proton. Thus the 
PhCH2 protons are magnetically inequivalent in 88 and one of the isomeric 89 (as 
expected for diastereotropic protons), but are accidentally equivalent in the other 
isomer of 89.
In isomer A, the 4-H signal (8 3.89) is more upfield to that of 5-H (8 4.39), whereas, in 
isomer B, the 4-H signal (8 4.13) is slightly more downfield than that of 5-H (8 4.00). 
Thus, 4-H is more upfield in isomer A than isomer B, whereas 5-H is significantly more 
downfield in isomer A than isomer B. The origins of the differences in chemical shifts 
for both 4-H and 5-H of the diastereomeric sulfoxides 89a/b were investigated by MM2 
energy-minimised calculations on the S-(R)- and S-(S)-isomers but no apparent 
reasons could be concluded to explain such effects (Figure 35).
S-(/?)-89 S-(S)-89
Figure 35. MM2-energy minimised models of S-(R)-89 and S-(S)-89. The red colour refers to oxygen, the 
yellow refers to sulfur, the maroon refers to bromine and the grey refers to the carbon atom.
Subsequently, 89a/b were converted to the diastereomeric N-TFA sulfoximines 90a/b 
via Rh(ll)-catalysed imination using Phl(OAc)2, Rh2(OAc)4, MgO and CF3CONH2 in 
DCM (vide supra, Scheme 45). TLC of 90a/b showed two visible spots in identical 
sizes. Unfortunately, attempts to separate the diastereoisomers chromatographically 
led to co-elution. Severe signal overlap of the 1H spectrum made determination of the
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diastereomeric ratio difficult. As observed with the non-substituted N-TFA sulfoximines 
103a/b, the diastereomeric ratio of 90a/b could not be determined by comparing the 
integrals of the singlet signals normally seen for the PhCH2 protons, since the signals 
appeared to have coincided with each other, giving one singlet. Therefore, the 
diastereomeric ratio was determined by a 10F NMR spectrum in which the two singlets 
for the CF3 fluorines at 5-76.0 and 5-75.9 were seen, in a 1:1 integral ratio. This 
finding was different to that of 103a/b, where asymmetric induction in the imination step 
slightly disrupted diastereoselectivity and changed the diastereomeric ratio from 1:1 (at 
the oxidation step) to 3:2. The presence of the 3-bromo substituent might play a role in 
determining the yields of the individual stereoisomers.
Due to the extensive signal overlap in the 1H NMR spectrum, interpretation of coupling 
constants was extremely difficult. As seen in the spectrum of the non-substituted 
N-TFA sulfoximines 103a/b, the signals for the SCH2 protons in 90a/b appeared more 
downfield than the BnOCH2 protons. Further proton and carbon assignments were 
conducted by the different spectroscopic data from the 13C NMR, 135-DEPT and 1H-13C 
COSY (HMQC) spectra. Cross-peaks between two SCH2 carbons at 5 58.4 and 5 59.4 
and the various SCH2 proton signals at 6 3.70 to 5 3.75,5 3.76,5 4.05 and 6 4.09, 
indicate that the signals for the SCH2 protons in 103a/b were shifted markedly 
downfield compared to the starting sulfoxides 102a/b where these protons resonated at 
5 3.04 to 5 3.18. Therefore, the presence of the TFA group caused a marked downfield 
effect in the region of the SCH2 protons, with the environment for the BnOCH2 protons 
being relatively unaffected and thus the relative locations of these two groups of 
protons were opposite to those in the starting materials 102a/b.
Removal of the TFA group afforded the free NH sulfoximine 91 as a mixture of 
diastereoisomers, which were separated chromatographically {vide supra, Scheme 45). 
The NMR spectra of both the S-(R)- and S-(S)-isomers of 91 were similar, with similar 
chemical shifts for the CMe2, SCH2, BnOCH2, 4-H, 5-H and PhCH2 protons. There was 
no apparent upfield or downfield shifts between the diastereomeric sulfoximines.
Interestingly, removal of the TFA group which, in the 1H spectra of the non-substituted 
S-(R)- and S-(S)-sulfoximines 104, led to a marked upfield shift of the double doublet 
signals of the SCH2 protons, did not cause this effect in the 3-bromophenyl 
sulfoximines S-(R)- and S-(S)-91. In the starting N-TFA compounds 90a/b, these 
protons resonated at 5 3.34 to 5 3.54. In S-(R)-91, the signals for SCH2 appeared at 5 
3.34 and 5 3.46, whereas in the (S)-isomer, they appeared at 5 3.38 and 5 3.54.
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Furthermore, the upfield effect observed for the CMe2 protons between the 
non-substituted N-TFA sulfoximines 103a/b and the corresponding NH sulfoximines 
S-(R)- and S-(S)-104 was also negligible in the 3-bromo derivatives. In the starting 
N-TFA sulfoximines 90a/b, these geminal methyl groups gave four singlet signals, each 
for one and a half protons, at a range of 5 1.15 to § 1.28. The signals of the CMe2 
protons of S-(R)-91 appeared as two singlets at § 1.22 and 5 1.32, each for three 
protons. In the S-(S)-isomer, these protons gave two singlets at 8 1.20 and 8 1.30.
Two-dimensional 1H NMR analyses provided useful information on the assignment of 
the spectra of the diastereomeric sulfoximines S-(R)- and S-(S)-91. The COSY 
spectrum for S-(R)-91 gave the expected coupling relationships, with a cross-peak 
between the SCH2 protons and the double-double doublet at 8 4.31, indicating that the 
latter signal is due to 5-H. A cross-peak between the BnOCH2 protons and the 
double-double doublet at 8 3.86 was also noted and it was concluded that this signal is 
due to 4-H. The NOESY spectrum of S-(R)-91 showed the expected connectivities 
between the PhCH2 protons and the BnOCH2 protons (vide infra, Figure 36a/b). A 
cross-peak between 4-H and the singlet signal of the CMe protons at 8 1.22 indicates 
that the latter signal was due to the geminal methyl group trans to BnOCH2. Similarly, a 
cross-peak between 5-H and the singlet at 8 1.32 indicates that the latter signal is due 
to the methyl group cis to BnOCH2. Weak connectivities were seen between the two 
double doublet signals for the SCH2 protons at 8 3.34 and 8 3.46 and 5-H. A stronger 
cross-peak noted between 5-H and one of the BnOCH protons at 8 3.53 confirms that 
5-H and the BnOCH2 protons are on the same face of the ring i.e. they are cis to each 
other. It is noteworthy that the cross-peak between 4-H and its cis partner, the SCH2 
protons, was found to be weaker compared to that between 4-H and the BnOCH2. 
Nevertheless, a weak NOE connectivity between 4-H and 5-H suggests that the 
protons are on the opposite face of the ring and thus are trans to each other, and this 
finding is supported by a vicinal coupling constant of 3J = 7.8 Hz between 4-H and 5-H.
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Figure 36b. 1H-1H NOESY spectrum of 4S,5f?,S(R)-4-(benzyloxymethyl)-2,2-dimethyl-5-(3-bromophenyl- 
sulfonimidoylmethyl)-1,3-dioxolane S-(R)-91.
The COSY spectrum of S-(S)-91 showed the anticipated coupling relationships. 
Cross-peaks were observed between the two double doublet signals for the SCH2 
protons at 6 3.38 and 8 3.52 and the double-double doublet at 8 4.33, indicating that 
the latter signal is due to 5-H. Connectivities were also seen between the pair of double 
doublets for the BnOCH2 protons at 8 3.52 and 3.66 and the double-double doublet at 8 
3.89, hence the latter signal is due to 4-H. This was further supported by cross-peaks 
between 4-H and 5-H.
The NOESY spectrum contains the expected through-space connectivities between the 
singlet signal for the PhCH2 protons at 8 4.53 and the two double doublets for the 
BnOCH2 protons (vide infra, Figure 37). A cross-peak between 4-H and the singlet for 
the CMe2 protons at 8 1.20 indicates that the latter refers to the geminal methyl group 
trans to BnOCH2. Similarly, the cross-peak between 5-H and the remaining CMe singlet 
8 1.31 indicates that this signal corresponds to the methyl group cis to BnOCH2. Due to
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overlapped cross-peaks, interpretation of the relative configuration between the two 
pairs of cis-partners, 4-H and the SCH2 protons and 5-H and the BnOCH2 protons, was 
difficult. A weak NOE connectivity between 4-H and 5-H suggests that the protons are 
on the opposite face of the ring and thus are trans to each other, and this finding is 
supported by a vicinal coupling constant of 3J = 8.0 between 4-H and 5-H.
PhCH2
CMe trans to 
BnOCH2
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Figure 37. 1H-1H NOESY spectrum of 4S,5R,S(S)-4-(benzyloxymethyl)-2,2-dimethyl-5-(3-bromophenyl- 
sulfonimidoylmethyl)-1,3-dioxolane S-(S)-91.
Crystals of S-(S)-91 were grown in an EtOH/hexane system and the X-ray 
crystallography data provided conclusive information on the relative configurations 
(vide infra, Figure 38). Extensive separation of the proton signals in the 1H NMR 
spectrum gave all the required coupling constant values, which could be compared with 
the corresponding dihedral angles calculated in the crystal structure. As mentioned
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above, a vicinal coupling constant o f3J = 8 Hz was measured between 4-H and 5-H. 
This corresponds to dihedral angle (C8-H)-(C8-C)-(C9-C)-(C9-H) of 147°. A coupling 
constant of 3J ~ 8.6 Hz between the double doublet signal at 8 3.38 for one of the SCH2 
protons and 5-H corresponds to the dihedral angle (C8-H)-(C8-C)-(C7-C)-(C7-HB) of 
177°. Similarly, a 3J value of -  3.0 Hz between the double doublet SCH proton signal at 
8 3.54 and 5-H corresponds to the dihedral angle (C8-H)-(C8-C)-(C7-C)-(C7-HA) of 67°. 
This allowed the assignment of the proton signal at 8 3.38 as arising from the axial 










Figure 38. X-ray crystal structure of 4S,5R,S-(S)-4-(benzyloxymethyl)-2,2-dimethyl-5-(3-bromophenyl- 
sulfonimidoylmethyl)-1,3-dioxolane S-{S)-91, with crystallographic numbering.
In the chloroform (CDCI3) solution of S-(S)-91, two vicinal coupling constants between 
the double doublet BnOCH proton signals at 8 3.52 and 8 3.66 and 4-H were found to 
be 3J = 5.1 Hz (for the signal at 8 3.66) and 6.3 Hz (for the signal at 8 3.52). In the solid 
state, the corresponding dihedral angles are 161° [(C9-H)-(C9-C)-(C13-C)-(C13-HA)] 
and 79° [(C9-H)-(C9-C)-(C13-C)-(C13-HB)], which are inconsistent with the coupling 
constants. This suggests that, similar to the observations noted with S-(S)-104, the 
conformations of S-(S)-91 in the solid state and liquid state are different.
Further examination of the dihedral angles was undertaken to explore the details of 
local conformations in the crystal of S-(S)-91 and compare to those in the crystal of the 
phenyl sulfoximine S-(S)-104. These are summarised in Table 10 (vide infra).
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C(14)-0(4)-C(10)-C(9) 173 C( 14 )-0 (4 )-C ( 13)-C(9) 177
C( 10)-O(4)-C( 14)-C( 15) 164 C( 13 )-0 (4 )-C ( 14)-C( 15) 171
0(4)-C(10)-C(9)-C (8) 170 0(4)-C(13)-C(9)-C (8) 164
0(4)-C(10)-C(9)-O (3) 75 0(4)-C (13)-C (9)-0 (3) 81
S(1 )-C(7)-C(8)-C(9) 177 S(2)-C(7)-C(8)-C(9) 176
S (1)-C (7)-C(8)-0(2) 66 S(2)-C (7)-C (8)-0(2) 67
C(6)-C(1)-S(1)-0(1) 14 C (2)-C (3)-S (2)-0(1) 20
C(6)-C(1 )-S(1 )-N(1) 148 C(2)-C(3)-S(2)-N(1) 155
C(1 )-S(1 )-C(7)-C(8) 82 C(3)-S(2)-C(7)-C(8) 76
Table 10. Comparative dihedral angles of the phenyl sulfoximine S-(S)-104 and 3-bromophenyl derivative 
S-{S)-91.
As observed in the phenyl sulfoximine S-(S)-104, the bulky groups in 3-bromophenyl 
sulfoximine S-(S)-91 are anti-periplanar with respect to the 0(4)-C(13) bond with 
dihedral angles C(14)-0(4)-C(13)-C(9) = 177° and C(13)-0(4)-C(14)-C(15) = 171°. The 
BnO substituent is anti-periplanar with respect to the C(9)-C(8) bond, with dihedral 
angle 0(4)-C(13)-C(9)-C(8) = 164°, but is gauche to 0(3) with dihedral angle 
0(4)-C(13)-C(9)-0(3) = 81°. The sulfoximine-3-bromophenyl group is anti-periplanar 
with respect to the C(9)-C(8) bond with dihedral angle S(2)-C(7)-C(8)-C(9) = 176°, but 
is gauche to 0(2) with dihedral angle S(2)-C(7)-C(8)-0(2) = 67°. The sulfoximine 
oxygen atom is syn-periplanar to C(2) with dihedral angle C(2)-C(3)-S(2)-0(1) = 20°. 
The imino nitrogen atom is anticlinal to C(2) with dihedral angle C(2)-C(3)-S(2)-N(1) = 
155°. The bulky sulfoximine-phenyl group and the dioxolane group are gauche with 
respect to the S(2)-C(7) bond with dihedral angle C(3)-S(2)-C(7)-C(8) = 76°.
The sulfoximine S=N bond length in S-(S)-91 was found to be 1.512 A, with a S=0 
bond length of 1.46 A. Bond angle was also established and these values are 
presented in Figure 39 (vide infra). The values are similar to those of the 
non-substituted sulfoximine S-(S)-104. In the sulfoximine of S-(S)-104, the bond angle 
0=S=N was calculated to be 121.8°, whereas in S-(S)-91 the corresponding angle was 
122 .2° .
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Sulfoximine moiety in S-(S)-104 Sulfoximine moiety in S-(S)-91
Figure 39. Bond angles (°) and bond lengths (A) of the two sulfoximines in 3-{3)-104 and S-(S)-91.
The next step of the synthesis was an acid-hydrolysis of the cyclic ketal in the 
S-(R)-sulfoximine 91, which gave the corresponding diol S-(/?)-92 in quantitative yield 
(vide supra, Scheme 45). Its IR spectrum showed a strong absorption of OH (3425 
cm'1). The 1H spectrum showed the lack of CMe2 signals with the signals for OH (two 
broad singlets at 5 3.00), SCH2 (a doublet at 8 3.13 and a double doublet at 5 3.45), 
BnOCH2 (a multiplet at 5 3.59 to 8 3.64), 2-H (a multiplet at 5 3.70), 3-H (a broad singlet 
at 5 4.55), PhCH2 (two doublets at 8 4.52 and 84.54) with nine aromatic protons. 
S-(R)-92 was subjected to the same intramolecular Mitsunobu cyclisation conditions as 
those for the model reaction (TBP/ADDP). However, even at extended reaction times, 
TLC of the reaction mixture revealed only the presence of starting materials. Changes 
in temperature (RT to 45°C) did not alter this outcome.
Failure of this intramolecular Mitsunobu cyclisation could be explained by the following 
possibilities:
1. The acidity of a sulfoximine NH was insufficient to take part in the reaction.
2. Formation of a four-membered ring involving the sulfoximine NH and the 3-OH 
(vide supra, Scheme 45).
3. The presence of two adjacent secondary alcohols might cause a diversion of 
reaction progress and a possible intramolecular cyclisation between the two OH 
groups, resulting in an oxirane.
To test the possible involvement of the hydroxy groups, a series of experiments was 
devised to protect the 3-OH selectively while leaving the 2-OH free for cyclisation to 
occur with the NH of the sulfoximine.
The wide application of the 4-methoxybenzyl (PMB) group for hydroxy group protection 
has been highlighted by Johansson et a/.190 It is a useful protecting group since it is 
often removable in the presence of other protecting groups such as benzyl ethers 
(OBn), by oxidation with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) or by acidolysis
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with TFA. The PMB group is usually prepared, like the Bn group, by etherification using 
the corresponding benzyl halide and a base. However, alternative synthesis of PMB 
groups via a diastereoselective reductive ring-opening of 4-methoxybenzylidene 
acetals has attracted considerable interest because of the potential regioselectivity. 
The 1 ,3-dioxane of the benzylidene acetal is ring-opened by a reducing agent, giving a 
mixture of two diastereoisomers. The traditional Lewis-acidic reducing agents include 
UAIH4-AICI3 in THF, NaCNBHs-Me3SiCI in acetonitrile and diisobutylaluminium hydride 
(DIBAL-H) in DCM. Regioselectivity is influenced by the steric bulk of the substituents 
at the oxygen atoms and the approaching electrophiles. The reducing agents named 
above are all sterically demanding, causing an attack on the less sterically bulky 
oxygen, and the more hindered alcohol is protected with the PMB group.190
Riley et al. described the use of 4-methoxybenzyiidene acetal as a protecting group for 
the hydroxy groups in ribofuranosides.191 Upon protection of the 2’-OH and 3-OH 
groups using 4-methoxybenzaldehyde dimethyl acetal, the resulting 4-methoxy- 
benzylidene derivative was afforded as a mixture of diastereoisomers. Cleavage of the 
acetal with DIBAL-H (best yielding reagent) proceeded with no regioselectivity and both 
the 2’- and 3’-0-(4-methoxybenzyl) ethers were obtained (1:1 ratio).
The investigation commenced with the N-TFA sulfoximines 90a/b (vide infra, Scheme 
46a) since nitrogen requires protection at this stage of the synthesis to avoid the PMB 
group being inserted at the nitrogen atom, with a view to separate the stereoisomers at 
the sulfur at an appropriate stage throughout the sequence. Therefore, 90a/b would 
first be hydrolysed to the corresponding diol compounds 108a/b. Treatment with acetal 
110 would give the 2,3-0-(4-methoxy)benzylidene derivatives 111a/b, and subsequent 
reductive cleavage of the acetal with DIBAL-H in DCM should give a mixture of 2- and
3-O-p-methoxybenzyl ethers 112a/b and 113a/b, respectively. Removal of the TFA 
group in 113a/b and possible separation of diastereoisomers gives the resulting
S-(/?)-sulfoximine 114, with the 2-OH free to participate in the subsequent step. Intra­
molecular Mitsunobu cyclisation would give the cyclic product 115 and subsequent 
removal of protecting groups and FGI (cyanation and hydration of nitrite) should afford 
the target compound 39.
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2. Removal of Bn
3. FGI (cyanation, hydration of nitrile)
Scheme 46a. Synthetic approaches to target benzamide 2-deoxyriboside analogue 39 via PMB-protected 
dioxolane derivatives 111a/bt allowing the required 2-OH free for cyclisation.
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By protecting the 3-OH selectively, a number of issues could be addressed:
1. The possible influence of the extra hydroxy group in the Mitsunobu reaction in 
the formation of a four-membered ring;
2. If this extra hydroxy group affects the formation of the Mitsunobu phosphonium 
intermediate.
In addition, since there are no known literature reports on the use of a sulfoximine NH 
group in Mitsunobu reactions, the presence of only one free hydroxy group and one 
sulfoximine NH as two reactive possibilities in 114 would allow the investigation of the 
compatibility of a sulfoximine NH as a potential nucleophilic component in Mitsunobu 
reactions.
If sulfoximines are to be proven as poor nucleophilic Mitsunobu reagents, a different 
and comparatively longer route for the synthesis of 115 could also be derived from 
113a/b. Replacement of the 2-OH with a reactive leaving group and subsequent 
removal of the TFA protecting group would result in an intermediate for a conventional 
Sn2 reaction, giving the ring-closed product 115 (Scheme 46b).





1. Activation of OH
2. Removal of TFA








Scheme 46b. A different route starting from 113a/b via a conventional Sn2 reaction would also give the 
cyclised product 115.
4-Methoxybenzaldehyde dimethyl acetal 110 is usually derived from the corresponding 
aldehyde 109 using trimethyl orthoformate/p-TsOH or MeOH/p-TsOH (vide infra, 
Scheme 47). Recently, De et al. reported the use of ruthenium(lll) chloride as a Lewis 
acid catalyst in the synthesis of 110 with MeOH.192 It was found that, with a catalytic 
amount of RuCI3, conversion was completed in 5 h, yielding 110 in 84%. Acetalisation 
is a common protecting method of carbonyl groups and Lewis acid catalysts are often 
used, and De et a/, applied this knowledge to the synthesis of various acetals.
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Scheme 47. Synthesis of 4-methoxybenzaldehyde dimethyl acetal 110. Reagents and conditions: (i) 
R11CI3, MeOH, reflux; fii) trimethyl orthoformate, p-TsOH, reflux.
However, subjecting 4-methoxybenzaldehyde 109 to the same conditions described by 
De et al. failed to produce the corresponding acetal 110.192 TLC of the reaction mixture 
after 48 h showed only traces of a new product, with the majority of the starting 
aldehyde 109 still present (Scheme 47).
The traditional method using trimethyl orthoformate and p-TsOH was followed as 
described by Johansson et al. (Scheme 47),190 and 4-methoxybenzaldehyde dimethyl 
acetal 110 was obtained in excellent yield.
With the acetal compound 110 in hand, attention was then turned to synthesise the 
required N-TFA diols 108a/b and pursue the subsequent steps in the study. 
Acid-hydrolysis of the acetal of dioxolanes 90a/b gave 108a/b in moderate yield {vide 
infra, Scheme 48). Unexpectedly, the NMR spectra of 108a/b showed the existence of 
only one diastereoisomer. In particular, the 13C spectrum revealed only one set of 
signals. Three CH2 carbon signals were observed at 5 59.6, 5 71.5 and 5 73.7 which 
represent the SCH2, BnOCH2 and PhCH2 carbons, respectively. Moreover, as only one 
singlet at 5 -76.0 was seen in the 19F spectrum, it was concluded that only one TFA 
group was present in the compound and thus there was only one diastereoisomer. 
Repeated attempts at recrystallisation to obtain a crystalline product failed.
Since X-ray analysis was not available for 108a/b, the configuration at the sulfur atom 
was unclear. Nevertheless, it was decided that this compound would be subjected to 
the subsequent reaction with acetal 110. The resulting benzylidene derivatives 111a/b 
should be obtained as a mixture of diastereoisomers (as described by Riley et a/.191) 
and separation of diastereoisomers and X-ray analysis might be possible at this stage. 
Disappointingly, the attempted acid-catalysed reaction of 108a/b with the acetal 110 
was unsuccessful. Increasing reaction temperature to 100°C and extending reaction 
duration to 36 h failed to give the benzylidene derivatives 111a/b. TLC of the reaction
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mixture indicated presence of only starting materials and no considerable progress was 











Scheme 48. Attempted synthesis of the benzylidene derivatives 111a/b. Reagents and conditions: (i) HCI, 
MeOH; (ii) 110, p-TsOH, DMF, 70°Cto 100°C.
An alternative procedure to discriminate between the two secondary alcohols in the 
sulfoximine diol S-(R)-92 was sought to protect 3-OH selectively and expose the free 
2-OH and the sulfoximine NH for subsequent SN2 ring-closure reaction {vide infra, 
Scheme 49). Reaction of S-(R)-92 with DMP would give either a five-membered ring 
dioxolane S-(f?)-91, which was synthesised previously {vide supra, Scheme 45), or a 
six-membered ring product. The two hydroxy groups in the latter would be 
discriminated. Replacement of the free 2-OH with a reactive leaving group and 
subsequent removal of the acetal would expose the sulfoximine NH. Similar to the PMB 
strategy, a SN2 reaction between the NH and 2-OH would give the ribosyl derivative 
107 (vide infra, Scheme 49).
It was reasoned that the third alternative product, a seven-membered ring product, 
would be thermodynamically unfavourable and the possibility of its formation would be 
small. Furthermore, the five- and six-membered products could be differentiated by 1H 
NMR analysis from the coupling constants of the SCH2 protons, since the 
six-membered product resembles a chair-conformation.
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Scheme 49. Alternative synthetic approaches to target 39 via an acid-catalysed PMB cyclisation.
Treatment of S-(R)-92 with DMP and p-TsOH in refluxing CHCI3gave three products in 
a 3:1:1 ratio (Scheme 50). The 1H NMR spectrum of the major product showed that it 
contained the previously-afforded five-membered ring dioxolane S-(R)-91, with the 
signals of CMe2(two singlets at 5 1.22 and 5 1.32), SCH2 (double doublet at 5 3.34, J = 
14.5, 8.6 Hz; double doublet at 5 3.47, J = 14.5, 2.7 Hz), BnOCH2 (double doublet at 5 
3.52, J = 9.8, 6.3 Hz; double doublet at 8 3.68, J = 9.8, 4.7 Hz), 4-H (double-double 
doublet at 8 3.89, J = 7.8, 6.3, 4.7 Hz), 5-H (double triplet at 8 4.31, J = 2.7, 8.6 Hz), 
PhCH2 (singlet at 8 4.53), and the S-Ph ortho-proton (triplet at 8 8.08, J = 1.7 Hz) all 
being extremely similar or identical to those from the 1H NMR spectrum of dioxolane 
S-(R)-91.





S-(R)-91 (60%) S-(R)-89 (19%)
S-(S)-89 (20%)
Scheme 50. Attempted DMP-reaction of the diol S-(R)-92. Reagents and conditions: (i) DMP, p-TsOH, 
CHCI3, reflux.
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Unexpectedly, this reaction also led to the formation of the diastereomeric sulfoxides 
89a/b which could be separated chromatographically. Comparision of the 1H NMR 
spectra of the two isolated minor products with that of the previously synthesised 
diastereomeric sulfoxides 89a/b showed that spectrum of each of these minor products 
was identical to one of the two sets of signals in 89a/b. This finding was further 
supported by the mass spectrum of one of the minor products, showing a probable 
molecular weight of 438. An even molecular weight number corresponds to a lack of 
nitrogen in the molecule.
There are two speculative mechanisms for the formation of the diastereomeric 
sulfoxides. Reduction of the sulfoximine S-(R)-91 would give the corresponding 
sulfoxide S-(/?)-89, and subsequent epimerisation at the sulfur atom leads to the 
generation of the S-(S)-isomer. However, since epimerisation at a sulfur centre is 
usually achieved in only harsh conditions (heat in concentrated acid), it is highly 
unlikely that the relatively mild reaction conditions used (a catalytic amount of p-TsOH 
in refluxing CHCI3) could cause this loss of chirality at the sulfur centre.
Therefore, the loss of the imino NH in S-(R)-92 did not proceed with retention or 
inversion of configuration at the sulfur. The exact mechanism for this loss of 
stereochemical integrity remains unclear.
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Synthetic approaches to a 2-deoxy-D-ribose-1
phosphate analogue
4.1 Retrosynthesis
Chapter 4 Results and Discussion II
Following the success with the synthesis of a sulfide dioxolane precursor to the target 
benzamide 2-deoxyriboside analogue 39, the same synthetic strategy was used to 
prepare a different target compound: the 2-deoxy-D-ribose-1a-phosphate analogue 37. 
The two targets are structurally similar, differing only at the sulfur substituents: the 
former contains an aromatic carboxamide group, whereas the latter has a 
carboxymethyl chain (Scheme 51).
Mitsunobu reaction between an alcohol of the dioxolane derivative 98 and a sulfur 
nucleophile has been proven to proceed smoothly, with thiophenol and 3-bromo- 
thiophenol giving positive results. Therefore, to synthesise the carboxymethyl 
side-chain of target 37, the same strategy could be used using an alkyl sulfur 
nucleophile. Methyl mercaptoacetate 116 was chosen as a reagent; reaction with 
dioxolane 98 should give the extracydic C-S bond in the alkylsulfide dioxolane 
precursor 117 (Scheme 51).








98 Benzamide 2'-deoxyriboside 
analogue 39
Proposed synthesis of target 37
98
HS C 0 2Me
-lie  Alkylsulfide dioxolane
precursor, 117
Target compound 37
Scheme 51. Proposed extracydic C -S  bond formation via a Mitsunobu reaction of dioxolane 98 and 
methyl mercaptoacetate 116.
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The proposed synthetic sequence to the target compound 37 is outlined in Scheme 52. 
Mitsunobu condensation of methyl mercaptoacetate 116 and dioxolane 98 gives the 
sulfide 117. Hydrolysis of the acetal generates the diol 118. An intramolecular 
cyclisation in situ between the OH and the ester carbonyl carbon would give the 
six-membered ring derivative 119. Introduction of the sulfoximine moiety is followed by 
an intramolecular Mitsunobu cyclisation. Since there is only one secondary alcohol 
available for ring closure, the reaction should proceed to form the fused ring (5/6) 
system in 121. The ester bond linkage is hydrolysed and subsequent removal of the Bn 
group would give the final target compound 37.
Methyl mercaptoacetate 116 and the dioxolane compound 98 were subjected to a 
variety of Mitsunobu conditions (vide infra, Route A, Scheme 53). They are 
summarised in Table 11 (vide infra). None of the reactions furnished the desired 
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Scheme 52. Proposed synthetic approaches to target compound 37.
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Table 11), which worked well with thiophenol and 3-bromothiophenol. The reactions 
failed to progress even under extended reaction duration and elevated temperature. 
TLC of reaction mixtures showed only the presence of starting materials in all cases.
Entry Conditions (stated in the order of addition in reaction mixture) Yield
(%)
1 TPP (2 equiv.), DIAD (2 equiv.), methyl mercaptoacetate 116 (1 equiv.), dioxolane 98
(1 equiv.), THF (10 mL)
2 TPP (2 equiv.), methyl mercaptoacetate 116 (1 equiv.), DIAD (2 equiv.), dioxolane 98
(1 equiv.), THF (10 mL)
3 TBP (1.5 equiv.), ADDP (1.5 equiv.), methyl mercaptoacetate 116 (1.5 equiv.),
dioxolane 98 (1 equiv.), THF (10 mL)
4 DPPE (0.75 equiv.), DIAD (1.5 equiv.), methyl mercaptoacetate 116 (1.3 equiv.),
dioxolane 98 (1 equiv.), THF (10 mL)
Table 11. Attempted Mitsunobu reaction conditions. (TPP = triphenylphosphine, DIAD = diisopropyl azo- 






















HS C 0 2Me 
116
Scheme 53. Attempts to synthesise sulfide intermediate 117 using methyl mercaptoacetate 116 and a 
variety of dioxolane derivatives. Reagents and conditions: (i) see Table 11; (ii) p-TsCI, EtsN, DMAP, DCM; 
(Hi) LHMDS, THF, -78°C /  t-BuOK, MeOH, 75°C/t-BuOK, DMF, 150°C; (iv) NaH, DMF, 0°C.
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It was postulated that a more efficient leaving group was required to increase the 
reactivity of the OH in 98. A tosylate derivative was considered first (Route B, Scheme 
53); tosylates (p-toluenesulfonate esters) are good substrates for substitution reactions 
with nucleophiles and they are better leaving groups than the corresponding alcohols. 
Tosylate 123 was prepared from the alcohol 98 using p-toluenesulfonyl chloride 
(p-TsCI), triethylamine and 4-dimethylaminopyridine (DMAP).
With the tosylate compound 123 in hand, a series of base-catalysed nucleophilic 
substitutions with methyl mercaptoacetate was attempted but to no avail. In all cases, 
TLC of the reaction mixtures indicated only the presence of starting materials. Changes 
in base [LHMDS, potassium ferf-butoxide (f-BuOK)], solvent (THF, MeOH, DMF), 
temperature and duration did not alter the outcome. Substituting DMF as an alternative 
solvent and heating the reaction to reflux for 72 h gave a complex mixture.
An alternative approach of generating the thiolate in situ by hydrolysis of a thioester 
was also investigated. Thioacetates are often prepared from the corresponding halides 
and potassium thioacetate in one simple step, and treatment with base (sodium 
hydroxide) gives the thiolate anion.193 Using this method, thioacetate 126 was obtained 
in quantitative yield. However, treatment of 126 with sodium hydroxide and subsequent 
addition of the tosylate 123 to the reaction mixture led only to the recovery of starting 
materials (Scheme 54).
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Scheme 54. Attempted synthesis of target intermediate 117 using thioacetate derivative 126. Reagents 
and conditions: (i) MeOH; (ii) 126, NaOH, MeOH.
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Bromide was investigated next to be a potential leaving group. However, treatment of 
the bromomethyl dioxolane 99 (vide supra, Scheme 38) with methyl mercaptoacetate 
116 and sodium hydride also failed to furnish the target intermediate 117 (vide supra, 
Route C, Scheme 53).
The above results called a halt to the synthesis of target 37 as it is fully demonstrated 
that the coupling of the thio ester to the dioxolane derivative is impossible even under 
harsh conditions. This is puzzling, since methyl mercaptoacetate is sterically less 
crowded than thiophenol and 3-bromothiophenol, and its approach to the electrophilic 
dioxolane should be favoured.
It was speculated that, since both thiophenol and 3-bromothiophenol are planar but 
methyl mercaptoacetate anion contains a tetrahedral carbon (CH2S~), the local shape of 
approaching nucleophiles might play an important role in the outcome of the reactions.
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Towards the synthesis of a PARP-1 
transition-state analogue and a 2-deoxy-D-
ribose analogue
5.1 Retrosynthesis
Chapter 5 Results and Discussion III
The second series of target compounds to be investigated are the 2-deoxy-D-ribose 
analogue 38a and the PARP-1 transition-state analogue 40. As in the previous targets 
studied, the anomeric carbon of this ribonucleoside analogue has been replaced by a 
tetrahedral sulfoximine. However, the structural scaffolding of this transition-state mimic 
is centred on the extracydic S=N bond, which mimics the C-N bond stretch observed 
when NAD+is docked into the substrate-binding site of PARP-1.
Scheme 55 (vide infra) illustrates how targets of more than one type can be produced 
by a single carefully-planned synthetic sequence. Disconnection of C-N bond of the 
transition-state analogue 40 led to two starting compounds: a 3-substituted benzamide 
and the 2-deoxy-D-ribose mimic 38a. The forward metal-catalysed N-arylation of 
sulfoximines has been studied. Palladium-catalysed N-arylation of sulfoximines was 
first reported by Bolm and Hildebrand using aryl bromides and aryl iodides as 
substrates.194,195 Different palladium catalysts and chelating phosphine ligands, the 
most reported being the Pd(OAc)2/BINAP [2,2’-bis(diphenylphosphino)-1,T-binaphthyl] 
system, were studied by the group and N-arylated sulfoximines were obtained in good 
yields. Furthermore, the reactions to convert enantiomerically pure sulfoximines to the 
arylated derivatives proceeded with retention of configuration at sulfur. A subsequent 
method reported by Harmata et al. demonstrated the use of Pd(OAc)2 with aryl 
chlorides.196 Recently, the Bolm group studied the use of copper catalysts in 
N-arylation of sulfoximines.197,198 They used Cul and base (Cs2C03, CsOAcj with aryl 
bromides and aryl iodides, and also Cu(OAc)2 with arylboronic acids for N-arylations of 
sulfoximines.198
References for the construction of a chiral 3,4-substituted tetrahydrothiophene are 
limited. However, in contemplating the syntheses of 38a, it was envisioned that the 
critical intermediate, the homochiral R,R-tetrahydrothiophene 127, could be formed 
through an asymmetric 1,3-dipolar cycloaddition similar to a published strategy. 
Karlsson and Hogberg described an efficient method to synthesise chiral tetra- 
hydrothiophenes via C-C bond forming asymmetric 1,3-dipolar cycloadditions of 
thiocarbonyl ylides.199,200 Upon reductive cleavage of the chiral auxiliary, the resulting 
trans-3,4-disubstituted tetrahydrothiophenes were obtained in high diastereomeric 
ratios and in high yields.
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By adopting this method, the C-3 and C-4 stereocentres of target compound 38a would 
be established at an early stage in a stereoselective manner. Stereocontrol at the sulfur 
atom to introduce the third chiral centre is viable using chiral sulfoxidation, resolution of 
diastereomeric sulfoximines using (+)-CSA or chromatographic separation of 
diastereoisomers after sulfoximination.134
X = Cl, Br, I, B(OH)2
c o n h 2
c o n h 2
Metal-catalysed
N-arylation
PARP-1 transition-state analogue 40 2-Deoxy-D-ribose mimic 38a
127
Scheme 55. Retrosynthetic analysis of target compounds 38a and 40.
5.2 Asymmetric 1,3-dipolar cycloaddition
Cycloadditions belong to the family of pericyclic reactions. One famous example is the 
Diels-Alder reaction, where a diene and a dienophile form a six-membered ring. 
1,3-Dipolar cycloaddition is a [3 + 2] reaction where two components, a 1,3-dipole 
(ylide) and a dipolarophile, react together to form a five-membered heterocycle (vide 
infra, Scheme 56).
Similar to a dienophile in the Diels-Alder reaction, a cycloaddition dipolarophile is a 
reactive alkene containing two 7t-electrons. Many examples of dipolarophiles include 
simple alkenes, a,p-unsaturated ketones, aldehydes and esters, alkynes and allylic 
derivatives.
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Diels-Alder
X X





Scheme 56. Mechanisms of the Diels-Alder reaction and the 1,3-dipolar cycloaddition.
The 1,3-dipole, or an ylide, is a ‘four-Tt-electron-component’ with an electrophilic end 
and a nucleophilic end. Many types of ylides exist containing nitrogen, carbon, sulfur or 
oxygen atoms and the ylides can contain one or more heteroatoms.
The cycloaddition reaction involves the four 7i-electrons of the ylide and the two 
7t-electrons of the dipolarophile in a concerted manner. The configurations of the chiral 
dipolarophiles have a major impact on the outcome of the diastereomeric products: 
frans-dipolarophiles give frans-cycloadduct, and c/s-dipolarophiles will thus yield the cis 
isomer (Scheme 57).
Scheme 57. Configuration of the dipolarophiles directly influence the geometry of the cycloadduct.
As described by Karisson and Hogberg, the asymmetric 1,3-dipolar cycloaddition 
reaction would involve a monohetero sulfur ylide with a (£)-dipolarophile linked to a
w Z-alkene gives cis isomer
©
E-alkene gives trans isomer
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chiral auxiliary, (1S)-(-)-2,10-camphorsultam (vide infra, Scheme 58).200 The sulfur 
ylide precursor, chloromethyl trimethylsilylmethyl sulfide, was desilylated with CsF, 
triggering an elimination to give the 1,3-dipole. Use of a chiral auxiliary gave high 
diastereoselectivities for a variety of dipolarophiles and allowed construction of 
enantiopure tetrahydrothiophenes. The reaction gave exclusively the two 
frans-diastereoisomers in excellent yield (88%) and high diastereoselectivity (87:13). 
The major (3R,4S)-isomer was generated together with the separable minor 
(3S,4R)-isomer. This method was, at the time, the first reported asymmetric 1,3-dipolar 














BnO, y ~ x
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Trans products
Scheme 58. Asymmetric 1,3-dipolar cycloaddition of a thiocarbonyl ylide and chiral benzyloxy 
dipolarophile, as demonstrated by Karlsson and Hdgberg.
The diastereoselectivity observed when reacting a ylide with a camphorsultam-derived 
dipolarophile was explained by Karlsson and Hogberg using a model depicted in Figure 
40 (vide infra).201 The group reasoned that the camphorsultam-linked dipolarophile 
reacts with 1,3-dipoles in a conformation where the sulfone oxygens of the sultam are 
frans-located to the carbonyl oxygen in relation to the C-N amide bond. To avoid 
possible interactions and steric clashes with the axial sulfone oxygen (Oa), attack of 
the ylide has to occur on the opposite side to that occupied by Oa. Thus, the major 
isomer obtained is the (3R,4S)-isomer.
This procedure was adopted and modified for the synthesis of the homochiral 
tetrahydrothiophene intermediate 127, using (£)-benzyloxy-a,p-unsaturated acid linked
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to (1fi)-(+)-2,10-camphorsultam as a chiral dipolarophile to give the desired relative 
configuration at C-3 and C-4.
Favoured face of attack
S -O B  H








Figure 40. Proposed diastereoselectivity mediated by (1 S )-(-)-2 ,10 -camphorsultam by Karlsson and 
Hogberg.201
5.2.1 Synthesis of the (E)-dipolarophile
Karlsson and Hdgberg prepared the chiral dipolarophile 132 using a one-pot synthesis: 
benzyl alcohol 128 and methyl propynoate 129 were treated with N-methylmorpholine 
to give the crude ester 130, which, upon hydrolysis in situ by potassium hydroxide, 
gave the acrylic acid 131 (Scheme 59).200 However, attempts to repeat this conjugate 
addition were unsuccessful. TLC of the reaction mixture prior to hydrolysis revealed the 
presence of an excess of benzyl alcohol, with little amounts of methyl propynoate and 
product, indicating that the Michael addition failed to proceed.







BnO v  OH 
131
<iv)|
BnO ^  Xc 
Xc = (1 /?)-(+)-2,10-camphorsultam 132
Scheme 59. Attempted synthesis of chiral (£)-benzyloxyacrylate dipolarophile 132. Reagents and 
conditions: (i) N-methylmorpholine, Et20; (ii) TBP, DCM; (iii) KOH, benzyl alcohol, propan-2-ol; (iv) 
conditions (vide infra, Scheme 61).
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A different catalyst was sought to encourage the conjugate addition. Trialkylphosphines 
have found a place as useful catalysts in addition of alcohols to electron-deficient 
alkynes.202 Inanaga et al. examined the use of several phosphine catalysts in the 
addition of benzyl alcohol to methyl propynoate and tributylphosphine (TBP) was found 
to be the best reagent due to its high nucleophilicity.203 The reaction mechanisms were 
postulated to involve initial addition of the phosphine to the |3-carbonyl of the propiolate 
to give a zwitterionic enolate intermediate which then deprotonates the alcohol. 
Subsequent addition of the benzyl alkoxide anion and phosphine elimination gives the 





Scheme 60. Proposed mechanism of TBP-catalysed conjugate addition reaction by Inanaga et a l203
Following the method of Inanaga et al-,203 (£)-3-benzyloxypropenoic acid 131 was 
obtained in good yield (vide supra, Scheme 59). The 1H NMR spectrum of 131 showed 
two doublets for the alkene protons, one at 5 5.29 corresponding to the CH next to the 
carbonyl group, and one further downfield at 5 7.74 for the CH next to the ether 
oxygen. Their coupling constants corresponded to those seen in trans double bond (J = 
12.8 Hz).
Karlsson and Hogberg converted the unsaturated acid 131 to the corresponding acid 
chloride 133 using thionyl chloride, and reaction with camphorsultam and MeMgBr 
gave the chiral dipolarophile 132 (vide infra, Scheme 61 J.200 Several attempts were 
made to synthesise this acid chloride, using a variety of reagents (thionyl chloride, 
oxalyl choride) in different solvents (DCM, toluene) and temperatures (RT to 85°C). In
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order to examine the formation of the acid chlorides, samples of the reaction mixtures 
were quenched with methanol to give the methyl ester, which was shown by TLC. 
However, these acid chlorides failed to react with the magnesium salt of the 
camphorsultam. Moreover, decomposition of the starting materials was noted from TLC 
of the reaction mixture, which made the recovery of the expensive camphorsultam 
extremely difficult.
Following this discouragement, a different leaving group, pentafluorophenoxy (OPFP), 
was considered. Pentafluorophenyl esters are usually stable crystalline compounds 
and they are relatively easy to prepare using pentafluorophenol (PFPOH) and /V,A/-di- 
cyclohexylcarbodiimide (DCC); the pentafluorophenoxide anion makes an excellent 
leaving group from these active esters. Synthesis of the PFP ester 134 proceeded 
swiftly and it was subsequently subjected to amidation with the camphorsultam under 
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Scheme 61. Attempts at synthesising the chiral dipolarophile linked with (1R)-(+)-2,10-camphorsultam 
(Xc). Reagents and conditions: (i) SOCI2, DMF, DCM, 85°C; (ii) (COCI)2, DMF, DCM, 85°C /  (COCI)2, 
DMF, toluene, RT; (Hi) PFPOH, DCC, EtOAc, 0°C; (iv) (1R)-(+)-2,10-camphorsultam, MeMgBr, THF, 0°C.
The prohibitive cost of camphorsultam deterred further investigation. Instead a more 
economical choice of chiral auxiliary, L-menthol 135, which is used frequently as a 
chiral auxiliary, was adopted as the reagent of choice.204,205 It is commercially available 
in both enantiomers and is cheap. The synthetic routes to the new chiral dipolarophile 
136 are presented in Scheme 62 (vide infra). Attempted condensation of the PFP ester 
134 with L-menthol 135 using Et3N failed. Therefore, a direct coupling of the acid 131 
with L-menthol 135 using DCC and DMAP was performed and gave product 136 as a 
colourless oil. The 1H NMR spectrum showed a downfield shift of the menthol H-1 (8 
3.39) to 8 4.77, corresponding with the attachment of a carbonyl group to the menthol 
oxygen.
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Despite the failed attempts to synthesise a camphorsultam-linked chiral dipolarophile, a 
new reagent was successfully obtained using /.-menthol as a potential chiral auxiliary. 
Having established a functional protocol for the preparation of this modified chiral 
dipolarophile, attention was then turned to construct a sulfur 1,3-dipole using the 
reaction sequence conducted by Karlsson and Hogberg.200
135 136
New chiral dipolarophile
Scheme 62. Synthesis of a new chiral dipolarophile 136 using L-menthol 135 as a chiral auxiliary. 
Reagents and conditions: (i) 134, EtsN, Et20; (ii) 131, DCC, DMAP, DCM, 0 0 .
5.2.2 Synthesis of a sulfur ylide
Karlsson and Hogberg reported that, since thiocarbonyl ylides are often reactive, short­
lived species, they have to be prepared in situ from a precursor.200 Chloromethyl tri- 
methylsilylmethyl sulfide 137 has been shown to be a useful thiocarbonyl ylide 
precursor by Hosomi et a/.206 CsF-catalysed elimination of Me3SiCI from this precursor 
gave the desired sulfur 1,3-dipole which readily underwent 1,3-dipolar cycloaddition 
reaction with different dipolarophiles and gave the corresponding adducts in good 










Scheme 63. Karlsson and Hogberg synthesis of a sulfur 1,3-dipole and subsequent 1,3-dipolar cyclo­
addition.200
A literature method by Block et a/, for the synthesis of the ylide precursor 137 was 
investigated (vide infra, Scheme 64).207 The chloromethyl compound 138 was treated 
with thiourea, and the solid S-alkylisothiouronium salt 139 was obtained in quantitative 
yield. It was subsequently hydrolysed with aqueous base to give the thiol 140. The 
presence of 140 was detected by the strong odour. However, isolation of this volatile
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thiol by distillation proved to be extremely difficult due to its low boiling point. All 
attempts to isolate the compound were unsuccessful.
Therefore, a new strategy was adopted to increase molecular weight and thus the 
boiling point by using a larger aromatic silyl group. Similar reaction of PhMe2SiCH2CI 
141 with thiourea gave the isothiouronium salt 142, which was hydrolysed to give the 
thiol 143 (Scheme 64). This thiol appeared to be easily autoxidised to the disulfide. 
Thus, after evaporation of the solvent, the crude 143 was directly and rapidly treated 
with 1,3,5-trioxane and dry HCI.208 Generation of the product 144 was detected in the 
crude reaction mixture via 1H NMR. However, it was not isolable by short-path 
distillation and the product present quickly decomposed at raised temperature.






^  X  X » M e ^ i '^ S H
1°°% M e 3 S i * ^ S ^ N H 2
139 140













/ Si\  SH
143
(ill) 27%
Si S Cl 
/  \
144
Scheme 64. Synthetic approaches to a sulfur 1,3-dipole. Reagents and conditions: (i) thiourea, Nal, EtOH, 
reflux; (ii) 40% aq. NaOH; (iii) 1,3,5-trioxane, dry HO, -10°C.
Nevertheless, CsF-catalysed 1,3-dipolar cycloaddition reaction with the menthol-linked 
dipolarophile 136 and the crude ylide precursor 144 was attempted but the reaction did
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not give the desired products (145a/b, Scheme 65), with TLC of the reaction mixture 
indicating decomposition of starting materials.
The complications in the isolation of the sulfur 1,3-dipole and the relatively lower yields 
observed for the previous steps warranted exploration of a new strategy.
Scheme 65. Attempted 1,3-dipolar cycloaddition reaction with new chiral dipolarophile 136 and new sulfur 
ylide precursor 144. Reagents and conditions: (i) CsF, MeCN.
5.3 Halocyclisation
Attention was turned to investigate literature methods in synthesising a racemic tetra- 
hydrothiophene skeleton, with the possibility of introducing enantiomeric purity at a 
later stage. Initial attempts involved the generation of a monobrominated tetrahydro- 
thiophene derivative from unsaturated sulfides, as described by Ren et a/.209,210 
Alkenylbenzyl sulfides were found to react with iodine or bromine at room temperature 




Desired cycloaddition products 145a/b
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Scheme 66. Synthetic approaches to the monobrominated tetrahydrothiophene 151. Reagents and 
conditions: (i) pyridine, p-TsCI, DCM; (ii) LHMDS, p-TsCI, THF, -7 8 cC ; (Hi) MeOH; (iv) NaOH, MeOH; (v) 
Br2, DCM, RT to 70 °C.
The mechanism of this reaction was demonstrated by Ren et al. and it is illustrated in 
Scheme 67.209,210 It was concluded that the halogen attacks an unsaturated sulfide by 
coordinating to the double bond to produce a halonium ion. Sulfur behaves as a 
nucleophile and addition to the electrophilic complex would give a cyclic benzyl- 
sulfonium ion. A final dealkylation step, found to be irreversible by the group, by the 
halide ion would produce benzyl halide and a five-membered ring product. 
Furthermore, Ren et al. also discovered that bromine is superior to iodine in these 
cyclisation reactions in terms of reaction rates, lodocyclisations proceeded more slowly 







Scheme 67. Synthesis of halogenated tetrahydrothiophenes by Ren et a/.209,210
Unsaturated sulfide Halonium ion
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This method would first be followed to synthesise the monobrominated tetrahydro- 
thiophene 151 in order to clarify synthetic difficulties. Once the reaction conditions have 
been studied, a disubstituted tetrahydrothiophene would be synthesised using the 
corresponding unsaturated sulfide.
Synthesis of 3-butenyl benzyl sulfide 150 commenced from commercially available 
3-buten-1-ol 146, benzyl chloride 148 and potassium thioacetate 124 for the 
preparation of two starting components: butenyl tosylate 147 and benzyl thioester 149 
(vide supra, Scheme 66).210
3-Buten-1-ol 146 was tosylated under traditional conditions (pyridine, p-TsCI) but the 
reaction failed to give the desired product (vide supra, Scheme 66).210 TLC of the 
reaction mixture showed that the reaction never showed considerable progress and 
only traces of a new product were formed. Therefore, a stronger base, LHMDS, was 
used to encourage the conversion and tosylate 147 was furnished in quantitative yield 
(vide supra, Scheme 66). Reaction of benzyl chloride 148 and potassium thioacetate 
124 afforded benzyl thioacetate 149 (vide supra, Scheme 66),193 which was 
subsequently treated with tosylate 147 to give the benzyl sulfide 150 in good yield 
(87%). Disappointingly, attempted bromination of this benzyl sulfide failed. At elevated 
temperature, only decomposition of starting materials was observed.
Failure to synthesise the brominated tetrahydrothiophene 151 using the Ren et a/.210 
protocol indicated that an alternative cyclisation strategy was required.
5.4 Dieckmann condensation
The Claisen condensation is described as a base-catalysed condensation of two esters 
containing a-hydrogens, forming p-ketoesters. The Dieckmann condensation is the 
intramolecular version of the Claisen condensation where the two esters are linked 
within the same molecule, giving cyclic p-ketoesters. Shinkwin et al. reported the use of 
a Dieckmann condensation in the synthesis of a disubstituted tetrahydrothiophene 
derivative as depicted in Scheme 68 (vide infra).2U The group discovered that, upon 
treatment of the dimethyl ester 153 with sodium ethoxide, 154 was afforded as the 
major product, with the isomeric compound 155 as the minor product, in poor overall 
yields (14% and 10%, respectively). Additionally, keto-enol tautomerism was observed 
in the 1H NMR spectrum of 154 and not in the minor product 155.
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Scheme 6 8 . Attempted synthesis of ethyl 4-oxotetrahydrothiophene-3-carboxylate 154 using the Shinkwin 
et at. method.211 Reagents and conditions: (i) piperidine, 45°C; (ii) NaOEt, EtOH, reflux.
Woodward et al. interpreted the formation of isomer 155, which was formed rapidly as 
a major product as low temperature (i.e. a kinetic product), was due to anion 
stabilisation by sulfur. However, at elevated temperature the major product was the 
isomer 154 (i.e. a thermodynamic product). The mechanisms of their formation are 
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212Scheme 69. Proposed mechanism of the formation of isomeric (3-ketoesters 154 and 155.
Following the methods by Shinkwin et al.,211 Dieckmann reagent 153 was obtained in 
quantitative yield from methyl acrylate 152 and methyl mercaptoacetate 116 with 
piperidine (Scheme 68). However, subsequent condensation using sodium ethoxide 
only afforded a mixture of unidentifiable products.
A different approach presented by Baraldi et al. was followed using methyl mercapto­
acetate 116 and acrylonitrile 156 (Scheme 70)213 This one-pot synthesis gave the 
required 3-oxotetrahydrothiophene-4-carbonitrile (±)-157 via a Dieckmann-like 
condensation of the cycloadduct intermediate (formed in situ) in 50% yield. This
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method provides the product (±)-157 in good yield and avoids the possibility of the 
formation of regioisomers, as the cyano group has a stronger acidifying effect on its 
a-protons and is a weaker electrophile than C02Me. Thus (±)-157 could be obtained in 
multi-gram scale.
MeO






Scheme 70. Dieckmann-like condensation of the Michael adduct between methyl mercaptoacetate 116 
and acrylonitrile 156 gave (±)-157 in moderate yield (50%). Reagents and conditions: (i) NaOMe, MeOH, 
reflux.
5.5 Synthesis of 3-benzyloxy-4-hydroxymethyltetrahydrothiophene
With (±)-157 being readily accessible, many functional-group transformations could be 
performed to give the required functional groups at C-3 and C-4. The first step was to 
reduce the ketone to an alcohol. Hoffmann et al. described an asymmetric yeast 
reduction of methyl-4-oxotetrahydrothiophene-3-carboxylate and the corresponding 
alcohol was obtained as the (3R,4R)-isomer in 7 days.214 This method was followed 
using (±)-157 (vide infra, Scheme 71) but the reaction failed to show any progress even 
at raised temperature and extended reaction duration (10 days).
A non-enantioselective approach was sought with the aim to introduce the required 
relative configuration at a later stage. Reduction of (±)-157 with NaBH4 in EtOH was 
anticipated to give a 1:1 mixture of diastereomeric alcohols, as described by Baraldi et 
al (vide infra, Scheme 71 ).215 However, a 2:3 mixture of products, which were 
separable by chromatography, was obtained instead. The more polar, minor product 
was unidentifiable. The 1H NMR spectrum of the major compound showed only one set 
of proton signals, indicating that it is solely one diastereomeric alcohol (±)-158. The 
minor product was not the diastereomeric cis alcohol.
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Scheme 71. Reductions of tetrahydrothiophene (±)-157. Reagents and conditions: (i) bakers’ yeast, 
sucrose, H2O, RT to 50 °C; (ii) NaBH4, EtOH, 0°C.
The 1H NMR spectrum and subsequent two-dimensional NMR analyses of (±)-158 
were conducted in a 600 MHz spectrometer to improve separation of the proton 
signals. Assignment of the proton signals was made possible by the 1H-1H COSY 
spectrum. A strong cross-peak between the double doublet at 5 2.88 and the double 
doublet at § 3.23 indicate that this pair of double doublets is due to the two geminal 
protons in the tetrahydrothiophene ring. A cross-peak was also noted between the 
signal at 5 2.88 and the quintet signal for 3-H at 5 4.71. It was reasoned that for a 
quintet signal to appear on the spectrum with such high downfield effect, it must be 
next to the electronegative oxygen of the OH with four neighbouring protons i.e. 3-H. 
This assignment was confirmed by the cross-peak between this quintet and the broad 
doublet for OH at 5 2.95. Therefore, the two double doublets at 5 2.88 and 5 3.23 must 
be the geminal protons at the 2-position to give a COSY cross-peak with 3-H. 
Correlation was observed between the multiplet for one proton at 8 3.09 and the 
multiplet for two protons at 8 3.17 to 8 3.20, indicating that the signal for the remaining 
pair of geminal protons at the 5-position coincided with the signal for 4-H. The location 
of both pairs of geminal CH2 protons was confirmed using a 1H-13C COSY (HMQC) 
spectrum, which, together with a 13C-DEPT spectrum, indicated that there are two CH2 
carbons in the molecule, as expected, with signals at 8 30.5 and 8 37.1. Cross-peaks 
between the latter and the signal for the 2-H geminal protons (as assigned in the 1H-1H 
COSY spectrum) show that these protons were attached to a CH2 carbon. Therefore, 
the CH2 carbon signal at 8 30.5 must be due to the carbon at the 5-position, and 
cross-peaks between this signal and the two multiplets at 8 3.09 and 8 3.17 to 8 3.20 
confirm that these signals are due to the geminal CH2 protons at the 5-position. Since 
the latter multiplet 8 3.17 to 8 3.20 integrates for two protons, the remaining proton 
must be that of 4-H and this was confirmed by a cross-peak in the HMQC spectrum 
between the carbon signal at 8 39.9 and the mutiplet.
Since the 1H and 13C NMR spectra indicated the presence of only one diastereoisomer, 
the NOESY spectrum was studied to establish the relative configuration of alcohol
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(±)-158 (Figure 41). However, overlap of connectivities and the presence of artefacts in 
the tetrahydrothiophene ring region of 8 2.8 to 5 3.3 made interpretation of the 
conformation and configuration difficult. A cross-peak was observed between 3-H and 
the OH as expected. Interestingly, the cross-peak between 3-H and 4-H was very 
weak, suggesting that these protons are far apart in space and thus might be trans to 
each other. The lack of a cross-peak between the 2-H at 8 2.88 and 3-H indicates that 
they are remote in space to each other and thus it is likely that this 2-H proton is the 
pseudo-axial geminal proton at the 2-position.
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Figure 41. 1H-1H NOSEY spectrum of (±)-frans-3-hydroxytetrahydrothiophene-4-carbonitrile (±)-158.
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Although the 1H NMR analysis indicated that alcohol (±)-158 was only one 
diastereoisomer, it was unclear, at this stage, which diastereoisomer this was. 
Therefore, it was decided that alcohol (±)-158 would be used in a series of experiments 
to explore different chemical approaches to a tetrahydrothiophene compound with the 
required functional groups at C-3 and C-4. Once synthetic difficulties have been 
clarified and an efficient sequence has been devised, it would be possible to study the 
configuration at C-3 and C-4 at a later stage by 1H and 13C NMR analysis or X-ray 
crystallography on crystalline products.
1. Synthetic approaches to the 2 -deoxy-D-ribose analogue template
HO
(±)-158
CN O-Benzylation c=^ > BnO >— OH <=> Precursor to primary alcohol
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Scheme 72. Attempted functional group introductions for (±)-158. Reagents and conditions: (i) mCPBA, 
DCM; 0°C; (ii) LHMDS, BnBr, THF, -78  C ; (Hi) K2CO3, BnBr, THF; (iv) dry H a , MeOH; (v) 35% aq. H20 2, 
NaOH, EtOH, H2O, 50°C; (vi) H a , 50°C.
131
Chapter 5 Results and Discussion III
Many attempts were made to perform functional group transformations on (±)-158 as 
illustrated in Scheme 72 (vide supra). Oxidation with mCPBA did not furnish the 
corresponding sulfoxide (±)-159 and led only to decomposition of the starting 
compound (±)-158.
An attempt was made to protect the secondary alcohol as the O-benzyl derivative. The 
alkoxide was formed by treatment with LHMDS but subsequent reaction with benzyl 
bromide did not give the anticipated product (±)-160 (vide supra, Scheme 72). The 1H 
NMR spectrum of the obtained product showed the signals for two distinctive alkenyl 
protons as two doublets for two protons at 5 6.02. A pair of double doublets for two 
protons appeared in the region normally occupied by the 2- and 5-protons of the 
five-membered tetrahydrothiophene ring, at 8 2.63 and 8 2.84. Furthermore, a broad 
singlet signal of an OH coincided with the latter, confirming that the O-benzylation did 
not occur as anticipated. A sharp singlet at 8 3.77 for two protons reveals the presence 
of a benzyl CH2 group at a chemical shift appropriate for SCH2Ph. The singlet also 
suggested that the benzyl group was remote from any chiral centre.
These 1-D 1H NMR data, together with the low-resolution mass spectrum, showed that 
the product was a structural isomer of the expected benzyloxy tetrahydrothiophene. 
Two-dimensional NMR analyses were carried out to elucidate its structure. In the 1H-1H 
COSY spectrum, the cross-peak between the double doublets at 8 2.63 and 8 2.84 
confirmed that these signals are due to the geminal protons. There were also COSY 
correlations between these peaks and the multiplet at 8 4.15. The chemical shift of the 
latter corresponds more to the CHOH of an allylic alcohol than a simple secondary 
saturated alcohol. The NOESY spectrum was particularly informative. As expected, 
there were NOESY cross-peaks between the signals at 8 2.63, 8 2.84 and 8 4.15 of the 
previously-identified SCH2CH(R)0 spin system (vide infra, Figure 42). A cross-peak 
was seen between the singlet at 8 3.77 and the signal for the phenyl protons, 
confirming the presence of an S-benzyl group. Thus the product is likely to contain 
PHCH2SCH2CH(R)0. N o NOE connectivities were seen from the alkene signals to 
other protons, indicating that they are remote in space. These data, together with the 
observation of a nitrile band in the IR and the high-resolution MS data, indicated that 
the structure was the ring-opened product (±)-161, as shown in Scheme 73 (vide infra).
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Figure 4 2 .1H-1H NOESY spectrum of 4-benzylthio-3-hydroxy-2-methylenebutanenitrile (±)-161.
Since LHMDS is a relatively strong base, it was postulated that removal of 4-H of 
(±)-158 by the oxygen anion formed led to the elimination product (±)-161 by a reverse 
aldol-like process (vide infra, Route A, Scheme 73). Therefore, a weaker base (K2C03) 
was employed in the subsequent attempt. Interestingly, the same alkenyl product was 
obtained. Since the ring-opening could be triggered by even a weak base, it was 
concluded that this side-reaction was caused by the nucleophilic attack of the sulfur to 
BnBr. In Route A (vide infra, Scheme 73), the alkoxide is readily generated by the 
strong base *N(SiMe3)2. This alkoxide is cis to the acidic proton a to the nitrile,
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facilitating the generation of a carbanion-like intermediate and triggering the 
elimination. The thiolate formed would then react rapidly with the benzyl bromide. 
However, RS" is only a moderate leaving group and rapid elimination by Route A is 
unlikely to be triggered by the weaker base K2C03. Thus Route B (Scheme 73) is 
proposed to be the mechanism followed. Nucleophilic attack of the sulfide on the 
benzyl bromide would give an intermediate sulfonium. This is now an excellent leaving 
group for the elimination triggered either by direct removal of the C-H or by initial 
formation of the alkoxide and subsequent intramolecular proton transfer.
Scheme 73. Proposed mechanisms of the base-catalysed ring-opening of (±)-158, leading to the formation 
of alkenyl compound (±)-161. Route A refers to the mechanism initially proposed upon reaction with a 
strong base (LHMDS). However, despite the use of a weaker base (K2CO3), the same ring-opened product 
was observed, leading to the conclusion that Route B is the mechanism followed.
Attempted conversion of the nitrile to the methyl ester (±)-163 using Pinner reaction 
conditions (dry HCI, MeOH) led only to the decomposition of starting material (vide 
supra, Scheme 72). Pinner reaction is the reaction of nitrites with alcohols via the 
formation of an imino ether hydrochloride salt (imidate) (±)-162 catalysed by acid. 
Imidate salts are relatively unstable compounds and are quickly hydrolysed in water to 
form the corresponding esters.
Hydration of the nitrile (±)-158 to amide (±)-164 was attempted using two methods 
(vide supra, Scheme 72). Watson et al. described a H20 2/Na0H system as a useful 
method for hydration of aromatic nitriles, giving the corresponding amides in almost 
quantitative yield.79 According to Payne and Williams,216 nucleophilic addition of the 
peroxide ion (HOO‘), a much more powerful nucleophile than HO', to the carbon atom 
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latter is then capable of oxidising another molecule of H20 2 to give the corresponding 
amide. However, reaction of nitrile (±)-158 under the same conditions failed to give the 
amide (±)-164 and led to decomposition of the starting material (vide supra, Scheme
Scheme 74. Proposed mechanism of the hydrogen peroxide-assisted hydrolysis of nitriles by Payne and 
Williams.216
Acid-hydrolysis of the nitrile compound (±)-158 generated 4-hydroxytetrahydro- 
thiophene-3-carboxamide (±)-164 (vide supra, Scheme 72). Work-up of this reaction 
was studied: Dehli et al. reported a HCI hydrolysis of a cyclopentanecarbonitrile 
derivative and the reaction mixture was neutralised with NaOH and NaHC03, and the 
corresponding amide was afforded in 96% yield by continuous extraction of the 
neutralised reaction mixture with EtOAc.217 This work-up procedure was followed and 
gave the amide (±)-164 in moderate yield (40%). An alternative work-up was sought to 
improve yield. It was postulated that the formation of a slurry mixture at the 
neutralisation stage and the need for continuous extraction with an organic solvent 
might contribute to the loss of product. Thefore, HCI was removed directly in vacuo, 
and the evaporation residue was triturated with Et20  to give (±)-164 in a much higher 
yield.
The 1H NMR spectrum of (±)-164 showed two broad singlets each for one proton at 5 
7.00 and 8 7.40, indicating the presence of a carboxamide NH2. The OH proton 
resonated at 8 5.29 as a sharp doublet for one proton. The NH signal at 8 7.40 is due to 
intramolecular hydrogen bonding (with either the OH oxygen or the carbonyl oxygen), 
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double doublet at 8 2.60. With this information and the 1H-1H COSY spectrum, 
assignment of protons was possible. A cross-peak between the 2-H at 8 2.60 and the 
double doublet at 8 2.91 for one proton indicates that the latter signal is due to the 
partner 2-H proton. This was confirmed by the 1H-13C COSY (HMQC) spectrum, 
showing the two CH2 carbon signals at 8 29.9 and 8 36.4. Cross-peaks between the 
two 2-H protons and the carbon signal at 8 36.4 show that these protons were directly 
attached to a CH2 carbon. Therefore, the remaining CH2 carbon at 8 29.9 must be C-5, 
and correlation between this carbon and the multiplet at 8 2.81 to 8 2.89 in the HMQC 
spectrum indicates that these protons are the geminal 5-H protons. A cross-peak 
between the 2-H protons and the quintet at 8 4.32 indicates that the latter is due to 3-H. 
Cross-peaks were also noted between 3-H and OH. A cross-peak was observed 
between 3-H and a double doublet at 8 2.71, indicating that this signal is due to 4-H.
The NOESY spectrum of (±)-164 showed the expected connectivity between the 2-H 
proton at 8 2.60 and its geminal partner at 8 2.91. Interestingly, no connectivities were 
observed between the remaining protons in the tetrahydrothiophene ring (5-H protons,
3-H, 4-H), with only weak NOE connections between the two carboxamide NH2 
protons. Thus the NOESY spectrum did not allow determination of the relative 
configuration.
Therefore, to aid the assignment of the relative configuration of compound (±)-164 and 
thus of the precursor nitrile (±)-158, a 1H NMR study was performed by the formation of 
a bicyclic system. Condensation of (±)-164 with 2,2-dimethoxypropane (DMP) under 
acid catalysis gave an inseparable mixture of two compounds in a 3:2 ratio (vide infra, 
Scheme 75). 1H NMR analysis of the mixture indicated that the major product was the 
thienooxazinone (±)-165. The spectrum of the minor product showed a tetrahydro­
thiophene ring, two C-methyl groups, one OH doublet, one broad singlet and a 
methoxy group. Its structure is therefore proposed to be the non-ring-closed 
intermediate (±)-166.
136
Chapter 5 Results and Discussion III
(±)-164 (±)-165 (±)-166
Major Minor
Scheme 75. Configuration of compound (±)-164 was assigned via the formation of the oxazin-2-one 
derivative (±)-l65. A non-ring-closed product (±)-166 was also generated in the DMP/p-TsOH reaction. 
Reagents and conditions: (i) DMP, p-TsOH, acetone, reflux.
There was extensive overlap of NMR signals in the region 5 2.4 to § 3.2, making 
measurement of individual coupling constants difficult. However, the 7a-proton of the 
bicycle (±)-165 gave a discrete double triplet signal at 5 4.17, with coupling constants of 
J = 6.2 Hz, 10.5 Hz. Since 7a-H cannot couple to both protons at the 7-position with 
large coupling constants of J = 10.5 Hz, owing to Karplus considerations, one of the J =
10.5 Hz couplings must be between 7a-H and 4a-H. This value of J = 10.5 Hz indicates 
that these protons are both axial with respect to the six-membered ring and thus must 
be trans to each other, confirming the trans relative configuration of the precursor 
amide (±)-164 and the precursor nitrile (±)-158.
Two-dimensional NMR analyses were also performed on the mixture of (±)-165 and 
(±)-166. The COSY spectrum showed the expected coupling relationships. In 
particular, a cross-peak connected the doublet signal at 5 5.23 to the 3-H in the mono­
cycle (±)-166, confirming that the former is due to the OH. The NOESY spectrum was 
informative (vide infra, Figure 43). For both compounds, cross-peaks indicating 
through-space connectivity were seen between the C-Me signals and the NH singlets. 
This allowed assignment of the broad singlet at 5 7.61 as arising from the NH of the 
monocycle (±)-166 and that at 5 8.10 to the NH of the bicycle (±)-165. In (±)-166, there 
was also a cross-peak connecting the NH and the 3-H signal but the corresponding 
cross-peak (NH-7a-H) was absent for (±)-165. These observations are consistent with 
the control of the orientation of the N-H bond in the oxazinone ring holding it away 
from the 7a-H. Interestingly, in (±)-165, there is a cross-peak connecting 7a-H with the 
C-Me signal at § 1.40, confirming that this signal is due to the methyl group c/s to the 
7a-H.
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Figure 43. 1H-1H NOESY spectrum of (±)-frans-2,2-dimethylhexahydrothieno[3,4-e][1,3]oxazin-4-one 
(±)-165 and (±)-frans-3-hydroxy-N-(1-methoxy-1-methylethyl)tetrahydrothiophene-4-carboxamide (±)-166.
MM2 energy-minimised calculations were also carried out to confirm the relative 
configuration of (±)-165. For the frans-model where 7a-H and 4a-H are trans-diaxial to
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each other with respect to the six-membered ring [(3), Figure 44], dihedral angle 
(4a-H)-(4a-C)-(7a-C)-(7a-H) of 177° was calculated which is consistent with the 
coupling constant of 3J = 10.5 Hz. Two c/s-compounds were similarly studied and 
dihedral angles (4a-H)-(4a-C)-(7a-C)-(7a-H) of 50° and 8° were calculated for the 
c/'s-diaxial [(1), Figure 44] and c/s-diequatorial [(2), Figure 44] bicycles, respectively. 
These are inconsistent with the coupling constant 3J of 10.5 Hz. In addition, modelling 
of structure (2) revealed severe ring strain, with the five-membered tetrahydro­
thiophene ring to be twisted out-of-plane, making this structure highly unfavourable.
(1) (2)
(3)
Figure 44. MM2-energy minimised models of the three relative configurations of (±)-165. The red colour 
refers to oxygen, the yellow refers to sulfur, the blue refers to nitrogen and the grey refers to the carbon 
atom. Structure (1) represents a c/s-configuration with dihedral angle (4a-H)-(4a-C)-(7a-C)-(7a-H) = 8°. 
Structure (2) represents a c/s-configuration with dihedral angle (4a-H)-(4a-C)-(7a-C)-(7a-H) = 50°. 
Structure (3) is a frans-configuration with dihedral angle (4a-H)-(4a-C)-(7a-C)-(7a-H) = 177°.
Although the NMR data suggested that amide (±)-164 is only one diastereoisomer, it 
was not clear whether this is the c/s- or trans-isomer. Therefore, crystals were grown in 
an EtOAc/EtOH system and X-ray analysis was conducted to study the relative 
configuration at C-3 and C-4. It is notable that, even though the bulk sample was 
racemic, individual crystals contained one enantiomer only. X-ray crystallography data 
of (±)-164 provided information on the relative configuration as illustrated in Figure 45 
(vide infra). A vicinal coupling constant of 3J ~ 7.9 Hz was measured between 3-H and
4-H, which is consistent with dihedral angle (C3-C)-(C3-H)-(C4-C)-(C4-H) = 172°,
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indicating a trans-diaxial configuration. A three-bond coupling constant of 3J ~ 7.3 Hz 
was measured between 3-H and one of the geminal protons at C(2). This is consistent 
with dihedral angle (C3-H)-(C3-C)-(C2-C)-(C2-HA) = 162°. Dihedral angle
(C3-H)-(C3-C)-(C2-C)-(C2-HB) = 42° was calculated between 3-H and the other 
geminal proton at C(2), and this is also consistent with a three-bond coupling constant 
of 3J ~ 5.9 Hz. Due to overlap of proton signals in the 1H NMR spectrum, coupling 
constants could not be determined between 4-H and the geminal protons at C(5). The 
corresponding dihedral angles (C4-H)-(C4-C)-(C5-C)-(C5-Ha) = 36° and
(C4-H)-(C4-C)-(C5-C)-(C5-Hb) = 156° were calculated. The two substituents are 











Figure 45. X-ray crystal structure of (±)-frans-3-hydroxytetrahydrothiophene-4-carboxamide (±)-164, with 
crystallographic numbering.
Interestingly, despite the presence of neighbouring primary carboxamide and alcohol 
groups, no intramolecular hydrogen bonding was observed in the crystal of (±)-164. 
Intermolecular hydrogen-bonding interactions were observed in the crystal structure of 
(±)-164 from the three hydrogen-bond donors (two N-H bonds and one 0-H) and both 
hydrogen-bond acceptors (carbonyl C=0 and alcohol 0). The N-H cis to the carbonyl 
oxygen makes a hydrogen bond to the alcohol oxygen of an adjacent molecule B 
whereas the N-H trans to the carbonyl oxygen hydrogen bonds to the carbonyl oxygen 
of a third molecule C. A hydrogen bond between the carbonyl oxygen and an N-H of 
molecule B completes a hydrogen-bonded ring in the structure. Finally, a chain is 
formed by the hydrogen bond between the 0-H  and a carbonyl oxygen of a fourth 
molecule D above (vide infra, Figure 46).
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Figure 46. X-ray crystal structure of (±)-164, showing the intermolecular hydrogen-bonding interactions. 
The red colour refers to oxygen, the yellow refers to sulfur, the blue refers to nitrogen and the grey refers 
to the carbon atom.
Having obtained this key amide intermediate (±)-164 and assigned the relative 
configuration, further approaches to perform functional group transformations were 
explored. The primary goal was to develop reliable and efficient synthetic routes to the 
required functional groups at C-3 and C-4 in the racemic series, so that the single 
enantiomer could be prepared later.
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2. Synthetic approaches to the 2-deoxy-D-ribose analogue template
O-Benzylation BnO / — OH Precursor to primary alcohol
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Scheme 76. Synthetic approaches to the 2-deoxy-D-ribose analogue 38a. Reagents and conditions: (i) 
H a , 50 °C; (ii) NaH, BnBr, DMF, 0°C; (Hi) mCPBA, DCM, -4 0  °C; (iv) CF3CONH2, Rh2(OAc)4, MgO, 
Phl(OAc)2, DCM; (v) HO, 50°C; (vi) TFA, H20 , 130<C.
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Initial investigations concentrated on converting the amide group to an acid with or 
without prior O-benzylation at the 3-OH. Reduction of the acid intermediate (±)-168 to a 
primary alcohol, followed by sulfoximination, would lead to the 2-deoxy-Z>ribose 
analogue 38a [vide supra, step (i), Pathway A, Scheme 76]. The synthetic sequence 
commenced with acid-hydrolysis of carboxamide (±)-164 [vide supra, step (i), pathway 
A, Scheme 76]. The corresponding carboxylic acid derivative (±)-167 formed would 
then be O-benzylated to give the mono- and the dibenzylated tetrahydrothiophenes. 
Both derivatives could be reduced to give the desired tetrahydrothiophene derivative 
with a primary alcohol at C-4 and O-benzylation at the 3-OH. However, the 
acid-hydrolysis failed to generate the carboxylic acid compound (±)-167 and the 
reaction led only to decomposition of the starting material.
Therefore, it was decided that the protection of the 3-OH of (±)-164 would be 
performed and the resulting amide compounds (±)-169 and (±)-170 could be 
hydrolysed to the carboxylic acids. As reported previously (vide supra, Section 3.2.2),
O-benzylation using an equivalent amount of benzyl bromide and freshly-washed (in 
pentane) sodium hydride gave the best result in terms of yield of the monobenzylated 
product and ratio of mono- and dibenzylation. The strong base sodium hydride is 
capable of removing both OH and NH protons but, since only one equivalent was used, 
it was expected that only the more acidic OH proton would be abstracted. Since only 
the alkoxide and amide-derived anions could be nucleophilic enough to react with the 
benzyl bromide, some nitrogen-based anion must have been formed to give the 
corresponding secondary amide. However, in this current synthesis, both the mono- 
and dibenzylated compounds could be used in the subsequent hydrolysis of the amide 
to the carboxylic acid, since the nitrogen (and its appended benzyl group) would be lost 
from both substrates. Therefore, compound (±)-164 was treated with an equivalent 
amount of benzyl bromide and the reaction gave the di- and monobenzylated products 
(±)-169 and (±)-170 in 18% and 62% yields, respectively [vide supra, step (ii), pathway 
A, Scheme 76]. It is noteworthy that the S-benzylation and reverse aldol-like 
ring-opening seen with the corresponding nitrile compound (±)-158 (vide supra, 
Scheme 73) did not occur during benzylation of the amide (±)-164. Perhaps the benzyl 
electrophile is consumed rapidly by both the oxygen and nitrogen nucleophiles before it 
can react at the sulfur. Moreover, the reverse aldol will be less favoured in the present 
carboxamide system, as the carboxamide carbonyl is less able to stabilise the 
intermediate a-anion than is the nitrile.
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Sulfoximination was studied using the monobenzylated amide compound (±)-170. 
Oxidation with mCPBA gave the corresponding sulfoxide (±)-171 in good yield [vide 
supra, step (iii), pathway B, Scheme 76].218 The 1H NMR spectrum of the sulfoxides 
showed the presence of two diastereoisomers in a 7:1 ratio. Both diastereoisomers 
retained the trans relationship at the C3-C4 bond and must therefore arise from 
different configurations at the chiral sulfur atom. It could not be determined whether the 
major isomer had the sulfoxide oxygen cis to the carboxamide or to the benzyl ether; 
arguments could be put forward for the formation of either through hydrogen-bonding of 
the peroxyacid to the amide carbonyl oxygen or to the ether oxygen leading to two 
alternative modes of stereocontrol. The diastereomeric mixture of sulfoxides was then 
subjected to the usual Rh(ll)-catalysed imination conditions [vide supra, step (iv), 
pathway B, Scheme 76] to generate the cyclic sulfoximine (±)-172, but no reaction was 
evident.
Attempted acid-hydrolysis, with aqueous hydrochloric acid and with aqueous trifluoro- 
acetic acid, of the amide of compound (±)-170 led only to decomposition of starting 
materials, rather than affording the desired carboxylic acid (±)-168 [vide supra, steps 
(v) and (vi), pathway B, Scheme 76].
The failure to introduce a sulfoximine moiety and to synthesise an appropriate primary 
alcohol precursor at the C-4 centre meant that the route outlined in Scheme 54 (vide 
supra) was no longer viable. Since the above route of conversion to the carboxylic acid, 
followed by reduction to the primary alcohol, was not possible, the reverse sequence of 
reduction of the amide, followed by conversion of the primary amine to a primary 
alcohol (e.g. by nitrosation) was investigated. Reduction of the carboxamide (±)-170 
with LAH in boiling THF gave the primary amine (±)-173 (Scheme 77). For ease of 
isolation, this was benzoylated in situ (after the aqueous quench) and the benzamide 
(±)-174 was obtained in good yield.
Scheme 77. Synthesis of the benzamide compound (±)-174. Reagents and conditions: (i) UAIH4, THF, 







In this section of the project, appropriately 3,4-disubstituted tetrahydrothiophene 
intermediates have been successfully synthesised through a key Dieckmann 
cydisation. These have the correct trans stereochemical relationship between the 
protected 3-oxygen substituent and the one-carbon unit at C-4. It only remains to 






Various synthetic strategies were explored towards potential inhibitors for TP, PARP-1 
and IMPDH, incorporating a sulfoximine group. These target compounds include the
2-deoxy-D-ribose-1 a-phosphate analogue 37 and the 2-deoxy-D-ribose analogue 38a 
as TP inhibitors, the benzamide 2-deoxyriboside mimic 39 and the transition-state 
analogue 40 for the inhibition of PARP-1, and upon conversion to the corresponding 
dinucleotide with adenosine, 39 is expected to be an inhibitor of IMPDH. The design of 
these cyclic sulfoximine mimics of ribosides and 2-deoxyribosides centres on the 
replacement of the anomeric carbon by the tetrahedral sulfoximine.
The initial synthetic plan relied on addition of an anion derived from a 
S-methyl-sulfoximine to a protected glyceraldehyde. The targets contain three chiral 
centres, one of which was supplied in the glyeraldehyde, one supplied as the 
sulfoximine and one being generated during the addition step. Some diastereocontrol 
may have been expected. Model reactions were investigated to study this novel 
addition. Several routes were investigated to produce sulfoximines from sulfoxides but 
the most effective was found to be the rhodium-catalysed oxidative imination of 
sulfoxides with trifluoro-acetamide and iodosobenzene diacetate. Treatment of anions 
derived from N-Booprotected and N-SiMe^-protected S-methyl-S-phenyl sulfoximines 
with a range of aldehydes gave only low yields of the required secondary alcohols, 
along with some products Of elimination. These additions were also found to be difficult 
to reproduce, with frequent degradation of the substrates and reduction of the 
aldehydes.
In an alternative scheme, a four-carbon unit, carrying two of the chiral centres, was to 
be attached to the sulfur of a 3-substituted thiophenol; the sulfoximine was then to be 
generated and cyclised to the target riboside mimic. Diethyl R,R-tartrate supplied the 
four-carbon unit with the correct configurations and was readily converted into
4S,5S-4,5-di(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane. This (^symmetric compound 
was desymmetrised by monobenzylation and the remaining primary alcohol was 
replaced by phenylthio- and 3-bromophenylthio groups by a thio-Mitsunobu coupling. 
Sulfoxidation proceeded without diastereocontrol but imination at sulfur gave separable 
diastereoisomers of the sulfoximines. These were identified by X-ray crystallography. 
Removal of the acetal protection revealed the vicinal diol but two preliminary attempts 
to use an intramolecular Mitsunobu reaction did not give the cyclised product. Thus the 
required carbon and sulfur framework of the target compounds has been assembled
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successfully, with appropriate functionality and with the correct configurations at all the 
chiral centres. It only remains to develop a cyclisation method to complete this 
sequence.
Synthetic approaches to the second series of targets, such as 38a and 40, were also 
studied. The first strategy involved assembly of the tetrahydrothiophene ring from a 
C-C unit and a C -S-C  unit through a dipolar cycloaddition. The C-C dipolarophile was 
to carry a chiral auxiliary. (E)-3-Benzyloxypropenoic acid was synthesised but could not 
be converted into the corresponding N-acyl-camphorsultam. The menthyl ester, 
however, was accessible. The 1,3-dipole, H2C=S+-C H 2‘ was to be generated in situ 
from a silylmethyl chloromethyl sulfide by desilylation with fluoride. However, the 
trimethylsilyl reagent was too volatile to be isolated. Increasing the molecular weight 
(and therefore decreasing the volatility) by having larger substituents on the silicon led 
to severe synthetic difficulties. Attempted 1,3-dipolar cycloaddition of a crude sulfur
1,3-dipole and a representative chiral dipolarophile only led to decomposition of starting 
materials.
Following an alternative strategy, a Dieckmann cyclisation furnished the racemic
3-oxo-tetrahydrothiophene-4-carbonitrile (±)-157. Reduction of the ketone gave a single 
diastereoisomer of the secondary alcohol. An attempt to protect the alcohol by 
benzylation led to an interesting S-benzylation and retro-aldol-like ring-opening. 
However, hydration of the nitrile gave the crystalline carboxamide, which was 
demonstrated by a careful NMR study and an X-ray-crystal determination to have the 
required trans relative configuration. Studies showed that the secondary alcohol could 
be protected without risk of the retro-aldol ring-opening and that the sulfur could be 
oxidised to the sulfoxide but imination at sulfur remains to be effected. In this 
sequence, it only remains to develop methods for imination at the sulfoxide and 
conversion of the carboxamide to a CH2OH group.
Much interesting chemistry was achieved in the synthetic approaches to all the named 
target compounds. This thesis has presented the use of sulfoximine chemistry in drug 
design, with major advances in several synthetic sequences. A solid foundation has 
been laid for later workers to complete the syntheses and evaluate the biological 
activities of the target cyclic sulfoximine riboside mimics. Further investigation of the 
potential role of sulfoximines in the design of nucleoside derivatives should lead to 






All melting points were determined using a Reichert-Jung Thermo Galen Kofler block 
and are uncorrected. IR spectra were recorded on a Perkin-Elmer RXI FT-IR 
spectrometer, either as a liquid (film) or as a KBr disc (KBr). values are given in 
cm'1. Optical rotations ([a]) were measured in a 1.0 dm cell on an Optical Activity Ltd. 
polarimeter and concentrations (c) were expressed in g/100 mL. NMR spectra were 
recorded on either a Jeol-Varian GX 270 (270.05 MHz 1H; 67.8 MHz 13C), Varian 
Mercury EX 400 (399.65 MHz 1H; 100.4 MHz 13C; 376.05 MHz 19F) or Varian Unity 
Inova 600 MHz (1H NMR only) spectrometers. Tetramethylsilane was used as an 
internal standard for samples dissolved in CDCI3 and (CD3)2SO. NMR spectra are 
reported in p.p.m. downfield from tetramethylsilane. Multiplicities are indicated by s 
(singlet), d (doublet), t (triplet), q (quartet), qn (quintet), m (multiplet) and br (broad). 
Coupling constants (J) are expressed in Hz. Where indicated, 2-D experiments were 
used to assign 1H and 13C NMR signals. Mass spectra were obtained by either Electron 
Impact (El), Electrospray (ES) or Fast Atom Bombardment (FAB) (with m-nitrobenzyl 
alcohol as the matrix) at the University of Bath Mass Spectrometry Service using a VG 
7070 mass spectrometer, the University of Bath Department of Pharmacy and 
Pharmacology High Resolution Mass Spectrometry Service using a Bruker 
microOTOF™ and the EPSRC Mass Spectrometry Service, Swansea. Microanalysis 
was carried out at the School of Pharmacy, University of London, Microanalysis 
Service. Thin layer chromatography (TLC) was performed on silica gel 60 F^-coated 
aluminium sheets (Merck) and visualisation was accomplished by UV light (254 nm), 
iodine vapour, solutions of iron(lll) chloride, 2,4-dinitrophenylhydrazine, phospho- 
molybdic acid, potassium permanganate or ninhydrin. Flash column chromatography 
was performed using silica gel 60 (0.040-0.063 mm, Merck) as the stationary phase.
All reagents for chemical synthesis were purchased from Sigma-Aldrich and Lancaster 
Chemical Company and were used without further purification. Experiments were 
conducted at ambient temperature, unless otherwise stated. Where experiments were 
repeated, only one description was provided. Solutions in organic solvents were dried 
using anhydrous MgS04 and solvents were evaporated under reduced pressure using 





Nal04 (10.7 g, 50 mmol) in water (15 mL) was added slowly to thioanisole (46, 6.2 g, 
50 mmol) in MeOH (100 mL). The mixture was stirred vigorously overnight then filtered. 
Drying and evaporation yielded 47 (6.5 g, 93%) as a colourless oil: TLC Rf = 0.1 
(EtOAc / hexane, 2:3); IR v™, (film) 1301 cm'1; 1H NMR (400 MHz, CDCI3) 8 2.69 (3 H, 
s, CH3), 7.47-7.56 (3 H, m, Ph 3,4,5-H3), 7.64-7.67 (2 H, m, Ph 2,6-Hj); 13C NMR (100 
MHz, CDCI3) 8 44.0 (CH3), 123.5 (Ph 4-CH), 129.4 (Ph 3,5-C2), 131.1 (Ph 2,6-Cj),
145.7 (Ph 1-Cq); HRMS (FAB+) m/z 141.0369 (M + H) (12C7H9OS requires 141.0374).
N-ferf-Butoxycarbonyl azide (53)
NaN02(1.17 g, 17 mmol) in water (10 mL) was added to terf-butyl carbazate (52, 2.02
g, 15 mmol), acetic acid (1.75 g) and water (2.4 mL) at 0°C during 1 h. After a further 1
h, water (2.4 mL) was added and the oil was extracted into DCM. The organic extract 
was washed with water and aq. NaHC03 (1 M) and dried. Concentration gave 53 (1.75 
g, 82%) as a yellow oil which was used in the next step without further purification: IR 
Vmax (film) 1731,2132 cm'1.
(±)-N-fert-Butoxycarbonyl-S-methyl-S-phenylsulfoximine (54)
NBoc
Method A: Compound 53 (1.75 g, 12 mmol) was added to 47 (1.70 g, 12 mmol) in
dry DCM at 0°C. FeCI2 (1.51 g, 12 mmol) was added. The mixture was warmed to RT
Experimental
and stirred overnight, then poured into water and extracted with DCM (x 2). The 
organic layers were washed with water and dried. Evaporation and chromatography 
(DCM / EtOAc, 1:1) gave 54 (1.62 g, 53%) as a white solid: TLC Rf = 0.7 (DCM / 
EtOAc, 1:1); mp 66-67°C (lit.153 mp 65-67°C); IR v™ (KBr) 1657 cm'1; 1H NMR (400 
MHz, CDCI3) 8  1.33 [9  H, s, C(CH3)3], 3.21 (3 H, s, CH3), 7.59-7.71 (3 H, m, Ph 
3,4,5-H3), 7.99 ( 2  H, m, Ph 2 .6 -H2); 13C NMR ( 1 0 0  MHz, CDCI3) 8  28.0 [(CH3)3], 44.7 
(SCH3), 80.6 (Cq), 127.4 ( 2  x CH), 129.6 (2 x CH), 133.7 (CH), 138.9 (Cq), 157.6 
(C=0); HRMS (FAB+) mfz 256.1016 (M + H) (12C,2H17N03S requires 256.1007), 182 
[M -OC(CH3)3],
Method B: NaH (60% in mineral oil, 133 mg, 3.32 mmol, pre-washed in dry
pentane) was added to a solution of compound 50 (370 mg, 2.38 mmol) in dry THF (0.5 
mL) and the mixture was stirred for 30 min. Di-fe/f-butyl dicarbonate (1.04 g, 4.76 
mmol) was added and the reaction mixture was stirred overnight. The mixture was 
quenched with aq. NH4CI (sat.) and extracted with DCM (x 3). The organic layers were 
collected and dried. Evaporation and chromatography (DCM / EtOAc, 1:1) afforded 54 
(500 mg, 82%) as a white solid. The data were identical to those above.
(±)-S-Methyl-S-phenylsuIfoximine trifluoroacetate salt (55)
Compound 54 (500 mg, 1.96 mmol) was treated with TFA (5 mL) in DCM (5 mL) at 
0°C. The mixture was warmed to RT and stirred for 60 min. Evaporation and trituration 
(Et20) gave 55 (150 mg, 28%) as pale buff crystals: TLC Rf = 0.2 (DCM / EtOAc, 1:1); 
mp 73-75°C; IR v™* (KBr) 1678, 3435 cm-1; 1H NMR (400 MHz, CDCI3) 5 3.51 (3 H, s, 
CH3), 7.66-7.68 (2 H, t, J = 7.5 Hz, Ph 3,5-H2), 7.76-7.79 (1 H, t, J = 7.5 Hz, Ph 4-H),
8.04-8.06 (2 H, d, J = 7.5 Hz, Ph 2,6-H2), 8.89 (2 H, br s, NH2); 13C NMR (100 MHz, 
CDCI3) 8 44.1 (CH3), 115.1 (CF3, q, J = 285 Hz), 128.3 (2 xCH), 130.1 (2xCH), 135.5 
(CH), 136.2 (Cq), 161.2 (CFaCO* q, J = 37.5 Hz); HRMS (FAB+) m/z 156.0485 (M -  




Method A: To a solution of 55 (130 mg, 0.48 mmol) in MeOH (1 mL) was treated
with Na2C03 (aq. sat.) to pH 7 and the mixture extracted with DCM (x 4). The organic 
layers were collected and dried. Evaporation and chromatography (MeOH / EtOAc, 7:3) 
afforded 50 (85 mg, 98%) as a pale yellow oil: TLC Rf = 0.2 (DCM / EtOAc, 1:1); IR Vmax 
(film) 1031, 3400 (NH) cm'1; 1H NMR (400 MHz, CDCI3) 8 3.03 (1 H, br s, NH), 3.10 (3 
H, s, CH3), 7.52-7.65 (3 H, m, Ph 3,4,5-H3), 8.01 (2H, m, Ph 2,6-H2); 13C NMR (100 
MHz, CDCIa) 8 46.2 (CH3), 127.7 (2 x CH), 129.3 (2 x CH), 133.1 (CH), 143.5 (CJ; 
HRMS (FAB+) m /i 156.0488 (M + H) (12C7H10NOS requires 156.0483).
Method B: Compound 65 (1.00 g, 3.97 mmol) was stirred with NH3 (35% in water,
10 mL) in MeOH (25 mL) for 16 h. Evaporation and chromatography (EtOAc / MeOH, 
7:3) gave 50 (616 mg, 100%) as a yellow oil. The data were identical to those above.
(±)-N-(T rimethylsilyl)-S-methyl-S-phenylsulfoximine (51)
To 50 (100 mg, 0.65 mmol) in MeCN (1 mL) at 65°C was added dropwise Et2NSiMe3 
(105 mg, 0.72 mmol). The mixture was stirred at 65°C for 4 h and at RT for 3 d. 
Evaporation gave 51 (145 mg, 98%) as a pale buff liquid: TLC Rf = 0.2 (EtOAc /
13C NMR (100 MHz, CDCI3) 5 2.3 (SiCH3), 49.3 (SCH3), 127.0 (2 x CH), 128.9 (2 x CH), 
129.3 (2 x CH), 132.2 (Cq).
0 " ||" M e
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hexane, 7:3); IR vmax (film) 847, 1077 cm’1; 1H NMR (400 MHz, CDCI3) 5 0.05 (9 H, s, 
SiMe3), 2.98 (3 H, s, CH3), 7.46-7.56 (3 H, m, Ph 3,4,5-H3), 7.91 (2 H, m, Ph 2,6-H2);
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Compound 54 (250 mg, 0.96 mmol) was treated with f-BuLi (1.7 M in pentane, 0.58 
mL, 0.98 mmol) in dry THF at -78°C under N2 for 2 h. Benzaldehyde (104 mg, 0.98 
mmol) in dry THF (1.0 mL) was added and the mixture was allowed to reach RT 
overnight. Evaporation residue, in EtOAc was washed with water (x 2) and dried. 
Evaporation and chromatography (EtOAc / hexane, 2:8) afforded first, in elution order, 
56 (11 mg, 3%) as a white solid: TLC Rf= 0.4 (EtOAc / hexane, 2:3); mp 33-35°C; 1H 
NMR (400 MHz, CDCI3) 5 1.37 [9 H, s, C(CH3)3], 6.87 (1 H, d, J = 15.3 Hz, PhCH), 
7.28-7.44 (5 H, m, C-Ph-H5), 7.46-7.61 (3 H, m, S-Ph 3,4,5-H3), 7.66 (1 H, d, J= 15.3 
Hz, SCH), 7.95-8.00 (2 H, m, S-Ph 2,6-H2); 13C NMR (100 MHz, CDCI3) (HMQC) 5 28.0 
[(CH3)3], 80.6 [C(CH3)3], 125.5 (PhCH), 127.5 (2 x CH), 128.6 (2 x CH), 129.1 (2 x CH),
129.5 (2 x CH), 131.3 (CH), 132.1 (Cq), 133.3 (CH), 139.2 (Cq), 143.3 (SCH), 157.3 
(O O ); MS (FAB+) mh 344 (M + H), 243 (M -  Boc).
Further elution gave 57a/b as a 7:1 mixture of diastereoisomers (220 mg, 62%) as a 
colourless oil: TLC Rf = 0.3 (EtOAc / hexane, 2:3); 1H NMR (400 MHz, CDCI3) 8 1.34 
[1.12 H, s, minor C(CH3)3], 1.36 [7.88 H, s, major C(CH3)3], 3.22 (0.12 H, dd, J = 14.0,
1.2 Hz, minor CHH), 3.48 (0.88 H, dd, J = 14.2,2.0 Hz, major CHH), 3.59 (0.88 H, dd, J 
= 14.2, 9.9 Hz, major CHIH), 3.72 (0.12 H, dd, J = 14.2, 9.9 Hz, minor CHH), 4.40 (0.88 
H, d, J = 2.0 Hz, major OH), 5.03 (0.12 H, d, J = 1.2 Hz, minor OH), 5.30 (0.88 H, d, J = 
9.9 Hz, major CHPh), 5.45 (0.12 H, d, J = 9.9 Hz, minor CHPh), 7.27-7.33 (5 H, m, 
C-Ph-Hg), 7.61-7.73 (3 H, m, S-Ph 3,4,5-H3), 7.98-8.00 (2 H, m, S-Ph 2,6-H2); 13C NMR 
(100 MHz, CDCI3) 8 28.0 [(CH3)3], 64.4 (CH2), 68.5 (PhCH) 81.1 [C(CH3)3], 125.8 (Ph
3,5-C2), 128.0 (Ph 2,6-C2), 128.6 (Ph 4-CH), 128.8 (S-Ph 3,5-C2), 129.8 (S-Ph 2,6-C2),
134.1 (S-Ph 4-CH), 137.8 (Ph 1-Cq), 157.1 (C=0); HRMS (FAB+) m/z 362.1432 (M + 




To NaN3 (520 mg, 8.0 mmol) in water (2 mL) at 0°C was added slowly fluoren-9-yl- 
methyl chloroformate (62, 1.35 g, 5.2 mmol) in acetone (2.5 mL). The mixture was 
stirred at 0°C for 2 h and at RT for a further 2 h. Filtration and recrystallisation 
(acetone) afforded 63 (1.14 g, 82%) as colourless crystals: TLC Rf = 0.8 (EtOAc / 
hexane, 2:3); mp 82-83°C (lit.161 mp 83-85°C); IR v,™ (KBr) 1716 (0=0), 2140 (N3), 
2197 cm'1; 1H NMR (270 MHz, CDCI3) 5 4.26 (1 H, t, J = 7.4 Hz, 9-H), 4.48 (2 H, d, J =
7.4 Hz, CH2), 7.33 (2 H, dt, J = 1.2, 7.4 Hz, fluorene 3,6-H2), 7.43 (2 H, t, J = 7.4 Hz, 
fluorene Ph 2,7-H2), 7.59 (2 H, d, J = 7.5 Hz, fluorene 4,5-H2), 7.78 (2 H, d, J = 7.5 Hz, 
fluorene 1,8-H2); 13C NMR (68 MHz, CDCI3) 8 46.6 (CH), 70.4 (CH2), 120.3 (2 x CH),
125.2 (2 x CH), 127.4 (2 x CH), 128.1 (2 x CH), 140.1 (2 x Cq), 143.0 (2 x Cq), 163.1 
(C=0); MS (FAB+) mfr 179 (M -  OCON3), 165 (M -  CH2OCON3).
(±)-N-(T rifluoroacetyl)-S-methyl-S-phenylsulfoximine (65)
To a suspension of compound 47 (1.40 g, 10.0 mmol), trifluoroacetamide (2.26 g, 20.0 
mmol), MgO (1.60 g, 40.0 mmol) and Rh2(OAc)4 (110 mg, 2.5 mol %) in DCM (50 mL) 
was added Phl(OAc)2 (4.83 mg, 15.0 mmol) and the mixture was stirred for 16 h. The 
suspension was filtered (Celite®); evaporation and chromatography (EtOAc/hexane, 
2:3) gave 65 (1.80 g, 72%) as a white solid: TLC Rf = 0.4 (EtOAc / hexane, 2:3); mp 
77-78°C (lit.151 mp 76.5-77.5°C); IR v max (KBr) 1131, 1189 (CF3), 1242, 1662 (C=0) 
cm'1; 1H NMR (400 MHz, CDCI3) 8 3.46 (3 H, s, CH3), 7.66 (2 H, m, Ph 3,5-H2), 7.76 (1 
H, m, Ph 4-H), 8.00 (2 H, m, Ph 2,6-H2); 13C NMR (100 MHz, CDCI3) 8 44.3 (CH3),
115.8 (Cq), 127.1 (2 x CH), 130.1 (2 x CH), 134.9 (CH), 136.5 (Cq), 163.9 (0=0); 19F




NMR (376 MHz, CDCI3) 8 -76.0 (3 F, s, CF3); HRMS (FAB+) mfz 252.0303 (M + H) 
(12C9H8N02F3S requires 252.0306), 182 (M -  CF3).
S-2,2-Dimethyl-1,3-dioxolane-4-carboxaldehyde (44)
Saturated aqueous NaHC03 (0.20 mL) was added to 1,2:5,6-diisopropylidene- 
D-mannitol (66, 250 mg, 0.96 mmol) in DCM (4.5 mL). Nal04 (810 mg, 3.80 mmol) was 
added and the mixture was stirred for 1.5 h and then filtered. Drying and evaporation 
afforded 44 (260 mg, 100%) as a colourless liquid: TLC Rf = 0.4 (DCM / EtOAc, 1:1); IR 
Vmax (film) 845, 1216, 1375, 1736 (O O ) cm-1; 1H NMR (400 MHz, CDCI3) 8 1.34 (3 H, 
s, CH3), 1.41 (3 H, s, CH3), 4.03 (1 H, dd, J = 8.8, 4.7 Hz, 5-H), 4.10 (1 H, dd, J = 8.8,
7.5 Hz, 5-H), 4.32 (1 H, ddd, J = 7.5, 4.7,1.9 Hz, 4-H), 9.64 (1 H, d, J=  1.9 Hz, CHO); 
13C NMR (100 MHz, CDCI3) (HMQC) 8 25.0 (CH3), 26.1 (CH3), 65.4 (CH2), 79.7 (CH),
111.1 [C(CH3)3], 201.7 (CHO); [ a f t  = +62° (c = 1.2, EtOAc) [lit.163 [ a f t  = +80° (c = 
1.5, EtOAc)].
3-(Methylthio)benzaldehyde (76)
3-Bromothioanisole (75, 203 mg, 1 mmol) was treated with n-BuLi (2.5 M in hexane,
1.2 mL, 3 mmol) in dry THF at -78°C under N2 for 2 h. Dry DMF (0.23 mL, 219 mg, 3 
mmol) in dry THF (1.0 mL) was added and the mixture was allowed to reach RT 
overnight. The evaporation residue, in EtOAc was washed with aq. NaHC03(1 M) and 
brine and dried. Evaporation and chromatography (EtOAc / hexane, 1:10) gave 76 (58 
mg, 38%) as a pale yellow liquid: TLC Rf = 0.7 (EtOAc / hexane, 2:3); 1H NMR (400 
MHz, CDCI3) 8 2.54 (3 H, s, CH3), 7.45 (1 H, t, J = 7.4, Ph 5-H), 7.51 (1 H, m, Ph 4-H), 





CHO); 13C NMR (100 MHz, CDCI3) 5 29.8 (CH3), 126.1 (Ph 6-CH), 126.8 (Ph 2-CH), 




NH2OH.HCI (48 mg, 0.69 mmol) and sodium acetate (94 mg, 1.20 mmol) in water (5 
mL) were added to compound 76 (58 mg, 0.38 mmol) in EtOH (5 mL) and heated at 
45°C overnight. Water was added and the mixture was extracted with EtOAc. The 
organic layer was washed with water, dried and evaporated to give 77 (25 mg, 39%) as 
pale yellow crystals: TLC Rf = 0.9 (EtOAc / hexane, 2:3); mp 53-54°C (lit.219 mp 
54-56°C); 1H NMR (270 MHz, CDCI3) 5 2.50 (3 H, s, CH3), 4.68 (1 H, s, OH), 7.27-7.32 
(3 H, m, Ph-H3), 7.47 (1 H, m, Ph 2-H), 8.09 (1 H, s, N=CH).
3-(Methylthio)benzonitrile (78)
SMe
3-Bromothioanisole (75, 1.00 g, 4.92 mmol), Zn(CN)2 (580 mg, 4.92 mmol) and 
Pd(PPh3)4 (284 mg, 5 mol %) in DMF (10 mL) were boiled under N2 for 3 d. The cooled 
suspension was filtered (Celite®), diluted with EtOAc, washed with 5% aq. Na2S20 3, 
10% aq. K2C03, water and brine and dried. Evaporation and chromatography (EtOAc / 
hexane, 1:4) gave 78 (735 mg, 100%) as a yellow oil: TLC Rf = 0.5 (EtOAc / hexane, 
1:4); IR vmax (film) 908, 2232, 2254 (CN) cm-1; 1H NMR (400 MHz, CDCI3) 8 2.52 (3 H, 
s, CH3), 7.30-7.47 (4 H, m, Ph-H4); 13C NMR (100 MHz, CDCI3) 8 60.3 (CH3), 112.9 (Ph
1-Cq), 118.3 (C=N), 128.1 (Ph 6-CH), 128.6 (Ph 5-CH), 129.2 (Ph 2-CH), 130.2 (Ph
4-CH), 140.8 (Ph 3-Cq); HRMS (FAB+) mfz 150.0301 (M + H) (12C8H8NS requires 
150.0377), 149.0299 (M) (12C8H7NS requires 149.0299).
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(S)-(-)-3-Bromophenyl methyl sulfoxide (79)
Experimental
Ti(0/Pr)4 (711 mg, 2.5 mmol) and (S,S)-(-)-diethyl tartrate (1.03 g, 5 mmol) were stirred 
in dry DCM (25 mL) for 15 min followed by addition of water (0.04 mL, 2.5 mmol).
3-Bromothioanisole (75, 508 mg, 2.5 mmol) was added after 20 min. The mixture was 
cooled to -20°C and aq. 'BuOOH (70%, 248 mg, 2.75 mmol) was added. After 3 h, 
water (328 mg, 18 mmol) was introduced and the mixture was vigorously stirred at 
-20°C for 1 h and at RT overnight. The white gel formed was filtered (Celite®) and 
washed well with DCM. The filtrate was treated with 5% aq. NaOH overnight, washed 
with brine and water and dried. Evaporation and chromatography (EtOAc / hexane, 1:4) 
gave 79 (270 mg, 49%) as a pale yellow oil: TLC Rf = 0.1 (EtOAc / hexane, 1:4); 1H 
NMR (400 MHz, CDCI3) 5 2.73 (3 H, s, CH3), 7.37 (1 H, t, J = 7.5 Hz, Ph 5-H), 7.52 (1 
H, dt, J = 7.5, 1.4 Hz, Ph 6-H), 7.60 (1 H, dt, J = 7.5,1.4 Hz, Ph 4-H), 7.79 (1 H, m, Ph
2-H); [a]20!} = -38.6° (c = 0.07, acetone), 33% ee. [lit.175 [a]25D for (R)-(+)-isomer = 
+116.3° (c = 1.2, acetone), 97% ee]
(±)-3-(Methylsulfinyl)benzonitrile (81)
0 ^ S "M e
Compound 78 (735 mg, 4.92 mmol) was treated with mCPBA (849 mg, 4.92 mmol) in 
DCM at 0°C for 2 h. The mixture was diluted with DCM (10 mL) and washed with aq. 
NaHC03 (1 M) and water and dried. Evaporation and chromatography (DCM / EtOAc, 
7:3) afforded 81 (550 mg, 68%) as a pale yellow solid: TLC Rf = 0.3 (DCM / EtOAc, 
1:1); mp 68-72°C; IR v ,*  (KBr) 911, 2254 (CN) cm'1; 1H NMR (400 MHz, CDCI3) 8 2.76 
(3 H, s, CH3), 7.67 (1 H, dt, J=  0.5, 7.8 Hz, Ph 5-H), 7.87 (1 H, dt, J= 7.8, 1.6 Hz, Ph
4-H), 7.90 (1 H, dt, J= 7.8, 1.6 Hz, Ph 6-H), 7.94 (1 H, dt, J= 0.5, 1.6 Hz, Ph 2-H); 13C 
NMR (100 MHz, CDCI3) 5 44.0 (CH3), 113.9 (Cq), 117.5 (Cq), 127.2 (CH), 127.7 (CH),
130.2 (CH), 134.4 (CH), 147.9 (Cq); HRMS (EI+) m/z 165.0245 (M) (12C8H7NOS
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requires 165.0248), 150 (M -  CH3), 134 (M -  OCH3), 102 (M -  SOCH3); HRMS (FAB+) 




To a suspension of compound 81 (70.0 mg, 0.42 mmol), trifluoroacetamide (95.0 mg, 
0.84 mmol), MgO (67.7 mg, 1.68 mmol) and Rh2(OAc)4 (4.60 mg, 2.5 mol %) in DCM 
(5 mL) was added Phl(OAc)2 (203 mg, 0.63 mmol) and the mixture was stirred for 16 h. 
The suspension was filtered (Celite®); evaporation and chromatography (DCM / EtOAc, 
7:3) gave 82 (52.0 mg, 45%) as a white solid: TLC Rf = 0.4 (DCM / EtOAc, 7:3); mp 
125-128°C; IR v ,*  (KBr) 911, 1171 (CF3), 1379, 2254 (CN) cm'1; 1H NMR (400 MHz, 
CDCI3) 5 3.49 (3 H, s, CH3), 7.82 (1 H, dt, J = 0.5, 7.8 Hz, Ph 5-H), 8.02 (1 H, dt, J =
7.8, 1.2 Hz, Ph 4-H), 8.21 (1 H, dt, J = 7.8, 1.2 Hz, Ph 6-H), 8.29 (1 H, dt, J = 0.5, 1.2 
Hz, Ph 2-H); 13C NMR (100 MHz, CDCI3) 5 44.1 (CH3), 114.9 (Cq), 116.3 (Cq), 130.9 
(CH), 131.1 (CH), 131.2 (CH), 137.8 (CH), 138.7 (Cq); 19F NMR (376 MHz, CDCI3) 5 
-76.0 (3 F, s, CF3); HRMS (FAB+) m/z 294.0517 (M + NH4) (^CkjHuNsO^S requires 





Compound 82 (52.0 mg, 0.21 mmol) was stirred with NH3 (35% in water, 1.0 mL) in 
MeOH (5 mL) for 2 h. Evaporation and chromatography (MeOH / EtOAc, 7:3) gave 83 
(37.5 mg, 99%) as a pale yellow oil: TLC Rf = 0.3 (DCM / EtOAc, 1:1); IR (film) 
756, 2237, 3020, 3402 cm-1; 1H NMR (400 MHz, CDCI3) 8 2.75 (1 H, br s, NH), 3.11 (3 
H, s, CH3), 7.69 (1 H, dt, J = 0.5, 7.9 Hz, Ph 5-H), 7.88 (1 H, dt, J = 7.9, 1.5 Hz, Ph
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4-H), 8.22 (1 H, dt, J = 7.9,1.5 Hz, Ph 6-H), 8.29 (1 H, t, J=  1.5 Hz, Ph 2-H); 13C NMR 
(100 MHz, CDCIa) 5 45.8 (CH3), 113.7 (Cq), 117.1 (Cq), 130.3 (CH), 131.4 (CH), 131.7
(CH), 136.2 (CH), 145.1 (Cq); HRMS (FAB+) m/z 181.0432 (M + H) (,2C8H8N2OS 
requires 181.0430).
3-[(±)*N-ferf-Butoxycarbonyl-S-methylsulfonimidoyl)]benzonitrile (84)
NaH (60% in mineral oil, 93 mg, 2.32 mmol, pre-washed with dry pentane) was added 
to compound 83 (300 mg, 1.66 mmol) in dry THF (2.5 mL) and the mixture was stirred 
for 30 min. Di-ferf-butyl dicarbonate (725 mg, 3.32 mmol) was added and the reaction 
mixture was stirred overnight. The mixture was quenched with sat. aq. NH4CI and 
extracted with DCM (x 3). The organic layers were collected and dried. Evaporation 
and chromatography (DCM / EtOAc, 1:1) afforded 84 (420 mg, 90%) as a white solid: 
TLC Rf = 0.7 (DCM / EtOAc, 1:1); mp 148-150°C; IR v,™ (KBr) 770, 1642, 2251 cm'1; 
1H NMR (400 MHz, CDCI3) 5 1.39 [9 H, s, C(CH3)3], 3.27 (3 H, s, CH3), 7.76 (1 H, t, J =
7.8 Hz, Ph 5-H), 7.96 (1 H, dt, J = 7.8, 1.4 Hz, Ph 4-H), 8.21 (1 H, dt, J = 8.1, 1.6 Hz, 
Ph 6-H), 8.28 (1 H, t, J = 1.6 Hz, Ph 2-H); 13C NMR (100 MHz, CDCI3) 5 26.7 [(CH3)3],
44.0 (SCH3), 81.8 [C(CH3)3], 114.2 (Cq), 116.1 (Cq), 130.3 (CH), 131.2 (CH), 131.5 
(CH), 136.3 (CH), 140.8 (Cq), 158.2 (Cq); HRMS (FAB+) m/z 281.0955 (M + H) 
(12C13H17N20 3S requires 281.0954), 165 (M -  NBoc), 102 (C6H4-CN).
(4R,5R)-Diethyl 2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate (95)
Et02C C 0 2Et
Diethyl (R,R)-2,3-dihydroxybutanedioate (93, 15.0 g, 70 mmol), 2,2-dimethoxypropane 
(94, 32 g, 320 mmol) and 4-toluenesulfonic acid monohydrate (198 mg, 1.02 mmol) in 
DCM (200 mL) were boiled under reflux in a Soxhlet apparatus for 7 d through





activated 4 A molecular sieves (33 g). Anhydrous Na2C03 (83 mg, 1.0 mmol) was 
added. Filtration, drying, evaporation and chromatography (EtOAc / hexane, 2:3) 
afforded 95 with some ester interchange, yielding ethyl methyl and dimethyl esters 
(total usable esters 12 g, ca. 67%) as a pale buff oil. TLC Rf = 0.4 (EtOAc / hexane, 
2:3); IR Vmax (film) 1385, 1753 (C=0), 2988, 3055 cm'1; 95:1H NMR (400 MHz, CDCI3) 
8 1.26 (6 H, t, J = 7.2 Hz, 2 x CH2CHj), 1.43 [6 H, s, (CHa)^, 4.21 (4 H, q, J = 7.2 Hz, 
CH2 CH3 ), 4.75 (2 H, s, 4,5-H2); ethyl methyl ester: 1H NMR (400 MHz, CDCI3) 8 1.19 
(3 H, t, J = 7.2 Hz, CH2 CHa), 1.43 [6 H, s, (CH3 )z], 3.76 (3 H, s, OCH3), 4.05 (2 H, q, J =
7.2 Hz, ChbCH3), 4.72 (1 H, s, 4-H), 4.74 (1 H, s, 5-H); dimethyl ester 1H NMR (400 
MHz, CDCI3) 81.43 [6 H, s, (CH^J, 3.76 (6 H, s, 2 x OCH3), 4.71 (2H, s, 4,5-H2); 13C 
NMR (100 MHz, CDCI3) (HMQC) 8 14.0 (CHjCHa), 26.2 x 3 [(C H ^ , 52.7 x 2 (OCH3),
61.8 x 2 (CH2CH3), 76.8, 77.0 (4-CH + 5-CH), 113.6, 113.7 x 2 [CfCHaJJ, 169.5,169.6 
(0=0); HRMS (FAB+) m/z 247.1182 [M (95) + H] (12CnH190 6 requires 247.1154),
233.2 (ethyl methyl ester + H), 217.2 (dimethyl ester -  H).
4S,5S-Di(hydroxymethyl)-2,2-dimethyl-1,3-dioxolane (96)
HO— ^  -OH
LiAIH4 (2.0 M in THF, 103 mmol, 51.5 mL) was added during 1.5 h to 95 (12 g, 49 
mmol) in dry THF (80 mL) and the mixture was boiled under reflux for a further 5 h. It 
was then cooled to 0°C and water (10 mL), aq. NaOH (4 M, 10 mL) and water (30 mL) 
were added cautiously in turn. The aluminium salts were removed by filtration. 
Evaporation of the filtrate gave crude 96. The aluminium salts were extracted with 
boiling 1,4-dioxane (3 x 100 mL) and removed by filtration; evaporation of the extracts 
gave further product (6.7 g, 85 %) as a pale yellow oil: TLC Rf = 0.2 (EtOAc / hexane, 
2:3); IR vmax (film) 3370 (OH) cm"1; 1H NMR (400 MHz, CDCI3) 8 1.40 [6 H, s, (CH3)2], 
2.83 (2 H, br s, 2 x OH), 3.69-3.73 (4 H, m, 2 x CH2); 13C NMR (100 MHz, CDCI3) 8
26.9 [(CH3)2], 62.0 (2 x CH2), 78.1 (2 x CH), 109.2 [C IC H ^; HRMS (FAB+) m/z 
163.0966 (M + H) (12C7H150 4 requires 163.0970), 147 (M + H -  O); [af°D = +4.4° (c 
4.0, CHCI3) [lit.177 [a]20D= +4.1° (c 5.0, CHCI3)].
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4S,5S-Di(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolane (97) and 4S,5S-4-benzyl- 
oxymethyl-5-hydroxymethyl-2,2-dimethyl-1,3-dioxolane (98)
Sodum hydride (60% dispersion in mineral oil, 1.9 g, 46 mmol, pre-washed with dry 
pentane) was stirred in dry DMF (20 mL) at 0°C under N2 for 30 min. Compound 96 
(6.7 g, 42 mmol) in dry DMF (20 mL) was then added dropwise and the reaction 
mixture was stirred for a further 30 min before benzyl bromide (7.35 g, 43 mmol) was 
added. The reaction mixture was stirred for 1.5 h at RT and was then poured into 
ice-water (250 mL) and extracted with Et20  (x 3). The combined extracts were washed 
with water and brine. Drying, evaporation and chromatography [pet. ether (40-60°C) / 
Et20, 1:1] gave 97 (500 mg, 6 %) as a pale yellow oil: TLC Rf = 0.8 [pet. ether 
(40-60°C) / Et20, 1:1]; IR (film) 650, 735, 910, 1454, 2988, 3054 cm'1; 1H NMR 
(400 MHz, CDCIs) 8 1.44 [6 H, s, (C H ^ , 3.61-3.62 (4 H, m, 2 x BnOCH2), 4.05 (2 H, s,
4,5-H2), 4.55 (2 H, d, J = 12.3 Hz, 2 x PhCH), 4.59 (2 H, d, J = 12.3 Hz, 2 x PhCH), 
7.27-7.38 (10 H, m, 2 x Ph-H5); 13C NMR (100 MHz, CDCI3) (HMQC) 8 26.9 [(C H ^,
70.6 (2 x BnOCH2), 73.4 (4-CH + 5-CH), 77.4 (2 x PhCH2), 109.6 [C(CH3)2], 127.6 
(CH), 128.3 (CH), 137.9 (Cq); HRMS (FAB+) mfz 343.1939 (M + H) (^ C ^ H ^  
requires 343.1909).
Further elution gave 98 (3.6 g, 71%) as a pale yellow oil: TLC Rf = 0.2 (hexane / Et20, 
1:1); IR (film) 701, 740, 910, 1454, 2989, 3055, 3468 (OH) cm*1; 1H NMR (400 
MHz, CDCIa) 8 1.40 (3 H, s, CH3), 1.41 (3 H, s, CH3), 2.40 (1 H, br s, OH), 3.55 (1 H, 
dd, J = 9.8, 5.5 Hz, BnOCH), 3.65-3.69 (2 H, m, CHOH + BnOCH), 3.75 (1 H, dd, J =
11.7, 4.3 Hz, CHOH), 3.93 (1 H, m, 5-H), 4.05 (1 H, m, 4-H), 4.57 (2 H, s, PhCH2),
7.26-7.36 (5 H, m, Ph-Hs); 13C NMR (100 MHz, CDCI3) (HMQC) 8 26.8 (CH3), 26.9 
(CH3), 62.3 (CH2OH), 70.2 (BnOCH2), 73.6 (PhCH2), 76.5 (5-CH), 79.5 (4-CH), 109.3 
[C(CH3)2], 127.7 (2 x CH), 127.8 (2 x CH), 128.4 (CH), 137.5 (Cq); HRMS (FAB+) m/z 
253.1435 (M + H) (12C14H210 4 requires 253.1440), 237 (M + H -  O); [af°D = +7.9° (c











To 98 (280 mg, 1.12 mmol) and CBr4 (409 mg, 1.23 mmol) in dry THF (2 mL) was 
added dropwise Pn3P (353 mg, 1.34 mmol) in dry THF (1 mL) at 0°C under N2 and the 
mixture was stirred for 3 h. Evaporation and chromatography (hexane / Et20 , 1:1) gave 
99 (240 mg, 69%) as a colourless oil: TLC Rf = 0.9 (hexane / Et20, 1:1); IR v,** (film)
CDCI3) 8 27.1 (CH3), 27.2 (CH3), 32.6 (BrCH2), 70.4 (BnOCH2), 73.6 (PhCH2), 77.2 
(5-CH), 78.8 (4-CH), 110.0 [C IC H ^, 127.7 (2 x CH), 127.8 (2 x CH), 128.4 (CH),
137.7 (Cq); HRMS (FAB+) m/z 317.0563 (M + H) (12C14H2o0381Br requires 317.0575); 
316.0503 (M) (12Ci4H190 381Br requires 316.0497), 235 (M -  81Br), 220 (M -  CH281Br); 
[a]20D = +3.6° (c 1.7, CHCI3).
4S,5R-4-(Benzyloxymethyl)-2,2-dimethyl-5-(phenylthiomethyl)-1,3-dioxolane (101)
Method A: A cooled (0°C) solution of thiophenol (100, 218 mg, 1.98 mmol) and 98
(500 mg, 1.98 mmol) in dry THF (3 mL) was added to a cooled (0°C) solution of 
triphenylphosphine (1.04 g, 3.96 mmol) and diisopropyl azodicarboxylate (800 mg, 3.96 
mmol) in dry THF (7 mL) under Ar and the reaction mixture was allowed to warm to RT 
and stirred overnight. Evaporation and chromatography [pet. ether (40-60°C) / Et20, 
1:1] gave 101 (150 mg, 22%) as a yellow oil: TLC Rf = 0.7 [pet. ether (40-60°C) / Et20, 
1:1]; IR vmax (film) 738, 1265, 1422, 2986, 3054 cm’1; 1H NMR (400 MHz, CDCI3) 8 1.40 
(3 H, s, CH3), 1.44 (3 H, s, CH3), 3.19 (1 H, d, J = 4.3 Hz, SCH), 3.20 (1 H, d, J = 4.3 
Hz, SCH), 3.63 (2 H, d, J = 4.7 Hz, BnOCH2), 4.04-4.09 (2 H, m, 4,5-H2), 4.54 (1 H, d, J
601, 740, 910, 1422, 2987, 3054 cm-1; 1H NMR (400 MHz, CDCI3) 8 1.43 (3 H, s, CH3),
1.45 (3 H, s, CH3), 3.46-3.54 (2 H, m, BrCH2), 3.62-3.69 (2 H, m, BnOCH2), 4.04-4.12 





= 14.9 Hz, PhCH), 4.57 (1 H, d, J = 14.9 Hz, PhCH), 7.16-7.36 (10 H, m, Ph-H,0); 13C 
NMR (100 MHz, CDCI3) 8 27.1 (CH3), 27.2 (CH3), 36.7 (SCH2), 70.7 (BnOCH2), 73.5 
(PhCH2), 77.0 (5-CH), 79.4 (4-CH), 109.7 [C[CH3)2], 126.2 (2 x CH), 127.8 (2 x CH),
128.4 (2 x CH), 128.9 (2 x CH), 129.2 (2 x CH), 135.8 (Cq), 137.8 (C,); HRMS (FAB+) 
m/z 345.1522 (M + H) (12C20H2«O3S requires 345.1519), 329 (M -  CH3), 109 (PhSH), 
91 (Bn); [app = +4.4° (c 2.0, CHCI3).
Method B: A cooled (0°C) solution of thiophenol (100, 567 mg, 5.15 mmol) and
triphenylphosphine (2.70 g, 10.3 mmol) in dry THF (7 mL) was stirred for 30 min under 
Ar and diisopropyl azodicarboxylate (2.08 g, 10.3 mmol) was added and the mixture 
was stirred for a further 30 min. 98 (1.30 g, 5.15 mmol) in dry THF (3 mL) was then 
added and the reaction mixture was allowed to warm to RT and stirred overnight. 
Evaporation and column chromatography [pet. ether (40-60°C) / Et20, 1:1] afforded 
101 (320 mg, 18%) as a yellow oil. The data were identical to those above.
Method C: To a cooled (0°C) solution of tributylphosphine (601 mg, 2.97 mmol) and
1,1’-(azodicarbonyl)dipiperidine (749 mg, 2.97 mmol) in dry THF (7 mL) was added 
thiophenol (100, 327 mg, 2.97 mmol) under Ar and the reaction vessel was sonicated 
for 30 min. While being sonicated, 98 (500 mg, 1.98 mmol) in dry THF (3 mL) was 
added and the reaction mixture was stirred at RT overnight. Filtration, evaporation and 
chromatography (hexane / Et20, 5:1) gave 101 (300 mg, 44%) as a yellow oil. The data 
were identical to those above.
4S,5R,S(±)-4-(Benzyloxymethyl)-2,2-dimethyl-5-(phenylsulfmylmethyl)-1,3- 
dioxolane (102a/b)
Ph— \  Ph
°x°
Compound 101 (180 mg, 0.52 mmol) was treated with mCPBA (111 mg, 0.52 mmol) in 
DCM (15 mL) at -78°C for 5 h. The mixture was diluted with DCM (10 mL) and washed 
with aq. NaHC03(1 M) and water. Drying and evaporation gave 102a/b (180 mg, 96%) 
as a 1:1 mixture of diastereoisomers as a yellow oil: TLC Rf = 0.7 (DCM / EtOAc, 1:1); 
IR vmax (film) 739, 1265, 3054 cm'1; 1H NMR (600 MHz, CDCI3) 8 1.37 (1.5 H, s, CH3),
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1.45 (1.5 H, s, CH3), 1.46 (1.5 H, s, CH3), 1.47 (1.5 H, s, CH3), 2.84 [0.5 H, dd, J =
13.2, 9.8 Hz, SCH (isomer A)], 3.04 [0.5 H, dd, J = 13.2, 4.2 Hz, SCH (isomer B)], 3.06 
[0.5 H, dd, J = 13.2, 2.2 Hz, SCH (isomer A)], 3.22 [0.5 H, dd, J = 13.2, 7.2 Hz, SCH 
(isomer B)], 3.51 [0.5 H, dd, J = 10.1, 5.7 Hz, BnOCH (isomer B)], 3.55 [0.5 H, dd, J =
9.8, 5.7 Hz, BnOCH (isomer A)], 3.62 [0.5 H, dd, J = 9.8, 4.9 Hz, BnOCH (isomer B)], 
3.68 [0.5 H, dd, J = 9.5, 5.3 Hz, BnOCH (isomer A)], 3.91 [0.5 H, dt, J = 5.3, 8.3 Hz,
4-H (isomer A)], 3.97 [0.5 H, m, 5-H (isomer B)], 4.15 [0.5 H, dt, J = 5.3, 8.3 Hz, 4-H 
(isomer B)], 4.41 [0.5 H, ddd, J = 9.8, 8.3, 2.3 Hz, 5-H (isomer A)], 4.50 (0.5 H, d, J -
12.1 Hz, PhCH), 4.52 (0.5 H, d, J = 12.1 Hz, PhCH), 4.55 (1 H, s, PhCH2), 7.23-7.35 (5 
H, m, Ph-Hg), 7.50-7.53 (3 H, m, S-Ph 3,4,5-H3), 7.65-7.67 (2 H, m, S-Ph 2,6-H2); 13C 
NMR (100 MHz, CDCI3) (HMQC, HMBC) 6 26.8 (CH3), 26.9 (CH3), 27.0 (CH3), 27.2 
(CH3), 60.2 [SCH2 (isomer B)], 62.2 [SCH2 (isomer A)], 69.6 [BnOCH2 (isomer B)], 70.0 
[BnOCH2 (isomer A)], 73.2 [5-CH (isomer A)], 73.5 [PhCH2 (isomer B)], 73.7 [PhCH2 
(isomer A)], 73.9 [5-CH (isomer B)J, 78.6 [4-CH (isomer B)], 79.0 [4-CH (isomer A)],
110.0 [C(CH3)2], 110.2 [C(CH3)2], 123.8 (CH), 124.3 (CH), 127.6 (CH), 127.7 (CH),
127.8 (CH), 128.4 (CH), 129.2 (CH), 129.3 (CH), 131.2 (S-Ph 4-CH), 131.3 (S-Ph
4-CH), 137.6 (C-Ph 1-Cq), 137.7 (C-Ph 1-Cq), 143.5 [S-Ph 1-Cq (isomer B)], 144.5 
[S-Ph 1-Cq (isomer A)]; MS (FAB+) m/z 361 (M + H), 303 (M + H -  Me2CO); [af°D = 
+4.4° (c 2.0, CHCI3).
4S,5R,S(±)-4-(Benzyloxymethyl)-2,2-dimethyl-5-[N-(trifluoroacetyl)phenyl- 
sulfonimidoylmethyl]-1,3-dioxolane (103a/b)




To a suspension of compounds 102a/b (180 mg, 0.5 mmol), trifluoroacetamide (113 
mg, 1.0 mmol), MgO (80.6 mg, 2.0 mmol) and Rh2(OAc)4 (5.52 mg, 2.5 mol %) in DCM 
(10 mL) was added Phl(OAc)2 (242 mg, 0.75 mmol) and the mixture was stirred for 6 d. 
The suspension was filtered (Celite®); evaporation and chromatography [pet. ether 
(40-60°C) / Et20, 1:1] afforded 103a/b (176 mg, 75%) as a 3:2 mixture of 
diastereoisomers as a pale yellow oil: TLC Rf = 0.2 [pet. ether (40-60°C) / Et20 , 1:1]; IR 
vmax (film) 705, 739, 1173 (CF3), 1265, 1422 cm'1; 1H NMR (400 MHz, CDCI3) 8 1.16 
(1.8 H, CH3), 1.21 (1.2 H, CH3), 1.25 (1.8 H, CH3), 1.26 (1.2 H, CH3), 3.42 (dd, J= 9.6,
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6.8 Hz, BnOCH) and 3.43 (dd, J = 9.7, 6.8 Hz, BnOCH) for a total of one proton, 3.65 
(dd, J = 10.7, 4.7 Hz, BnOCH) and 3.66 (dd, J = 10.2, 4.7 Hz, BnOCH) for a total of 
one proton, 3.79 (dd, J = 14.1, 8.6 Hz, SCH) and 3.81 (dd, J -  14.4, 9.7 Hz, SCH) for a 
total of one proton, 3.86-3.92 (1 H, m, 4-H), 3.99 (dd, J -  11.2, 2.3 Hz, SCH) and 4.03 
(dd, J = 11.2, 2.2 Hz, SCH) for a total of one proton, 4.14-4.19 (1 H, m, 5-H), 4.49 (2 H, 
s, PhCH2), 7.23-7.37 (5 H, m, Ph-H5), 7.54-7.60 (2 H, m, S-Ph 3,5-H2), 7.70 (1 H, t, J = 
8 Hz, S-Ph 4-H), 7.94 (2 H, d, J = 8 Hz, S-Ph 2,6-H2); 13C NMR (100 MHz, CDCI3) 
(HMQC, HMBC) 8 26.4 (CH3), 26.6 (CH3), 58.5 (SCH2), 59.3 (SCH2), 69.6 (BnOCH2),
69.7 (BnOCH2), 72.9 (5-CH), 73.3 (5-CH), 73.6 (PhCH2), 73.7 (PhCH2), 78.1 (4-CH),
78.2 (4-CH), 110.8 [CfCH^J, 127.7 (CH), 127.8 (CH), 127.9 (C-Ph 2-CH or 6-CH),
128.0 (CH), 128.2 (S-Ph 2-CH or 6-CH), 128.3 (CH), 128.47 (CH), 128.49 (CH), 128.53 
(C-Ph 3-CH or 5-CH), 129.0 (CH), 129.5 (S-Ph 3-CH or 5-CH), 134.6 (S-Ph 4-CH),
134.8 (S-Ph 4-CH), 135.3 (S-Ph 1-Cq), 135.4 (S-Ph 1-Cq), 137.32 (C-Ph 1-Cq), 137.35 
(C-Ph 1-Cq); 19F NMR (376 MHz, CDCI3) 8 -76.0 (1.8 F, s), -75.9 (1.2 F, s); HRMS 
(FAB+) m/z 472.1382 (M + H) (^CzjH^NOgFaS requires 472.1406), 472 (M + H -  O), 
414 (M + H -  Me2CO); [a]20D = +5.1° (c 2.6, CHCI3).
4S,5R,S(R)- and 4S,5R,S(S)-4-(Benzyloxymethyl)-2,2-dimethyl-5-(phenyl- 
sulfonimidoylmethyl)-1,3-dioxolane (104)
Ph—\  HNvX Ph
O—\  ^ —SjRj/fS)
O
X
Compounds 103a/b (176 mg, 0.37 mmol) were stirred with NH3 (35% in water, 2 mL) in 
MeOH (5 mL) overnight. Evaporation and chromatography (EtOAc / hexane, 2:3) 
yielded S-(R)-104 (42 mg, 30%) as a pale yellow oil: TLC Rf = 0.5 (EtOAc / hexane, 
7:3); IR v,™ (film) 733, 2926, 3332 cm'1; 1H NMR (400 MHz, CDCI3) 8 1.33 (3 H, s, 
CH3), 1.37 (3 H, s, CH3), 3.10 (1 H, br s, NH), 3.30 (1 H, dd, J = 13.6, 8.7 Hz, SCH),
3.45 (1 H, dd, J=  13.6, 2.9 Hz, SCH), 3.53 (1 H, dd, J=  9.8, 5.8 Hz, BnOCH), 3.67 (1 
H, dd, J = 9.8, 5.3 Hz, BnOCH), 3.90 (1 H, dt, J = 7.7, 5.3 Hz, 4-H), 4.45 (1 H, dt, J =
2.9, 8.7 Hz, 5-H), 4.51 (2 H, s, PhCH2), 7.27-7.35 (5 H, m, Ph-H5), 7.48-7.52 (2 H, m,
S-Ph 3,5-H2), 7.57-7.61 (1 H, m, S-Ph 4-H), 7.98-8.01 (2 H, m, S-Ph 2,6-H2); 13C NMR 
(100 MHz, CDCI3) (HMQC) 8 26.8 (CH3), 26.9 (CH3), 61.3 (SCH2), 70.0 (BnOCH2), 73.6 
(PhCH2), 73.7 (5-CH), 78.7 (4-CH), 110.4 [C£CH3)2], 127.6 (2 x CH), 127.7 (CH), 128.4
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(2 x CH), 128.5 (S-Ph 2-CH and 6-CH), 129.0 (S-Ph 3-CH and 5-CH), 133.1 (S-Ph
4-CH), 137.6 (Cq), 141.5 (Cq); MS (FAB+) m/z 376 (M + H); HRMS (ES+) m/z 775 (2 M 
+ Na), 399 (M + Na), 375 (M); [a ]^  = +8.4° (c 2.3, CHCI3).
Further elution gave S-(S)-104 (47 mg, 34%) as a white solid: TLC Rf = 0.4 (EtOAc / 
hexane, 7:3); mp 86-88°C; IR v™* (KBr) 734, 2934, 2990, 3332 cm'1; 1H NMR (400 
MHz, CDCI3) 8 1.21 (3 H, s, CH3), 1.29 (3 H, s, CH3), 3.39 (1 H, dd, J = 14.2, 8.2 Hz, 
SCH), 3.50-3.54 (2 H, m, SCH + BnOCH), 3.64 (1 H, dd, J -  9.7, 5.3 Hz, BnOCH), 3.93 
(1 H, dt, J = 7.6, 5.3 Hz, 4-H), 4.31 (1 H, dt, J = 3.4, 8.2 Hz, 5-H), 4.51 (2 H, s, PhCH2),
7.26-7.35 (5 H, m, Ph-H5), 7.45-7.50 (2 H, m, S-Ph 3,5-H2), 7.55-7.60 (1 H, m, S-Ph
4-H), 7.94-7.97 (2 H, m, S-Ph 2,6-H2); 13C NMR (100 MHz, CDCI3) (HMQC) 8 26.7 
(CH3), 26.8 (CH3), 61.0 (SCH2), 69.9 (BnOCH2), 73.5 (5-CH), 73.6 (PhCH2), 78.6 
(4-CH), 110.1 [CiCH3)2], 127.6 (2 x CH), 127.7 (CH), 128.4 (2 x CH), 128.5 (S-Ph 2-CH 
and 6-CH), 128.8 (S-Ph 3-CH and 5-CH), 133.0 (S-Ph 4-CH), 137.6 (Cq), 141.5 (Cq); 
MS (FAB+) m/z 376 (M + H); [a]2^  = +7.8° (c 2.3, CHCI3).
2S,3R,S(R)-1 -(Benzyloxy)-4-(phenylsulfonimidoyl)butane-2,3-diol (105)
P h - \  H N /Ph
HO OH
Compound S-(R)-104 (38 mg, 0.1 mmol) was treated with aq. HCI (9 M, 1 mL) in 
MeOH (5 mL) for 4 h. Evaporation and chromatography (EtOAc / MeOH, 7:3) afforded 
105 (37 mg, 100%) as a pale yellow oil: TLC R^  = 0.8 (EtOAc / MeOH, 7:3); IR Vmax 
(film) 3305 (OH) cm'1; 1H NMR (400 MHz, CDCI3) 8 2.68 (1 H, br, OH), 3.13 (1 H, dd, J 
= 13.8, 1.7 Hz, SCH), 3.45 (1 H, dd, J = 13.8, 10.1 Hz, SCH), 3.59-3.63 (2 H, m, 
BnOCH2), 3.69 (1 H, m, 3-H), 4.54-4.56 (3 H, m, PhCH2 + 4-H), 7.27-7.35 (5 H, m, 
Ph-Hg), 7.53-7.58 (2 H, m, S-Ph 3,5-H2), 7.64 (1 H, m, S-Ph 4-H), 7.98 (2 H, m, S-Ph
2,6-H2); 13C NMR (100 MHz, CDCI3) (HMQC, HMBC) 8 59.8 (SCH2), 66.4 (4-CH), 71.0 
(BnOCH2), 72.4 (3-CH), 73.5 (PhCH2), 127.7 (2 x CH), 127.8 (CH), 128.1 (2 x CH),
128.5 (S-Ph 2-CH and 6-CH), 129.4 (S-Ph 3-CH and 5-CH), 133.5 (S-Ph 4-CH), 137.7 
(Cq), 142.6 (Cq); MS (FAB+) m/z 336 (M + H); HRMS (ES+) m/z 693 (2 M + Na), 671 (2 
M + H), 336.1264 (M + H) (12C17H23N04S requires 336.1264); MS (ES-) m/z 372/370 
(M + Cl); MS (EI+) mb 336 (M + H), 244 (M -  Bn), 214 (M -  BnOCH2), 91 (Bn); [a]20D = 





Method A: A cooled (0°C) solution of 3-bromothiophenol (87, 374 mg, 1.98 mmol)
and 98 (500 mg, 1.98 mmol) in dry THF (5 mL) was added to a cooled (0°C) solution of 
triphenylphosphine (1.04 g, 3.96 mmol) and diisopropyl azodicarboxylate (800 mg, 3.96 
mmol) in dry THF (7 mL) under Ar and the reaction mixture was allowed to warm to RT 
and stirred overnight. Evaporation and chromatography (hexane / Et20, 5:1) gave 88 
(410 mg, 49%) as a yellow oil: TLC R, = 0.7 (hexane / Et20, 5:1); 1H NMR (400 MHz, 
CDCI3) 5 1.39 (3 H, s, CH3), 1.43 (3 H, s, CH3), 3.16-3.19 (2 H, m, SCH2), 3.59-3.66 (2
H, m, BnOCHs), 4.03-4.05 (2 H, m, 4,5-H2), 4.57 (2 H, s, PhCH2), 7.08 (1 H, t, J=  8.0 
Hz, Ar 5-H), 7.22 (1 H, ddd, J = 8.1, 1.8, 1.0 Hz. Ar 6-H), 7.42-7.46 (5 H, m, Ph-H5), 
7.48-7.51 (2 H, m, Ar 2,4-H2); 13C NMR (100 MHz, CDCI3) (HMQC) 6 27.0 (CH3), 27.1 
(CH3), 36.3 (SCH2), 70.5 (BnOCH2), 73.6 (PhCH2), 77.2 (5-CH), 79.1 (4-CH), 110.0 
[C(CH3)2], 122.8 (C„), 127.3 (CH), 127.8 (2 x CH), 128.4 (2 x CH), 129.0 (CH), 130.2 
(CH), 131.2 (CH), 132.3 (CH), 137.7 (C„), 138.5 (C,); [<xf’D = +6.10 (c 2.5, CHCI3).
Method B: To a cooled (0°C) solution of tributylphosphine (670 mg, 3.31 mmol) and
I,1 ’-(azo<iicarbonyl)dipiperidine (835 mg, 3.31 mmol) in dry THF (7 mL) was added
3-bromothiophenol (87, 625 mg, 3.31 mmol) under Ar and the reaction mixture was 
sonicated for 30 min. While the mixture was being sonicated, 98 (558 mg, 2.21 mmol) 
in dry THF (3 mL) was added and the reaction mixture was stirred at RT overnight. 
Filtration, evaporation and chromatography (hexane / Et20, 5:1) gave 88 (650 mg, 





Compound 88 (1.06 g, 2.5 mmol) was treated with mCPBA (559 mg, 2.5 mmol) in DCM 
at -78°C for 5 h. The mixture was diluted with DCM (10 mL) and washed with aq. 
NaHC03(1 M) and water. Drying and evaporation gave 89a/b (1.62 g, 68%) as a 1:1 
mixture of diastereoisomers as a yellow oil: TLC Rf = 0.2 [pet. ether (40-60°C) I Et20, 
1:1]; 1H NMR (600 MHz, CDCfe) 8 1.36 (1.5 H, s, CH3), 1.41 (1.5 H, s, CH3), 1.45 (3 H, 
CH3), 2.83 [0.5 H, dd, J=  13.2, 9.9 Hz, SCH (isomer A)], 3.04 [0.5 H, dd, J=  13.4, 3.4 
Hz, SCH (isomer B)], 3.06 [0.5 H, dd, J = 13.0, 3.6 Hz, SCH (isomer A)], 3.18 [0.5 H, 
dd, J=  13.4, 7.0 Hz, SCH (isomer B)], 3.46-3.54 [1 H, m, BnOCH (both isomers)], 3.62 
[0.5 H, dd, J = 10.1, 4.6 Hz, BnOCH (isomer B)], 3.68 [0.5 H, dd, J = 9.6, 4.6 Hz, 
BnOCH (isomer A)], 3.89 [0.5 H, m, 4-H (isomer A)], 4.00 [0.5 H, ddd, J=  8.1, 7.2, 4.2 
Hz, 5-H (isomer B)], 4.13 [0.5 H, dt, J = 8.1,10.4 Hz, 4-H (isomer B)], 4.39 [0.5 H, ddd, 
J= 10.1, 8.3, 2.3 Hz, 5-H (isomerA)], 4.51 (1 H, s, PhCH2), 4.52 (0.5 H, d, J=  12.0 Hz, 
PhCH), 4.55 (0.5 H, d, J = 12.0 Hz, PhCH), 7.23-7.84 (9 H, Ph-H5 + Ar-H4); 13C NMR 
(100 MHz, CDCIa) (HMQC) 8 26.8 (CH3), 26.91 (CH3), 26.94 (CH3), 27.1 (CH3), 60.0 
[SCH2 (isomer B)], 62.3 [SCH2 (isomer A)], 69.5 (CH2), 70.0 (CH2), 73.2 [5-CH (isomer 
A)J, 73.59 [5-CH (isomer B)], 73.66 (PhCH2), 73.70 (PhCH2), 78.5 [4-CH (isomer B)],
78.9 [4-CH (isomer A)], 110.1 [C(CH3)2], 110.3 [C(CH3)2], 122.4 (CH), 122.9 (CH),
123.4 (Cq), 123.6 (Cq), 127.6 (CH), 127.78 (CH), 127.81 (CH), 128.42 (CH), 128.45 
(CH), 128.46 (CH), 130.6 (CH), 130.8 (CH), 132.0 (CH), 132.1 (CH), 134.20 (CH), 





To a suspension of compounds 89a/b (1.62 g, 3.69 mmol), trifluoroacetamide (834 mg, 
7.38 mmol), MgO (595 mg, 14.8 mmol) and Rh2(OAc)4 (41.0 mg, 2.5 mol %) in DCM 
(50 mL) was added Phl(OAc)2 (1.78 g, 5.54 mmol) and the mixture was stirred for 6 
days. The suspension was filtered (Celite®); evaporation and chromatography [pet. 
ether (40-60°C)/Et20, 1:1] afforded 90a/b (1.69 g, 83%) as a 1:1 mixture of 
diastereoisomers as a pale yellow oil: TLC Rf = 0.2 [pet. ether (40-60°C) / Et20 , 1:1]; IR 
vmax (film) 733, 908,1176 (CF3), 1216 (CF3), 1383 [CfCHsU, 1746 (C=0) cm'1; 1H NMR 
(400 MHz, CDCI3) 5 1.15 (1.5 H, s, CH3), 1.21 (1.5 H, s, CH3), 1.26 (1.5 H, s, CH3), 
1.28 (1.5 H, s, CH3), 3.43-3.54 (1 H, m, BnOCH), 3.66 (0.5 H, dd, J = 8.2, 4.8 Hz, 
BnOCH), 3.68 (0.5 H, dd, J = 8.2, 4.8 Hz, BnOCH), 3.70-3.75 (0.5 H, m, SCH), 3.76 
(0.5 H, dd, J = 14.6, 9.8 Hz, SCH), 3.83-3.91 (1 H, m, 4-H), 4.05 (0.5 H, dd, J = 10.0,
2.2 Hz, SCH), 4.09 (0.5 H, dd, J = 9.9 Hz, 2.3 Hz, SCH), 4.14-4.22 (1 H, m, 5-H), 4.51 
(2 H, s, PhCH2), 7.27-7.40 (5 H, m, Ph-H5), 7.43 (1 H, dt, J = 1.9, 8.0 Hz, Ar 5-H), 
7.72-7.85 (2 H, m, Ar4,6-H2), 8.08 (0.5 H, t, J= 1.6 Hz, Ar 2-H), 8.11 (0.5 H, t, J= 1.9 
Hz, Ar 2-H); 13C NMR (100 MHz, CDCfe) (HMQC) 5 26.4 (CH3), 26.5 (CH3), 26.6 (CH3),
58.6 (SCH2), 59.4 (SCH2), 69.5 (BnOCH2), 69.6 (BnOCH2), 72.9 (5-CH), 73.4 (5-CH),
73.8 (PhCH2), 77.97 (4-CH), 78.02 (4-CH), 110.8 [C(CH3)2], 110.9 [CfCH^J, 123.3 
(Cq), 126.7 (CH), 126.8 (CH), 127.8 (CH), 128.0 (CH), 128.1 (CH), 128.5 (CH), 128.6 
(CH), 130.83 (Ar 5-CH), 130.85 (Ar 5-CH), 131.3 (Ar 2-CH), 131.4 (Ar 2-CH), 137.2 
(Cq), 137.3 (Cq), 137.4(Cq), 137.5 (Cq), 137.7 (CH), 137.8 (CH); 19F NMR (376 MHz, 






4S,5R,S(R)- and 4S,5fl,S(S)-4-(Benzyloxymethyl)-2,2-dimethyl-5-(3-bromophenyl- 
sulfonimidoylmethyl)-1,3-dioxolane (91)
S  (R)/(S)
Compounds 90a/b (2.00 g, 3.63 mmol) were stirred with NH3 (35% in water, 5 mL) in 
MeOH (20 mL) overnight. Evaporation and chromatography (EtOAc / hexane, 7:3) 
yielded S-(R)-91 (472 mg, 29%) as a pale yellow oil: TLC Rf = 0.6 (EtOAc / hexane, 
7:3); 1H NMR (400 MHz, CDCI3) 8 1.22 (3 H, s, CH3), 1.32 (3 H, s, CH3), 3.34 (1 H, dd, 
J = 14.5, 9.0 Hz, SCH), 3.46 (1 H, dd, J = 14.5, 2.7 Hz, SCH), 3.52 (1 H, dd, J = 9.8,
6.3 Hz, BnOCH), 3.69 (1 H, dd, J = 9.8, 5.1 Hz, BnOCH), 3.86 (1 H, ddd, J = 7.8, 6.3,
4.7 Hz, 4-H), 4.31 (1 H, ddd, J = 8.6, 7.8,2.7 Hz, 5-H), 4.53 (2 H, s, PhCH2), 7.29-7.37 
(5 H, m, Ph-Hs), 7.38 (1 H, t, J = 7.8 Hz, Ar 5-H), 7.75 (1 H, ddd, J = 7.8,2.0, 0.8 Hz, Ar
4-H or Ar 6-H), 7.82 (1 H, ddd, 7.8, 2.0, 0.8 Hz, Ar 6-H or Ar 4-H), 8.08 (1 H, t, J = 1.9 
Hz, Ar 2-H); ,3C NMR (100 MHz, CDCI3) (HMQC) 5 26.7 (CH3), 26.8 (CH3), 59.7 
(SCHa), 69.9 (BnOCH2), 73.6 (5-CH), 73.7 (PhCH2), 78.4 (4-CH), 110.3 [CfO-WJ,
122.8 (Cq), 126.9 (Ar 6-CH or Ar 4-CH), 127.7 (2 x CH), 127.9 (CH), 128.5 (2 x CH),
130.4 (Ph 5-CH), 131.6 (Ar 2-CH), 136.7 (Ar 4-CH or Ar 6-CH), 137.5 (Cq), 141.6 (Cq); 
HRMS (ES+) m/z 456.0642 (91Br-M + H), 455.0585 (81Br-M), 454.0669 (79Br-M + H) 
(^MHas^BrNOqS requires 454.0682), 453.0604 (™Br-M); [otpo = +3.2° (c 1.5, CHCI3).
Further elution gave S-(S)-91 (530 mg, 32%) as a white solid; TLC Rf = 0.5 (EtOAc / 
hexane, 7:3); mp 75-77°C; 1H NMR (400 MHz, CDCI3) 6 1.20 (3 H, s, CH3), 1.31 (3 H, 
s, CH3), 2.32 (1 H, br s, NH), 3.38 (1 H, dd, J = 14.3, 8.7 Hz, SCH), 3.52 (1 H, dd, J = 
9.5, 6.3 Hz, BnOCH), 3.54 (1 H, dd, J=  14.3, 3.0 Hz, SCH), 3.66 (1 H, dd, J=  9.5, 5.1 
Hz, BnOCH), 3.89 (1 H, ddd, J = 8.0,6.3, 5.1 Hz, 4-H), 4.33 (1 H, ddd, J = 8.5, 8.0,2.9 
Hz, 5-H), 4.53 (2 H, s, PhCH2), 7.27-7.39 (5 H, m, Ph-H5), 7.36 (1 H, t, J = 8.0 Hz, Ar
5-H), 7.70 (1 H, ddd, J=  8.0,2.1,1.0 Hz, Ar4-H or Ar 6-H), 7.90 (1 H, ddd, J=  8.0, 2.1,
1.0 Hz, Ar 6-H or Ar 4-H), 8.14 (1 H, t, J = 1.9 Hz, Ar 2-H); 13C NMR (100 MHz, CDCI3) 
(HMQC) 5 26.7 (CH3), 26.8 (CH3), 61.0 (SCH2), 69.9 (BnOCH2), 73.7 (PhCH2 + 5-CH),
78.4 (4-CH), 110.3 [C(CH3)2], 122.7 (Cq), 127.2 (Ar 6-CH or Ar 4-CH), 127.7 (2 x CH),
127.9 (CH), 128.5 (2 x CH), 130.3 (Ar 5-CH), 131.8 (Ar 2-CH), 136.0 (Ar 4-CH or Ar
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6-CH), 137.5 (C,), 144.3 (Cq); Anal. Calcd. for Czoh^BrNOqS: C, 52.87; H, 5.32; N, 
3.08. Found: C, 52.82; H, 5.22; N, 3.06; [cc]20D = +2.6° (c 1.5, CHCI3).
2S,3R,S(R)-1-(Benzyloxy)-4-(3-bromophenylsulfonimidoyl)butane-2,3-diol (92)
Compound S-(R)-91 (200 mg, 0.44 mmol) was treated with aq. HCI (9 M, 1 mL) in 
MeOH (5 mL) for 4 h. Evaporation and chromatography (EtOAc / MeOH, 7:3) afforded 
92 (180 mg, 100%) as a pale yellow solid: TLC Rf = 0.8 (EtOAc / MeOH, 7:3); mp 73- 
76°C; IR v™ (KBr) 3425 (OH) cm"1; 1H NMR (400 MHz, CDCI3) 8 3.00 (2 H, br, 2 x 
OH), 3.13 (1 H, d, J = 14 Hz, SCH), 3.45 (1 H, dd, J = 13.9, 10.1 Hz, SCH), 3.59-3.64 
(2 H, m, BnOCH2), 3.70 (1 H, m, 2-H), 4.52 (1 H, d, J= 11.7 Hz, PhCH), 4.54 (1 H, d, J 
= 11.7 Hz, PhCH), 4.55 (1 H, br d, J = 10 Hz, 3-H), 7.27-7.36 (5 H, m, Ph-H5), 7.43 (1 
H, t, J = 7.9 Hz, Ar 5-H), 7.75 (1 H, ddd, J = 8.0, 1.9, 0.8 Hz, Ar 4-H or Ar 6-H), 7.91 (1 
H, ddd, J = 8.0, 1.9, 0.8 Hz, Ar 6-H or Ar 4-H), 8.12 (1 H, t, J = 1.8 Hz, Ar 2-H); 13C 
NMR (100 MHz, CDCI3) 8 59.9 (SCH2), 66.5 (3-CH), 71.0 (BnOCH2), 72.3 (2-CH), 73.6 
(PhCH2), 123.4 (Cq), 126.7 (Ar 6-CH or Ar 4-CH), 127.9 (2 x CH), 128.0 (CH), 128.6 (2 
xCH), 130.9 (Ar 5-CH), 131.1 (Ar2-CH), 136.7 (Ar4-CH or Ar 6-CH), 137.6 (Cq), 141.0 
(Cq); Anal. Calcd. for C17H2oBrN04S: C, 49.28; H, 4.87; N, 3.38. Found: C, 49.48; H, 
4.61; N, 2.95; [<x]20D = +2.5° (c 1.7, CHCI3).
2S,3R,S-1-(Benzyloxymethyl)-4-[N-(trifluoroacetyl)-3-bromophenylsulfonimidoyl]- 
butane-2,3-diol (108)
Configuration at sulfur not known since 
crystalline product (thus X-ray crystal data) 
could not be obtained
Compounds 90a/b (1.50 g, 2.73 mmol) were treated with aq. HCI (9 M, 4 mL) in MeOH 
(15 mL) for 4 h. Evaporation and chromatography (CHCI31 MeOH, 10:1) afforded 108
f3c o c n
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(620 mg, 45%) as a single diastereoisomer (unknown configuration at sulfur) as a pale 
yellow solid: TLC Rf = 0.5 (CHCI3 / MeOH, 10:1); mp 84-85°C; IR vmax(KBr) 736, 1293 
(CF3), 1314 (CF3), 1407, 1454, 2867, 2924, 3436 (OH) cm'1; 1H NMR (400 MHz, 
CDCI3) 5 3.11 (2 H, br s, OH), 3.33 (1 H, dd, J = 14.4, 3.1 Hz, SCH), 3.44 (1 H, dd, J =
14.6, 8.9 Hz, SCH), 3.58 (2 H, d, J = 5.1 Hz, BnOCH2), 3.73 (1 H, dt, J = 2.9, 5.1 Hz, 2- 
H), 4.31 (1 H, dt, J = 8.9, 2.9 Hz, 3-H), 4.49-4.53 (2 H, m, PhCH2), 7.23-7.37 (5 H, m, 
Ph-H5), 7.44 (1 H, t, J = 7.9 Hz, Ar 5-H), 7.77 (1 H, ddd, J = 7.9, 1.9, 1.0 Hz, Ar 4-H or 
Ar 6-H), 7.84 (1 H, ddd, J = 7.9, 1.9,1.0 Hz, Ar 6-H or Ar 4-H), 8.07 (1 H, t, J = 1.9 Hz, 
Ar 2-H); 13C NMR (100 MHz, CDCI3) (HMQC) 5 59.6 (SCH2), 67.1 (3-CH), 71.3 (2-CH),
71.5 (BnOCH2), 73.7 (PhCH2), 123.2 (Cq), 126.6 (Ar 6-CH or Ar4-CH), 127.8 (2 x CH),
128.0 (CH), 128.5 (2 x CH), 130.8 (Ar 5-CH), 130.9 (Ar 2-CH), 137.0 (Ar 4-CH or Ar
6-CH), 137.2 (Cq), 141.4 (Cq); 19F NMR (376 MHz, CDCI3) 5 -76.0 (3 F, s, CF3); [af°D = 
+3.1° (c 2.1, CHCI3).
4-Methoxybenzaldehyde dimethyl acetal (110)
Me<X JDMe
OMe
A mixture of 4-methoxybenzaldehyde (109, 5.61 g, 41 mmol) and 4-toluenesulfonic 
acid monohydrate (39 mg, 21 mmol) in trimethyl orthoformate (50 mL) was heated at 
78°C for 4 h. The evaporation residue, in DCM, was washed with aq. NaHC03 (1 M) 
and dried. Evaporation gave 110 (6.81 g, 91%) as a colourless liquid: TLC Rf = 0.6 
(hexane / EtOAc, 10:1); IR v™* (film) 823, 2832 (OCH3), 2938 cm'1; 1H NMR (400 MHz, 
CDCIa) 8 3.30 [6 H, s, C(OCH3)2), 3.79 (3 H, S, OCH3), 5.34 [1 H, s, CfcKOCHaH 6.88 
(2 H, d, J = 8.9 Hz, Ph 3,5-H2), 7.34 (2 H, dd, J = 8.9, 0.6 Hz, Ph 2,6-H2); 13C NMR (100 
MHz, CDCI3) (HMQC) 8 52.5 (2 x CH3), 55.2 (CH3), 103.0 (CH), 113.4 (Ph 3.5-C2),
127.8 (Ph 2,6-C2), 130.3 (Ph 1-C„), 159.6 (Ph 4-Cq).
171
Experimental
[4S,5R-5-(Benzyloxymethyl)-2,2-dimethyl-1,3-d ioxolan-4-yl]metliyl tosylate (123)
Ph— \
— OT s
To a solution of 98 (500 mg, 1.98 mmol), DMAP (24.0 mg, 0.26 mmol) and 
triethylamine (401 mg, 3.96 mmol) in dry DCM (3 mL) was added toluene-4-sulfonyl 
chloride (566 mg, 2.97 mmol) at 0°C under N2 and the reaction mixture was sonicated 
for 15 minutes and then stirred overnight. The evaporation residue, in EtOAc, was 
washed with water, brine and 5% aq. citric acid. Drying and evaporation afforded 123 
(730 mg, 91%) as a pale yellow oil: TLC Rf = 0.5 [pet. ether (40-60°C) / Et20, 1:1]; IR 
Vmax (film) 738, 1266, 1365 (S03), 1711, 2988, 3055 cm'1; 1H NMR (400 MHz, CDCI3) 5
1.32 (3 H, s, CH3), 1.36 (3 H, s, CH3), 2.42 (3 H, s, ArCH3), 3.52 (1 H, dd, J= 10.2, 4.7 
Hz, BnOCH), 3.60 (1 H, dd, J = 10.2, 4.7 Hz, BnOCH), 3.97-4.09 (3 H, m, TsOCH +
4,5-H2), 4.19 (1 H, dd, J = 10.2, 3.1 Hz, TsOCH), 4.53 (2 H, s, PhCH2), 7.28-7.36 (7 H, 
m, Ph-H5 + Ar 3,5-H2), 7.75 (2 H, d, J = 8.2 Hz, Ar 2,6-H2); 13C NMR (100 MHz, CDCI3) 
(HMQC) 8 21.7 (ArCH3), 26.7 (CH3), 26.9 (CH3), 69.3 (TsOCH2), 70.0 (BnOCH2), 73.6 
(PhCH2), 76.7 (4-CH + 5-CH), 110.2 [C(CH3)2], 127.6 (2 x CH), 127.8 (CH), 128.0 (2 x 
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Methyl bromoacetate (125, 1.53 g, 10 mmol) was added to a vigorously stirred solution 
of potassium thioacetate (124, 1.14 g, 10 mmol) in MeOH (80 mL) under N2. The 
mixture was stirred overnight and the organic layer was extracted with DCM and 
washed with water. Evaporation afforded 126 (1.46 g, 100%) as a colourless liquid: 
TLC Rf = 0.5 (hexane / EtOAc, 10:1); IR (film) 1135, 1300, 1436, 1744 (0=0), 
2956, 3000 cm'1; 1H NMR (400 MHz, CDCI3) 8 2.37 (3 H, s, CH3CO), 3.69 (2 H, s, 
CH2), 3.72 (3 H, s, C02CH3); 13C NMR (100 MHz, CDCI3) 8 30.1 (CH3), 31.2 (CH2), 






Methyl propynoate (129, 8.18 g, 84 mmol) was added to benzyl alcohol (128, 11.2 g, 
84 mmol) in DCM (20 mL), followed by Bu3P (2.1 g, 8.4 mmol) and the mixture was 
stirred overnight. Propan-2-ol (120 mL), water (120 mL) and aq. KOH (20%, 72 mL) 
were added and the mixture was stirred overnight. The solution was diluted with water 
(50 mL) and extracted with Et20  (x 2). The aq. phase was acidified with aq. HCI (9 M) 
and extracted with Et20. The organic phase was washed (water) and dried. 
Evaporation and recrystallisation (EtOAc / hexane) afforded 131 (10.0 g, 67%) as pale 
yellow crystals: TLC Rf = 0.4 (EtOAc / hexane, 2:3); mp 116-117°C (lit.200 mp 
117-118°C); IR Vmax (KBr) 1609, 1668, 2500-3200 cm'1; 1H NMR (400 MHz, CDCI3) 5 
4.91 (2 H, s, PhCH2), 5.29 (1 H, d, J = 12.8 Hz, CHC02H), 7.32-7.41 (5 H, m, Ph-H5), 
7.75 (1 H, d, J = 12.8 Hz, BnOCH); 13C NMR (100 MHz, CDCI3) 5 73.2 (CH2), 96.8 
(CH), 127.8 (CH), 128.7 (2 x CH), 128.8 (2 x CH), 135.0 (Cq), 164.1 (CH), 173.7 (C=0); 
HRMS (FAB+) m/z 179.0706 (M + H) (12Ci0HhO3 requires 179.0708), 91.0 (Bn).
Pentafluorophenyl (£)-3-benzyloxypropenoate (134)
Pentafluorophenol (1.03 g, 5.62 mmol) was added to 131 (1.05 g, 5.62 mmol) in EtOAc 
at 0°C during 15 min. DCC (1.16 g, 5.62 mmol) was then added and the mixture was 
stirred at 0°C overnight. The suspension was filtered (Celite®) and the solid was 
washed with cold EtOAc. The combined organic phases were kept at 4°C for 48 h and 
filtered. Evaporation afforded 134 (1.20 g, 62%) as white crystals which were used in 
the next step without further purification: TLC Rf = 0.9 (EtOAc I hexane, 2:3); mp 
98-100°C; IR Vmax (KBr) 1750 cm-1; 1H NMR (400 MHz, CDCI3) 8 5.02 (2 H, s, PhCH2), 
5.55 (1 H, d, J=  12.5 Hz, CHC02), 7.38-7.41 (5 H, m, Ph-H5), 7.92 (1 H, d, J= 12.5 Hz, 




CH), 129.0 (2 x CH), 134.5 (C„), 163.3 (O O ), 165.7 (CH); 19F NMR (376 MHz, CDCI3) 
S -162.8 (2 F, m, 3\5’-F2), -158.7 (1 F, t, J = 21.7 Hz, 4-F), -152.8 (2 F, m, 2’,6’-F2); 
HRMS (FAB+) m/z 345.0573 (M + H) (’^ H k A F s  requires 345.0550), 161.1 (M -  
OC6F5), 91 (Bn).
(1 R,2S,5f?)-NIenthyl (E)-3-benzyloxypropenoate (136)
10
DCC (1.16 mg, 5.62 mmol) was added to 131 (1.00 g, 5.62 mmol) and L-menthol (135, 
0.88 g, 5.62 mmol) in dry DCM. The mixture was stirred at 0°C for 10 min and DMAP 
(0.69 g, 5.62 mmol) was added. The mixture was stirred at 0°C for 2 h and at RT for 16 
h. The suspension was filtered (Celite®) and the filtrate was washed with water and aq. 
CuS04 and kept at 4°C for 48 h. Filtration, drying, evaporation and chromatography 
(EtOAc / hexane, 1:4) gave 136 (0.48 g, 27%) as a colourless oil: TLC Rf = 0.7 (EtOAc 
/ hexane, 1:4); IR v,™ (film) 1705 cm'1; 1H NMR (400 MHz, CDCI3) 6 0.77 (3 H, d, J =
6.6 Hz, menthol C10-H3), 0.90 (6 H, dd, J = 6.6, 2.7 Hz, menthol C8’9-H6), 0.98-2.04 (10 
H, m, menthol-H10), 4.77 (1 H, dt, J = 4.3, 17.2 Hz, menthol C1-H), 4.88 (2 H, s, 
PhCH2), 5.30 (1 H, d, J = 12.7 Hz, CHC02), 7.32-7.39 (5 H, m, Ph-H5), 7.66 (1 H, d, J =
12.7 Hz, BnOCH); 13C NMR (100 MHz, CDCI3) 8 16.0 (CH3), 20.8 (CH3), 22.1 (CH3),
23.6 (CH2), 26.4 (CH), 31.4 (CH), 34.3 (CHz), 41.1 (CH2), 47.2 (CH), 72.7 (CHz), 73.5 
(CH), 97.7 (CH), 127.8 (CH), 128.6 (2 x CH), 128.7 (2 x CH), 135.3 (Cq), 161.8 (CH),
167.3 (C=0); HRMS (FAB+) m/z 317.2137 (M + H) (^CzoH^Oa requires 317.2117), 
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Chloromethyltrimethylsilane (138, 2.0 g, 16 mmol), thiourea (2.4 g, 32 mmol) and Nal 
(5 mg) were boiled under reflux in dry EtOH (20 mL) for 48 h. Evaporation and 
trituration (Et20) gave 139 (3.20 g, 100%) as a white solid which was used in the next 
step without further purification: mp 140-142°C (lit.220 mp 141.5-143°C); 1H NMR [270 
MHz, (CD3)2SO] 8 0.15 [9 H, s, (CH3)3Si], 2.42 (2 H, s, CH2), 7.11 (2 H, br s, NH2), 9.11 
(2 H, br s, NH2).
S-[(Dimethylphenylsilyl)methyl]isothiouronium chloride (142)
Si 'S ' NH2/  \  ^
Chloromethyldimethylphenylsilane (141, 3.72 g, 20 mmol), thiourea (1.52 g, 20 mmol), 
and Nal (5 mg) were boiled under reflux in dry EtOH (30 mL) for 5 d. Evaporation and 
trituration (Et20) afforded 142 (4.86 g, 93%) as a white solid which was used in the 
next step without further purification: mp 113-115°C; 1H NMR (400 MHz, CDCI3) 8 0.45 
[6 H, s, (CH3)2Si], 2.12 (1 H, br s, NH), 2.67 (2 H, s, CH2), 7.35-7.42 (3 H, m, Ph
3,4,5-H3), 7.50-7.55 (2 H, m, Ph 2,6-H2), 7.91 (1 H, br s, NH), 9.16 (1 H, br s, NH); 13C 
NMR (100 MHz, CDCI3) 8 16.1 (CH2), 128.1 (2 x CH), 130.2 (CH), 133.7 (2 x CH),
134.9 (Cq), 174.1 (CJ; MS (FAB+) mh. 227 (M), 225 (M), 147 [M -  HSC(NH2)=NH2].
Dimethylphenylsily Imethanethiol (143)
Compound 142 (4.86 g, 20 mmol) was stirred with aq. NaOH (40%, 100 mL, 1 mol) 
under N2 overnight. The aqueous layer was washed with Et20  and acidified with aq.
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HCI (9 M). This was then extracted with Et20  (x 3) and washed with brine. Drying and 
evaporation yielded 143 (3.45 g, 87%) as a pale yellow liquid: 1H NMR (270 MHz, 
CDCI3) 8 0.37 [6 H, s, (CH3)2Si], 1.08 (1 H, t, J = 7.2 Hz, SH), 1.84 (2 H, d, J = 7.2 Hz, 
CH2), 7.35-7.37 (3 H, m, Ph 3,4,5-H3), 7.50-7.57 (2 H, m, Ph 2,6-H2). No further data 
could be obtained due to fast oxidation.
Chloromethyl (dimethylphenylsilylmetnyi) sulfide (144)
Si^ S ' 'Cl
HCI was bubbled through 1,3,5-trioxane (1.02 g, 11 mmol) and 143 (3.45 g, 19 mmol) 
at -10°C until saturated. After 12 h at 0°C, the mixture was dried over anhydrous CaCI2 
at 0°C for 2 h to give crude 144 (1.29 g, 29%) as a pale yellow oil: 1H NMR (270 MHz, 
CDCI3) 8 0.40 [6 H, s, (CH3)2Si], 2.25 (2 H, s, CH2Si), 4.67 (2 H, s, CH2CI), 7.36-7.43 (3 
H, m, Ph 3,4,5-H3), 7.55-7.59 (2 H, m, Ph 2,6-H2). No further data could be obtained 
owing to decomposition.
But-3-enyl tosylate (147)
LiN(SiMe3)2 (1.0 M in THF, 6.93 mL, 6.93 mmol) was added to but-3-en-1-ol (146, 500 
mg, 6.93 mmol) in dry THF (5 mL) at -78°C under Ar during 30 min. Toluene-4-sulfonyl 
chloride (1.32 g, 6.93 mmol) was added and the mixture was allowed to reach RT 
during 16 h. The evaporation residue, in EtOAc, was washed with aq. HCI (1 M), aq. 
NaHC03 (1 M), water and brine and was dried. Evaporation gave 147 (1.56 g, 100%) 
as a pale buff oil: TLC Rf = 0.4 (EtOAc / hexane, 2:3); IR Vmax (film) 821, 907, 1184, 
1420,1600 cm'1; 1H NMR (400 MHz, CDCI3) 8 2.31-2.38 (2 H, m, CH2CH=CH2), 2.41 (3 
H, s, CH3), 4.02 (2 H, t, J = 6.7 Hz, TsOCH2), 5.01-5.06 (2 H, m, C=CH2), 5.64 (1 H, m, 
CH=CH2), 7.31 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 7.75 (2 H, d, J = 8.6 Hz, Ph 2,6-H2); 13C 
NMR (100 MHz, CDCI3) 8 21.5 (CH3), 33.0 (CH2), 69.3 (CH2), 118.1 (CH2), 127.7 (2 x 
CH), 129.7 (2 x CH), 132.3 (CH), 132.8 (Cq), 144.7 (Cq); MS (FAB+) m/z 227 (M + H), 





Benzyl chloride (148, 1.27 g, 10 mmol) was added to a vigorously stirred solution of 
potassium thioacetate (124, 1.14 g, 10 mmol) in MeOH (80 mL) under N2. The mixture 
was stirred at RT overnight and the organic layer was extracted with DCM and washed 
with water. Evaporation afforded 149 (1.70 g, 100%) as a colourless liquid: TLC Rf = 
0.7 (EtOAc / hexane, 1:4); IR Vmsa (film) 1691 (C=0) cm'1; 1H NMR (400 MHz, CDCI3) 8
2.32 (3 H, s, CH3), 4.12 (2 H, s, CH2), 7.24-7.40 (5 H, m, Ph-Hs); 13C NMR (100 MHz, 
CDCI3) 8 30.0 (CH2), 33.1 (CH3), 127.0 (CH), 128.4 (2 x CH), 128.6 (2 x CH), 137.4 
(C,), 194.7 (C-O).
4-(Benzylthio)but-1-ene (150)
To 147 (500 mg, 2.20 mmol) in MeOH (10 mL) at 0°C was added slowly NaOH (0.5 M 
in water, 4.40 mL, 2.20 mmol)) and 149 (366 mg, 2.20 mmol) under N2 and the mixture 
was stirred at RT for 4 h. Evaporation and chromatography (EtOAc / hexane, 1:10) 
gave 150 (340 mg, 87%) as a colourless oil: TLC Rf = 0.8 (EtOAc / hexane, 1:4); IR 
Vmax (film) 825, 970, 1467 cm'1; 1H NMR (270 MHz, CDCI3) 5  2.25-2.34 (2 H, m, 
CH2CH=CH2), 2.47 (2 H, t, J = 7.3 Hz, BnSCH2), 3.72 (2 H, s, PhCH2), 4.99-5.07 (2 H, 
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Methyl propenoate (152, 2.25 g, 26 mmol) was added during 30 min to methyl 
mercaptoacetate (116, 2.65 g, 25 mmol) and piperidine (0.025 mL) at 40°C. Piperidine 
(0.05 mL) was then added dropwise over 10 min. The mixture was warmed to 50°C for 
5 min and cooled and Et20  was added. The organic layer was washed with water and 
brine and dried. Evaporation yielded 153 (5.00 g, 100%) as a colourless oil: TLC Rf = 
0.4 (EtOAc / hexane, 1:4); IR vmax (film) 1741 (C=0) cm'1; 1H NMR (400 MHz, CDCI3) 5 
2.63 (2 H, t, J = 7.3 Hz, Me02CH2CH2), 2.87 (2 H, t, J = 7.3 Hz, CHzCHaS), 3.23 (2 H, 
s, SCH2CO), 3.69 (3 H, s, CH3), 3.74 (3 H, s, CH3); 13C NMR (100 MHz, CDCI3) 8 27.4 
(CH2), 33.3 (CH2), 33.9 (CH2), 51.7 (CH3), 52.3 (CH3), 170.6 (C-O), 171.9 (C=0); MS 
(FAB+) m/z 193 (M + H), 192 (M), 165 (M -  OMe), 133 (M -  C02Me).
(±)-3-Oxotetrahydrothiophene-4-carbonitrile (157)
Na (1.32 g, 57 mmol) was stirred with dry MeOH (20 mL) at 0°C for 45 min. Methyl 
mercaptoacetate (116, 2.16 g, 20 mmol) was added dropwise. Acrylonitrile (156, 4.30 
g, 81 mmol) was then added and the mixture was boiled under reflux for 1 h. The 
evaporation residue, in Et20, was washed with water (x 2). The aqueous layers were 
acidified with aq. HCI (10%) and extracted with Et20  (x 4). The organic layers were 
dried. Evaporation and chromatography (EtOAc / hexane, 2:3) gave 157 (1.28 g, 50%) 
as a yellow solid: TLC Rf = 0.3 (EtOAc / hexane, 2:3); mp 71-73°C (lit.213 mp 71-72°C); 
IR (KBr) 1742 (0=0), 2245 (CN), 2360 cm'1; 1H NMR (400 MHz, CDCI3) 8 3.25 (1 
H, m, 4-H), 3.34 (1 H, dd, J = 11.9, 7.9 Hz, 5-H), 3.40 (2 H, s, 2-H2), 3.65 (1 H, dd, J = 
10.9, 7.9 Hz, 5-H); 13C NMR (100 MHz, CDCI3) 8 29.4 (CH2), 36.3 (CH2), 41.1 (CH),




NaBH4(380 mg, 10 mmol) was added to 157 (1.27 g, 10 mmol) in EtOH (10 mL) at 0°C 
and the mixture was stirred at RT for 1 h. It was then cooled to 0°C and acidified with 
AcOH to pH 6. The evaporation residue, in EtOAc, was washed with water and brine 
and was dried. Evaporation and chromatography (EtOAc / hexane, 2:3) yielded 158 
(780 mg, 60%) as a pale yellow oil: TLC Rf = 0.4 (EtOAc / hexane, 1:4); IR vmax (film) 
2246 (C=N), 3435 (OH) cm'1; 1H NMR (600 MHz, CDCI3) 6 2.88 (1 H, dd, J = 11.7, 4.7 
Hz, 2-H), 2.95 (1 H, br d, J = 5.9 Hz, OH), 3.09 (1 H, m, 5-H), 3.17-3.20 (2 H, m,
4,5-H2), 3.23 (1 H, dd, J = 11.7, 4.7 Hz, 2-H), 4.71 (1 H, qn, J = 4.7 Hz, 3-H); 13C NMR 
(100 MHz, CDCIs) (HMQC) 8 30.5 (5-CH2), 37.1 (2-CH2), 39.9 (4-CH), 76.7 (3-CH),
118.9 (C=N); MS (FAB+) m/z 130 (M + H), 112 (M -  OH); HRMS (EI+) m/z 129.0254 
(M) (12C5H7NOS requires 129.0248).
(±)-4-BenzyKhio-3-hydroxy-2-methylenebutanenitrile (161)
Method A: To 158 (200 mg, 1.56 mmol) in dry THF (5 mL) was added LiN(SiMe3)2
(1.0 M in THF, 1.87 mL, 1.87 mmol) at -78°C under Ar and the mixture was stirred for 
30 min. Benzyl bromide (320 mg, 1.87 mmol) was added and the mixture was allowed 
to reach RT during 16 h. The evaporation residue, in EtOAc, was washed with water 
and dried. Evaporation and chromatography (EtOAc / hexane, 2:3) afforded 161 (120 
mg, 35%) as a pale yellow oil: TLC Rf = 0.2 (EtOAc / hexane, 2:3); IR vmax (film) 908, 
2253 (CN), 3435 (OH) cm"1; 1H NMR (400 MHz, CDCI3) 8 2.63 (1 H, dd, J = 14.3, 8.4 
Hz, 4-H), 2.84 (1 H, dd, J = 14.3, 8.4 Hz, 4-H), 2.85 (1 H, d, J = 4.0 Hz, OH), 3.77 (2 H, 
s, PhCH2), 4.15 (1 H, m, 3-H), 6.02 (2 H, dd, J= 12.6, 1.3 Hz, 1-H2), 7.37-7.26 (5 H, m, 
Ph-Hg); 13C NMR (100 MHz, CDCI3) (HMQC) 8 36.4 (PhCH2), 37.6 (4-CH2), 69.6 
(3-CH), 116.6 (C=N), 124.4 (2-Cq), 127.5 (CH), 128.8 (2 x CH), 128.9 (2 x CH), 130.9
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(l-CHz), 137.4 (Ph 1-Cq); HRMS (FAB+) m/z 220.0791 (M + H) (,2Ci2H13NOS requires 
220.0791), 202 (M -  OH), 91 (Bn).
Method B: To 158 (40 mg, 0,31 mmol) in dry THF (1 mL) was added K2C03 (26 mg,
0.37 mmol) at -78°C under Ar and the mixture was stirred for 30 min. Benzyl bromide 
(75 mg, 0.37 mmol) was added and the mixture was allowed to reach 20°C during 16 h. 
The evaporation residue, in EtOAc, was washed with water and dried. Evaporation and 
chromatography (EtOAc I hexane, 2:3) afforded 161 (30 mg, 44%) as a pale yellow oil. 
The data were identical to those above.
(±)-Trans-3-Hydroxytetrahydrothiophene-4-carboxamide (164)
Compound 158 (340 mg, 2.63 mmol) was stirred in aq. HCI (9 M, 5.26 mL) at 50°C for 
2 h. Evaporation (with addition of toluene and EtOH to aid evaporation of water) and 
trituration (Et20) yielded 164 (350 mg, 91%) as a white solid: TLC Rf = 0.3 (CHCI3/ 
MeOH, 9:1); mp 120-123°C; IR vmax (KBr) 1635 (0=0), 3446 (OH) cm’1; 1H NMR [400
13C NMR [100 MHz, (CD3)2SO] (HMQC) 5 29.9 (5-CH2), 36.4 (2-CH2), 54.0 (4-CH),
76.3 (3-CH), 173.4 (OO); HRMS (EI+) m/z 148.0427 (M + H) (12C5H9N02S requires 
148.0427), 147 (M), 129 (M -  OH -  H), 85 (M + H -  OH -  CONH2).
o
MHz, (CD3)2SO] 5 2.60 (1 H, dd, J = 10.6, 7.3 Hz, 2-H), 2.71 (1 H, dd, J = 15.9, 7.9 Hz,
4-H), 2.81-2.89 (2 H, m, 5-H2), 2.91 (1 H, dd, J = 10.2, 5.9 Hz, 2-H), 4.32 (1 H, ca. qn, J 
= 7 Hz, 3-H), 5.29 (1 H, d, J = 5.1 Hz, OH), 7.00 (1 H, br s, NH), 7.40 (1 H, br s, NH);
180
Experimental
(±)-7ra/is-2,2-Dimethylhexahydrothieno[3,4-e][1,3]oxazin~4-one (165) and (±)- 
7rans-3-hydroxy-N-(1 -methoxy-1 -methylethyl)tetrahydrothiophene-4- 
carboxamide (166)
Compound 164 (130 mg, 0.88 mmol) and 4-toluenesulfonic acid monohydrate (2.0 mg, 
0.01 mmol) were boiled under reflux with 2,2-dimethoxypropane (4 mL) and acetone (2 
mL) for 15 h. The evaporation residue, in EtOAc, was washed with water and aq. 
NaHC03and was dried. Evaporation and chromatography (EtOAc / hexane, 4:1) gave 
165 and 166 as an inseparable mixture (104 mg, 3:2 ratio) as a white solid: TLC Rf =
0.4 (EtOAc / hexane, 4:1); mp 112-113°C; IR (KBr) Vrrax 1668 (O O ), 3394, (NH) cm’1; 
165:1H NMR [400 MHz, (CDsJaSO] 5 1.37 (3 H, s, CH3), 1.40 (3 H, s, CH3), 2.69-2.77 
(2 H, m) and 2.86-3.00 (3 H, m) (4a,5,5,7,7-H5), 4.17 (1 H, dt, J = 6.2,10.5 Hz, 7a-H), 
8.10 (1 H, br s, NH); 166:1H NMR [400 MHz, (CD^zSO] 5 1.26 (3 H, s, CH3), 1.27 (3 H, 
s, CH3), 2.52-2.61 (2 H, m) and 2.69-2.92 (3 H, m) (2,2,4,5,5-Hs), 3.34 (3 H, s, OMe), 
4.30 (1 H, qn, J = 6.2 Hz, 3-H), 5.23 (1 H, d, J = 5.2 Hz, OH), 7.61 (1 H, br s, NH); 13C 
NMR [100 MHz, (CD3)2SO] (HMQC, HMBC) 6 25.3 (CH2), 27.0 (CH3), 27.1 (CH3), 27.2 
(CH3), 29.9 (Cq), 30.7 (CH2), 31.6 (CH3), 32.1 (CH2), 36.4 (CH2), 47.9 (CH), 50.7 (CH2),
51.4 (Cq), 54.3 (CH), 74.5 (CH), 76.2 (CH), 87.5 (Cq), 168.1 (Cq), 170.9 (Cq), 207.4 
(Cq); HRMS (EI+) (data for 165) m/z 188.0701 (M + H) (12C8H14N02S requires 




(±)-7~rans-N-Benzyl-3-benzyloxytetrahydrothiophene-4-carboxamide (169) and 
(±)-7ra/is-3-benzyloxytetrahydrothiophene-4-carboxamide (170)
NaH (60% in mineral oil, 13.6 mg, 0.34 mmol, pre-washed in dry pentane) was stirred 
in dry DMF (0.5 ml) under N2 for 30 min. Compound 164 (50 mg, 0.34 mmol) in dry 
DMF (0.4 mL) was added and the mixture was stirred for a further 30 min. Benzyl 
bromide (58.2 mg, 0.34 mmol) was added and the mixture was stirred overnight. 
Ice-water (10 mL) was added and the organic layer was extracted with Et20  (x 3) and 
dried. Evaporation and chromatography (EtOAc / hexane, 7:3) afforded 169 (20 mg, 
18%) as a white solid: TLC Rf = 0.8 (EtOAc / hexane, 7:3); mp 73-74°C; IR (KBr) 
734, 1524 (NH), 1665 (C=0), 3437 (NH) cm'1; 1H NMR (400 MHz, CDCI3) 8 2.81 (1 H, 
m, 2-H), 2.91-3.03 (2 H, m, 4,5-H2), 3.16 (2 H, m, 2,5-H2), 4.27 (1 H, dt, J = 6.3, 8.3 Hz, 
3-H), 4.35 (1 H, dd, J = 14.6, 5.4 Hz, NCH), 4.45 (1 H, d, J = 11.7 Hz, PhCH), 4.47 (1 
H, dd, J = 14.6, 6.3 Hz, NCH), 4.51 (1 H, d, J = 11.7 Hz, PhCH), 6.51 (1 H, br, NH), 
7.15-7.32 (10 H, m, 2 x  Ph-Hs); 13C NMR (100 MHz, CDCI3) (HMQC) 8 28.5 (5-CH2),
34.2 (2-CH2), 43.6 (NCH2), 53.1 (4-CH), 72.6 (PhCH2), 83.9 (3-CH), 127.5 (CH), 127.8 
(2 x CH), 128.0 (2 x CH), 128.1 (CH), 128.6 (2 x CH), 128.7 (2 x CH), 137.1 (Cq), 138.0 
(Cq), 170.8 (C=0); MS (FAB+) m/z 328 (M + H), 220 (M -  NHCH2Ph); Anal. Calcd. for 
Ci9H21N02S: C, 69.69; H, 6.46; N, 4.28. Found: C, 69.52; H, 6.41; N, 4.30.
Further elution afforded 170 (50 mg, 62%) as a white solid: TLC Rf = 0.4 (EtOAc / 
hexane, 7:3); mp 80-81°C; IR v^iKBr)  735, 1454, 1671, 2920, 3344 cm'1; 1H NMR 
(400 MHz, CDCI3) 8 2.85 (1 H, dd, J = 10.6, 7.7 Hz, 2-H), 2.96-3.03 (2 H, m, 4 ,5 ^ ,  
3.10-3.16 (2 H, m, 2,5-H2), 4.27 (1 H, dt, J = 9.2, 6.2 Hz, 3-H), 4.54 (1 H, d, J = 11.4 
Hz, PhCH), 4.63 (1H, d, J = 11.4 Hz, PhCH), 5.6 (1 H, br s, NH), 6.2 (1 H, br s, NH), 
7.28-7.37 (5 H, m, Ph-H5); 13C NMR (100 MHz, CDCI3) (HMQC) 8 28.5 (5-CH2), 34.3 
(2-CH2), 52.6 (4-CH), 72.5 (PhCH2), 83.7 (3-CH), 127.9 (2 x CH), 128.2 (CH), 128.6 (2 
x CH), 137.2 (Cq), 173.4 (C=0); MS (FAB+) m/z 238 (M + H); Anal. Calcd. for 









Compound 170 (100 mg, 0.42 mmol) was treated with mCPBA (73 mg, 0.42 mmol) in 
DCM (7 mL) at -40°C for 5 h. The mixture was diluted with DCM (10 mL) and washed 
with aq. NaOH (1 M) and water and dried. Evaporation and chromatography (CHCI3 / 
MeOH, 4:1) afforded 171 (94 mg, 88%) as a pale yellow solid: TLC Rf = 0.2 (CHCI3 / 
MeOH, 4:1); mp 78-80°C; 1H NMR (270 MHz, CDCI3) (data given for major 
diastereoisomer) 8 3.18 (1 H, dd, J = 14.1, 6.0 Hz, 2-H or 5-H), 3.26-3.46 (4 H, m,
2,4,5-H3 + 5-H or 2-H), 4.54 (1 H, d, J = 11.7 Hz, PhCH), 4.65 (1 H, d, J = 11.7 Hz, 
PhCH), 4.96 (1 H, dt, J = 4.0, 5.9 Hz, 3-H); HRMS (FAB+) m/z 254.0811 (M + H) 
(12C12H16N03S requires 254.0851), 253.0780 (M) (12C12H15N03S requires 253.0073), 
210 (M + H -  CONH2), 147 (M -  OBn).
(±)-7rans-N-[(3-Benzyloxytetrahydrothiophen-4-yl)methyl]benzamide (174)
To a solution of 170 (238 mg, 1 mmol) in dry THF (2 mL) was added LiAIH4 (2.0 M in 
THF, 10 mmol, 5 mL) under N2 and the mixture was boiled under reflux overnight. It 
was then cooled to 0°C and water (2 mL) was added dropwise. After stirring for 1 h, it 
was poured into hot MeOH (10 mL), filtered (Celite®) and evaporated. The evaporation 
residue was dissolved in boiling CHCI3 and dried. Evaporation gave the crude primary 
amine (173, 200 mg, 0.90 mmol), which was immediately treated with triethylamine 
(273 mg, 2.7 mmol) in dry DCM (5 mL) for 10 minutes. Benzoyl chloride (190 mg, 1.35 
mmol) was added and the mixture was stirred overnight. The evaporation residue, in 
DCM, was washed with 5% citric acid and aq. NaHC03 (1 M) and dried. Evaporation 
and chromatography (hexane / Et20, 5:1) gave 174 (130 mg, 40% overall yield) as a 




1536, 1640, 3401 cm'1; 1H NMR (400 MHz, CDCI3) 6 2.51 (1 H, m, 4-H), 2.63 (1 H, dd, 
J= 10.6, 9.0 Hz, 5-H), 2.89 (1 H, dd, J = 10.4, 7.5 Hz, 2-H), 2.98 (1 H, dd, J= 10.8, 7.3 
Hz, 5-H), 3.18 (1 H, dd, J = 10.4, 5.8 Hz, 2-H), 3.32 (1 H, ddd, J = 12.4, 8.7, 3.7 Hz, 
NCH), 3.81 (1 H, ddd, J=  11.7, 6.9, 4.8 Hz, NCH), 4.01 (1 H, dt, J=  5.8, 8.0 Hz, 3-H), 
4.49 (1 H, d, J=  11.1 Hz, PhCH), 4.67 (1 H, d, J=  10.9 Hz, PhCH), 6.92 (1 H, br, NH), 
7.25-7.30 (2 H, m, Ph’ 3,5-H2), 7.31-7.53 (5 H, m, Ph-H5), 7.41-7.45 (1 H, m, Ph’ 4-H), 
7.50-7.53 (2 H, m, Ph’ 2,6-H2); 13C NMR (100 MHz, CDCI3) (HMQC) 6 29.8 (5-CH2),
33.9 (2-CH2), 42.0 (NCH2), 46.5 (4-CH), 72.3 (PhCH2), 85.6 (3-CH), 126.8 (2 x CH),
128.2 (2 x CH), 128.4 (2 x CH), 128.7 (2 x CH), 134.0 (Cq), 137.4 (Cq), 167.1 (C=0); 
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Largest diff. peak and hole
Compound S-(S)-104  





P 2i2 i2 i
a = 5.5540(1 )A a  = 90° 
b = 18.4970(3)A p = 90° 






0.20 x 0.20 x 0.10 mm 
3.93 to 27.46°
-7<=h<=7; -24<=k<=24; -24<=l<=24  
31757
4490 [R(int) = 0.0497]
3837
0.995
Semi-empirical from equivalents 
0.98 and 0.94
Full-matrix least-squares on F2
4 4 9 0 /1 0 4 /3 0 4
1.036
R1 = 0.0358 w R2 = 0.0772 
R1 = 0.0479 w R2 = 0.0824  
-0.05(6)
0.191 and -0.307 eA'3
Table A. Crystal data and structure refinement for S-(S)-104
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Atom X y z U(eq)
S(1) 940(1) 1574(1) 9277(1) 29(1)
0 (1 ) -1619(2) 1747(1) 9233(1) 36(1)
0 (2 ) 1342(2) 2741(1) 8016(1) 43(1)
0 (3 ) 3119(2) 3841(1) 7998(1) 46(1)
0 (4 ) 3829(2) 4794(1) 9204(1) 41(1)
N(1) 2046(3) 1253(1) 9929(1) 38(1)
0(1 ) 1580(3) 1038(1) 8530(1) 31(1)
0(2 ) 3706(3) 646(1) 8510(1) 45(1)
0(3 ) 4167(4) 205(1) 7942(1) 54(1)
0(4 ) 2536(4) 155(1) 7411(1) 58(1)
0(5 ) 445(4) 552(1) 7429(1) 63(1)
0(6 ) -40(3) 1000(1) 7990(1) 46(1)
0 (7 ) 2631(3) 2382(1) 9188(1) 31(1)
0 (8 ) 1511(3) 2953(1) 8725(1) 33(1)
0(9 ) 3078(3) 3641(1) 8714(1) 33(1)
0(10) 2053(3) 4239(1) 9145(1) 38(1)
0(11) 2878(4) 3197(1) 7608(1) 46(1)
0(12) 1592(4) 3390(1) 6941(1) 62(1)
0(13) 5264(4) 2824(2) 7499(1) 79(1)
0(14) 3120(30) 5352(10) 9679(8) 49(3)
0(15) 5050(40) 5882(12) 9673(7) 48(4)
0(16) 6234(18) 6090(4) 10279(5) 67(2)
0 (17) 8133(19) 6571(5) 10300(6) 74(3)
0(18) 8860(18) 6882(6) 9683(6) 71(3)
0(19) 7832(14) 6672(4) 9062(4) 77(2)
C(20) 5902(18) 6199(5) 9069(4) 58(2)
C(14A) 2870(30) 5420(10) 9543(8) 61(4)
C(15A) 5060(40) 5887(12) 9777(7) 40(3)
C(16A) 5924(15) 5832(4) 10436(4) 49(2)
C(17A) 7874(11) 6224(4) 10631(3) 65(1)
C(18A) 8907(18) 6717(6) 10174(6) 71(3)
C(19A) 8060(20) 6765(5) 9515(6) 84(3)
C(20A) 6129(19) 6348(5) 9314(4) 73(3)




S (1)-0 (1) 1.4588(11) S(1)-N(1) 1.5173(15)
S(1)-C(7) 1.7735(15) S(1)-C(1) 1.7830(16)
0(2 )-C (8) 1.422(2) 0(2)-C (11) 1.433(2)
0(3 )-C (11) 1.413(2) 0(3 )-C (9) 1.4271(19)
0(4)-C (14A) 1.431(17) O(4)-C(10) 1.429(2)
0(4)-C (14) 1.434(16) C(1)-C(6) 1.377(2)
C(1)-C(2) 1.386(2) C(2)-C(3) 1.387(3)
C(3)-C(4) 1.368(3) C(4)-C(5) 1.374(3)
C(5)-C(6) 1.388(3) C(7)-C(8) 1.516(2)
C(8)-C(9) 1.541(2) C(9)-C(10) 1.494(2)
C(11)-C(13) 1.509(3) C(11)-C(12) 1.511(3)
C(14)-C(15) 1.45(2) C(15)-C(16) 1.394(10)
C(15)-C(20) 1.385(10) C(16)-C(17) 1.380(10)
C(17)-C(18) 1.379(12) C(18)-C(19) 1.381(10)
C(19)-C(20) 1.383(10) C(14A)-C(15A) 1.56(2)
C(15A)-C(16A) 1.359(11) C(15A)-C(20A) 1.369(10)
C(16A)-C(17A) 1.357(9) C(17A)-C(18A) 1.391(9)
C(18A)-C(19A) 1.356(12) C(19A)-C(20A) 1.376(10)
0 (1  )-S(1 )-N(1) 121.90(8) 0(1)-S(1)-C (7) 109.01(7)
N(1)-S(1)-C(7) 101.28(8) 0(1)-S(1)-C (1) 105.64(7)
N(1)-S(1)-C(1) 111.55(8) C(7)-S(1)-C(1) 106.55(7)
C (8)-0(2)-C (11) 108.87(12) C (11)-0(3)-C (9) 107.01(13)
C( 14A )-0(4)-C ( 10) 111.2(8) C( 14A )-0(4)-C ( 14) 12.9(12)
C(10)-O(4)-C(14) 112.3(7) C(6)-C(1)-C(2) 120.57(16)
C(6)-C(1)-S(1) 120.44(13) C(2)-C(1)-S(1) 118.97(13)
C(1)-C(2)-C(3) 119.16(18) C(4)-C(3)-C(2) 120.36(19)
C(3)-C(4)-C(5) 120.30(18) C(4)-C(5)-C(6) 120.2(2)
C(1)-C(6)-C(5) 119.41(18) C(8)-C(7)-S(1) 115.27(11)
0(2)-C (8)-C (7) 113.48(13) 0(2)-C (8)-C (9) 104.63(12)
C(7)-C(8)-C(9) 110.55(13) O(3)-C(9)-C(10) 110.46(14)
0(3)-C (9)-C (8) 103.60(12) C(10)-C(9)-C(8) 112.87(13)
O(4)-C(10)-C(9) 108.29(13) 0(3 )-C (11 )-0 (2 ) 105.16(14)
0(3)-C (11)-C (13) 112.09(17) 0(2)-C(11)-C(13) 109.27(18)
0(3)-C(11)-C(12) 107.21(17) 0(2)-C(11)-C(12) 108.80(16)
C(13)-C(11)-C(12) 113.90(18) 0(4)-C(14)-C(15) 106.1(14)
C( 16)-C( 15)-C(20) 115.1(8) C(16)-C(15)-C(14) 121.8(10)
C(20)-C(15)-C(14) 123.1(11) C(17)-C(16)-C(15) 124.2(8)
C(16)-C(17)-C(18) 117.9(7) C(17)-C(18)-C(19) 120.4(8)
C(20)-C(19)-C(18) 119.3(7) C(19)-C(20)-C(15) 122.8(8)
0 (4 )-C ( 14A)-C( 15A) 106.9(15) C(16A)-C(15A)-C(20A) 119.9(7)
C( 16A)-C( 15A)-C( 14A) 120.3(9) C(20A)-C(15A)-C(14A) 119.8(10)
C( 17A)-C( 16A)-C( 15A) 120.1(7) C( 16A)-C( 17A)-C( 18A) 120.3(7)
C( 19A)-C( 18A)-C( 17A) 119.4(8) C(18A)-C(19A)-C(20A) 119.7(7)
C(19A)-C(20A)-C(15A) 120.4(8)
Table C. Bond lengths [A] and angles [°] for S-(S)-104.
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Atom U11 U22 U33 U23 U13 U12
S(1) 26(1) 30(1) 32(1) -4(1) 2(1) -1(1)
0 (1 ) 25(1) 40(1) 42(1) -8(1) 3(1) -1(1)
0 (2 ) 46(1) 44(1) 38(1) -1(1) -11(1) -10(1)
0 (3 ) 55(1) 49(1) 33(1) 3(1) 1(1) -18(1)
0 (4 ) 47(1) 28(1) 47(1) -5(1) 4(1) -3(1)
N(1) 40(1) 39(1) 35(1) 1(1) -1(1) -4(1)
C(1) 30(1) 28(1) 36(1) -3(1) 4(1) -3(1)
0(2 ) 36(1) 46(1) 52(1) -12(1) -3(1) 6(1)
0(3 ) 43(1) 51(1) 68(1) -20(1) 9(1) 9(1)
C(4) 55(1) 59(1) 60(1) -29(1) 6(1) 0(1)
0(5 ) 57(1) 82(2) 49(1) -29(1) -9(1) 10(1)
0(6 ) 40(1) 54(1) 45(1) -14(1) -5(1) 7(1)
0(7 ) 26(1) 31(1) 37(1) -6(1) -1(1) -4(1)
0(8 ) 29(1) 33(1) 37(1) -1(1) 0(1) -1(1)
0(9 ) 31(1) 36(1) 33(1) 1(1) 0(1) -3(1)
0(10) 36(1) 31(1) 47(1) 1(1) 0(1) 0(1)
0(11) 42(1) 60(1) 36(1) -7(1) 1(1) -9(1)
0(12) 65(1) 82(2) 38(1) 1(1) -7(1) -17(1)
0(13) 53(1) 120(2) 63(1) -31(2) 3(1) 8(1)
0(14) 53(6) 43(4) 52(4) -11(3) 8(5) 12(4)
0(15) 65(7) 33(6) 45(5) -2(4) -14(4) 15(5)
0(16) 85(5) 71(6) 44(4) -1(4) 4(4) 17(4)
0(17) 78(7) 56(6) 88(7) -22(4) -24(5) -16(5)
0(18) 54(4) 38(4) 121(7) -16(4) -24(5) 5(3)
0(19) 86(4) 43(3) 102(5) 2(4) -5(5) -21(3)
C(20) 70(3) 46(3) 57(4) 9(3) -21(4) -13(3)
C(14A) 56(4) 43(5) 83(8) -26(5) -27(4) 10(4)
C(15A) 47(6) 26(5) 46(5) -16(4) 0(4) 2(4)
C(16A) 55(3) 60(4) 33(3) -1(2) 2(2) -1(3)
C(17A) 58(3) 75(4) 62(4) -29(3) 2(3) -6(3)
C(18A) 58(5) 35(4) 119(7) -25(4) 11(5) -14(3)
C(19A) 95(9) 39(5) 117(9) 14(6) 30(7) -5(5)
C(20A) 105(7) 66(6) 48(4) 10(4) -19(4) 23(5)
Table D. Anisotropic displacement parameters (A2 x 103) for S-{S)-104.
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Atom X y z U(eq)
H(2) 4832 678 8880 54
H(3) 5623 -64 7921 64
H(4) 2852 -155 7028 69
H(5) -671 519 7056 75
H(6) -1478 1278 8001 55
H(7A) 2878 2593 9655 37
H(7B) 4237 2257 8999 37
H(8) -130 3076 8903 39
H(9) 4745 3524 8875 40
H(10A) 583 4433 8921 46
H(10B) 1615 4056 9611 46
H(12A) 136 3667 7050 93
H(12B) 1148 2946 6694 93
H(12C) 2659 3681 6648 93
H(13A) 6278 3119 7194 118
H(13B) 4994 2350 7285 118
H(13C) 6068 2759 7948 118
H(14C) 2903 5152 10152 59
H(14D) 1586 5576 9529 59
H(16) 5699 5888 10706 80
H(17) 8916 6683 10725 89
H(18) 10074 7244 9686 85
H(19) 8445 6849 8634 92
H(20) 5130 6088 8642 69
H(14A) 1895 5276 9951 73
H(14B) 1838 5697 9219 73
H(16A) 5162 5519 10759 59
H(17A) 8536 6162 11082 78
H(18A) 10195 7018 10323 85
H(19A) 8797 7085 9192 100
H(20A) 5535 6381 8852 88
H(1) 1410(30) 830(5) 10030(10) 50(6)
Table E. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2 x 103) for S-(S)-104.
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Data Completeness 
Absorption correction 
Max. and min. transmission 
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Final R indices [l>2a(l)]
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Absolute structure parameter 
Largest diff. peak and hole
Compound S-(S)-91






a = 12.3520(2)A a  = 90° 
b = 5.5440(1 )A p = 103.459(1)°






0.35 x 0.30 x 0.30 mm 
3.79 to 29.97°
-17<=h<=16; -7<=k<=7; -20<=l<=22 
15898
5447 [R(int) = 0.0506]
4752
0.939
Semi-empirical from equivalents 
0.55 and 0.40
Full-matrix least-squares on F2
5447 / 2 / 248
1.032
R1 = 0.0347 wR2 = 0.0731 
R1 = 0.0454 wR2 = 0.0780  
-0 .010(6)
0.479 and -0.498 eA'3
Table A. Crystal data and structure refinement for S-(S)-91.
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Atom X y z U(eq)
Br(1) 9339(1) 1118(1) 4107(1) 49(1)
S(2) 5641(1) 3026(1) 1400(1) 21(1)
0 (1 ) 5839(1) 459(3) 1296(1) 26(1)
0 (2 ) 8156(1) 3911(3) 1157(1) 31(1)
0 (3 ) 8751(1) 5205(3) -20(1) 32(1)
0 (4 ) 7261(1) 5741(3) -1835(1) 30(1)
N(1) 4483(2) 4054(4) 1289(1) 28(1)
0 (1 ) 8084(2) 3068(5) 3598(2) 33(1)
C(2) 7426(2) 2368(4) 2798(2) 26(1)
C(3) 6526(2) 3822(4) 2436(1) 23(1)
0 (4 ) 6284(2) 5910(5) 2845(1) 32(1)
0 (5 ) 6959(2) 6506(5) 3654(2) 42(1)
0(6 ) 7860(2) 5090(5) 4032(2) 40(1)
0(7 ) 6162(2) 4702(4) 621(1) 23(1)
0(8 ) 7224(2) 3715(4) 429(1) 24(1)
0(9 ) 7568(2) 5166(4) -298(1) 25(1)
0(10) 8998(2) 5364(4) 906(2) 29(1)
0(11) 8924(3) 7928(6) 1204(2) 59(1)
0(12) 10124(2) 4260(5) 1262(2) 39(1)
0(13) 7190(2) 4007(5) -1181(1) 28(1)
0(14) 6964(3) 4714(5) -2685(2) 43(1)
0(15) 6884(2) 6732(5) -3329(2) 35(1)
0(16) 5866(2) 7784(6) -3703(2) 42(1)
0(17) 5798(3) 9730(6) -4271(2) 47(1)
0(18) 6742(3) 10640(6) -4463(2) 50(1)
0(19) 7763(3) 9605(6) -4098(2) 52(1)
C(20) 7829(3) 7650(6) -3538(2) 46(1)




Br(1)-C(1) 1.906(3) S (2)-0 (1) 1.4599(16)
S(2)-N(1) 1.512(2) S(2)-C(7) 1.775(2)
S(2)-C(3) 1.795(2) 0(2 )-C (8) 1.427(3)
O(2)-C(10) 1.442(3) O(3)-C(10) 1.421(3)
0(3 )-C (9) 1.425(3) 0(4)-C (14) 1.422(3)
0(4 )-C (13) 1.426(3) C(1)-C(6) 1.374(4)
C(1)-C(2) 1.388(3) C(2)-C(3) 1.384(3)
C(3)-C(4) 1.391(4) C(4)-C(5) 1.390(3)
C(5)-C(6) 1.378(4) C(7)-C(8) 1.516(3)
C(8)-C(9) 1.537(3) C(9)-C(13) 1.506(3)
C(10)-C(12) 1.504(3) C(10)-C(11) 1.507(4)
C(14)-C(15) 1.499(4) C(15)-C(20) 1.382(4)
C(15)-C(16) 1.387(4) C(16)-C(17) 1.392(4)
C(17)-C(18) 1.368(5) C(18)-C(19) 1.383(5)
C(19)-C(20) 1.387(5)
0(1)-S (2)-N (1) 122.22(11) 0(1)-S (2)-C (7) 109.61(10)
N(1)-S(2)-C(7) 102.01(10) 0(1)-S(2)-C (3) 105.03(10)
N(1)-S(2)-C(3) 111.85(11) C(7)-S(2)-C(3) 104.96(10)
C(8)-O(2)-C(10) 108.70(17) C(10)-O(3)-C(9) 106.00(17)
C (14)-0(4)-C (13) 111.3(2) C(6)-C(1)-C(2) 122.5(2)
C(6)-C(1)-Br(1) 119.46(18) C(2)-C(1)-Br(1) 118.1(2)
C(3)-C(2)-C(1) 117.1(2) C(2)-C(3)-C(4) 122.2(2)
C(2)-C(3)-S(2) 119.45(18) C(4)-C(3)-S(2) 118.33(17)
C(5)-C(4)-C(3) 118.3(2) C(6)-C(5)-C(4) 120.8(3)
C(1)-C(6)-C(5) 119.0(2) C(8)-C(7)-S(2) 114.78(15)
0(2)-C (8)-C (7) 112.66(18) 0(2)-C (8)-C (9) 104.34(18)
C(7)-C(8)-C(9) 111.19(18) 0(3)-C (9)-C (13) 111.42(19)
0(3)-C (9)-C (8) 102.72(17) C(13)-C(9)-C(8) 112.65(19)
O (3)-C(10)-O(2) 104.51(18) O(3)-C(10)-C(12) 108.5(2)
O(2)-C(10)-C(12) 109.51(19) O(3)-C(10)-C(11) 111.4(2)
O (2)-C(10)-C(11) 110.0(2) C(12)-C(10)-C(11) 112.6(2)
0(4)-C (13)-C (9) 108.76(19) 0(4)-C (14)-C (15) 107.5(2)
C(20)-C(15)-C(16) 118.5(3) C(20)-C( 15)-C( 14) 120.7(3)
C(16)-C(15)-C(14) 120.8(3) C(15)-C(16)-C(17) 120.8(3)
C(18)-C(17)-C(16) 120.1(3) C(17)-C(18)-C(19) 119.8(3)
C(18)-C(19)-C(20) 120.1(3) C(19)-C(20)-C(15) 120.7(3)
Table C. Bond lengths [A] and angles [°] for S-(S)-91.
208
Appendices
Atom U11 U22 U33 U23 U13 U12
Br(1) 29(1) 68(1) 40(1) 13(1) -10(1) -1(1)
S(2) 21(1) 21(1) 19(1) 0(1) 1(1) -1(1)
0 (1 ) 31(1) 21(1) 24(1) -1(1) -1(1) 0(1)
0 (2 ) 21(1) 44(1) 27(1) 11(1) 1(1) 4(1)
0 (3 ) 26(1) 39(1) 29(1) 5(1) 5(1) -5(1)
0 (4 ) 36(1) 35(1) 20(1) -2(1) 8(1) -2(1)
N(1) 23(1) 31(1) 29(1) 4(1) 4(1) -1(1)
C(1) 25(1) 45(1) 24(1) 9(1) -2(1) -6(1)
0(2 ) 25(1) 31(1) 21(1) 3(1) 2(1) -3(1)
C(3) 25(1) 24(1) 20(1) 0(1) 4(1) -5(1)
0 (4 ) 39(1) 28(1) 28(1) -3(1) 4(1) -3(1)
0 (5 ) 56(2) 36(2) 31(1) -11(1) 6(1) -9(1)
0(6 ) 47(2) 48(2) 23(1) -4(1) 0(1) -16(1)
0 (7 ) 24(1) 23(1) 20(1) 2(1) 1(1) 3(1)
0 (8 ) 27(1) 23(1) 23(1) 1(1) 5(1) 3(1)
0 (9) 25(1) 24(1) 25(1) 3(1) 6(1) 0(1)
0(10) 31(1) 26(1) 30(1) 4(1) 4(1) -3(1)
0(11) 84(2) 32(1) 47(2) -6(1) -10(2) 4(2)
0(12) 24(1) 44(2) 46(2) 2(1) 1(1) -3(1)
0(13) 28(1) 30(1) 25(1) 0(1) 7(1) 0(1)
0(14) 60(2) 43(2) 26(1) -8(1) 7(1) -1(1)
0(15) 45(1) 41(2) 20(1) -7(1) 7(1) 0(1)
0(16) 42(2) 53(2) 31(1) -2(1) 11(1) -2(1)
0 (17) 59(2) 51(2) 29(1) -4(1) 7(1) 3(1)
0 (18) 86(2) 42(2) 26(1) -1(1) 19(1) -5(2)
0(19) 62(2) 62(2) 38(2) -10(2) 24(2) -19(2)
C(20) 42(2) 63(2) 33(1) -8(1) 11(1) 0(1)
Table D. Anisotropic displacement parameters (A2 x 103) for S-(S)-91.
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Atom X y z U(eq)
H(2) 7586 951 2510 31
H(4) 5672 6904 2579 38
H(5) 6798 7907 3949 50
H(6) 8318 5505 4585 49
H(7A) 5582 4756 70 27
H(7B) 6300 6379 835 27
H(8) 7112 1986 248 29
H(9) 7268 6845 -313 30
H(11A) 9477 8919 1009 88
H(11B) 9070 7971 1843 88
H(11C) 8177 8563 955 88
H(12A) 10147 2645 1014 59
H(12B) 10260 4143 1899 59
H(12C) 10698 5274 1106 59
H(13A) 7668 2601 -1227 33
H(13B) 6413 3435 -1264 33
H(14A) 6241 3869 -2771 52
H(14B) 7535 3535 -2762 52
H(16) 5207 7170 -3569 50
H(17) 5095 10426 -4527 56
H(18) 6697 11979 -4846 60
H(19) 8420 10233 -4231 62
H(20) 8532 6936 -3296 55
H(1) 4151 3051 1534 58(10)
Table E. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2 x 103) for S-(S)-91.
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Appendix 3. X-ray crystallography data for compound (±)-164
Identification code Compound (±)-164






Unit cell dimensions a = 8.0940(2)A a  = 90° 
b = 9.5710(3)A p = 107.961(1)° 
C = 8.9660(3)A y = 90°
Volume 660.73(3) A3
Z 4
Density (calculated) 1.480 Mg/m3
Absorption coefficient 0.411 mm'1
F(000) 312
Crystal size 0.25 x 0.20 x 0.15 mm
Theta range for data collection 4.26 to 27.47 °.
Index ranges -10<=h<=10; -12<=k<=12; -11<=|<=11
Reflections collected 9540
Independent reflections 1505 [R(int) = 0.0363]
Reflections observed (>2o) 1307
Data Completeness 0.996
Absorption correction Multiscan
Max. and min. transmission 0.942, 0.893
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 1 5 0 5 / 0 / 8 6
Goodness-of-fit on F2 1.064
Final R indices [l>2a(l)J R1 = 0.0325 w R2 = 0.0804
R indices (all data) R1 = 0.0389 w R2 = 0.0833
Largest diff. peak and hole 0.212 and -0.333 eA'3
Table A. Crystal data and structure refinement for (±)-164. Notes: The lattice contains a racemate. Gross 
structure dominated by hydrogen-bonding.
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Atom X y z U(eq)
8(1) 3463(1) 1935(1) 9122(1) 36(1)
0 (2 ) -943(1) -961(1) 7170(1) 26(1)
0 (3 ) 2740(1) -492(1) 5415(1) 26(1)
N(1) 763(2) -2712(1) 6818(1) 26(1)
C(2) 3797(2) 1400(2) 7297(2) 31(1)
C(3) 2349(2) 364(1) 6559(2) 24(1)
C(4) 2142(2) -546(1) 7905(2) 22(1)
0(5 ) 2063(2) 459(2) 9196(2) 28(1)
0(41) 529(2) -1441(2) 7286(2) 22(1)
Table B. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2 x 103) for (±)- 
164.
S(1)-C(2) 1.8127(16) S(1)-C(5) 1.8306(15)
0(2)-C (41) 1.2506(16) 0 (3 )-C (3) 1.4229(16)
N(1)-C(41) 1.3198(18) C(2)-C(3) 1.522(2)
C(3)-C(4) 1.5386(18) C(4)-C(41) 1.5163(18)
C(4)-C(5) 1.5238(19)
C(2)-S(1)-C(5) 94.73(7) C(3)-C(2)-S(1) 105.52(9)
0(3)-C (3)-C (2) 112.08(11) 0(3)-C (3)-C (4) 109.96(11)
C(2)-C(3)-C(4) 106.45(11) C(41)-C(4)-C(5) 113.42(11)
C(41)-C(4)-C(3) 108.82(11) C(5)-C(4)-C(3) 106.29(11)
C(4)-C(5)-S(1) 106.48(9) 0(2)-C (41)-N (1) 122.59(12)
0(2)-C (41)-C (4) 120.90(12) N(1)-C(41)-C(4) 116.44(11)
Table C. Bond lengths [A] and angles [°] for (±)-164.
Atom U11 U22 U33 U23 U13 U12
S(1) 45(1) 27(1) 35(1) -8(1) 13(1) -11(1)
0 (2 ) 22(1) 28(1) 28(1) 3(1) 7(1) 3(1)
0 (3 ) 30(1) 27(1) 23(1) 3(1) 9(1) 6(1)
N(1) 21(1) 25(1) 33(1) -5(1) 8(1) -3(1)
0(2 ) 34(1) 27(1) 32(1) 2(1) 10(1) -6(1)
0(3 ) 26(1) 22(1) 24(1) 2(1) 9(1) 1(1)
0(4 ) 22(1) 21(1) 23(1) 1(1) 6(1) 0(1)
0(5 ) 32(1) 25(1) 27(1) -3(1) 10(1) -4(1)
0(41) 22(1) 24(1) 18(1) 3(1) 6(1) 0(1)
Table D. Anisotropic displacement parameters (A2 x 103) for (±)-164.
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Atom X y z U(eq)
H(3) 2268 -157 4518 40(5)
H(1A) -137 -3258 6405 33(4)
H(1B) 1819 -3013 6918 39(5)
H(2B) 3728 2214 6600 37
H(2A) 4948 953 7497 37
H(3A) 1244 884 6062 28
H(4) 3182 -1163 8304 26
H(5A) 2461 -5 10232 33
H(5B) 845 782 9016 33
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Abstract presented at the American Chemical Society (ACS) 232nd National Meeting, 
San Francisco, U.S.A., 1 0 -14  September 2006.
Design, synthetic approaches and characterisation of a novel cyclic sulfoximine NAD* 
(nicotinamide adenine dinucleotide) analogue
Joey S. W. Kwong, Matthew D. Lloyd and Michael D. Threadgill, Department of Pharmacy and 
Pharmacology, University of Bath, Claverton Down, Bath, BA2 7 AY, United Kingdom, Fax: 
+44(0)1225386114, J.S.W.Kwong@bath.ac.uk
Nicotinamide adenine dinucleotide (NAD*, 1) is the substrate for both poly(ADP-ribose) 
polymerase-1 (PARP-1) and inosine-5’-monophosphate dehydrogenase (IMPDH), important 
enzymes implicated in cancer development. We herein describe an innovative approach to the 
synthesis of a cyclic sulfoximine 2-deoxyriboside mimic, where the anomeric carbon has been 
replaced by the sulfoximine group. Sulfoximines possess extremely versatile chemistry and their 
use in the design of ribose mimics has not been reported previously. A key step in our ongoing 
studies towards the target 2 involves a thio-Mitsunobu reaction of a sulfur nucleophile 3 and a 
homochiral dioxolane compound 4. The two diastereoisomers of an important, novel 
intermediate 5 have been separated and the stereochemistry at the sulfur centre established by 
X-ray crystallography. Development of synthetic routes from this intermediate to the target cyclic 
sulfoximine will be reported.
.CONH-
NAD4,1 2 3 R ■ H or Br 4 5
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Abstract presented at the Conferences Europeenes du Groupement Des 
Pharmacochimistes de L’Arc Atlantique (GP2A) Meeting, Bath, U.K., 7 - 8  September, 
2006 and the 2nd National Cancer Research Institute (NCRI) Cancer Conference, 
Birmingham, U.K., 8 -1 1  October 2006.
Design and synthesis of a novel transition-state mimic for 
poiy(ADP-ribose) polymerase 1 (P ARP-1) inhibition
Joey S. W. Kwong*, Matthew D. Lloyd and Michael D. Threadgill
Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, 
Bath, BA2 7AY, United Kingdom. E-mail J.S.W.Kwong@bath.ac.uk
Nicotinamide adenine dinucleotide (NAD+, 1) is the substrate for poly(ADP-ribose) 
polymerase-1 (PARP-1). PARP-1 is responsible for cellular DNA repair and high levels 
in tumours confer resistance to DNA-damaging chemotherapy and hence lead to 
treatment failure.1 Inhibition of PARP-1 is therefore of great clinical interest in cancer 
therapy. Here we report on the synthesis of a cyclic sulfoximine NAD+ transition-state 
analogue 2 where the anomeric carbon of the ribosyl ring has been replaced by a 
sulfoximine group. The sulfoximine functional group is configurationally and 
chemically stable; it is tetrahedral and, when the two carbon substituents attached to the 
sulfur atom are different, is chiral. The imino nitrogen is weakly basic.2 Sulfoximines 




OH OH OH OBn
NAD'1’, 1 PARP-1 transition state analogue, 2 3
The important, novel lead compound, (±)-3-benzyloxytetrahydrothiophene-4- 
carboxamide (3) was obtained with moderate yield. Dieckmann cyclisation of 
acrylonitrile and methyl mercaptoacetate with sodium and anhydrous methanol gave 
(±)-3-oxotetrahydrothiophene-4-carbonitrile.3 Subsequent reduction of the ketone 
afforded the corresponding hydroxyl compound Separation of the diastereoisomers was 
achieved by column chromatography and the stereochemistry was determined by X-ray 
crystallography of the amide compound, synthesised by acid-hydrolysis of the nitrile. 
O-benzylation gave rise to the target lead compound. Development of synthetic routes 
from this intermediate to the target cyclic sulfoximine w ill be reported. In conclusion, 
we have herein described a highly novel and efficient reaction sequence towards the 
synthesis of a cyclic sulfoximine NAD+ transition-state mimic, the enzyme inhibitory 
profile of which will be investigated by biological assay.
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